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SUMMARY 
 
Neurons and glial cells of the central nervous system (CNS) communicate and work together to 
function and execute an array of complex tasks. In addition to them a third cell type which also 
works to keep the brain alive are the cerebral endothelial cells that create the vascular system 
which supply and deliver oxygen and nutrients. The cerebral endothelium is also specialized 
with a blood-brain barrier (BBB) that is important for protecting the CNS from harmful 
substances and for regulating access only to certain ions and nutrients for optimal maintenance 
and support of CNS activities. A complex of tight junction proteins which include occludin, 
Claudin-1/3, Claudin-5, and ZO1-3 are thought to keep the endothelium impermeable, while a 
system of transporters, such as GLUT1 and P-gp are involved in regulating the molecular 
trafficking across the BBB. The endothelium is also characterized by a low pinocytotic activity 
compared to vessels in peripheral organs. A lot is known on the formation and composition of 
the BBB, but less is understood on the maintenance. This is probably due to the heterogeneity 
of the cerebral endothelium, which makes it difficult to study. However, the cerebrovascular 
function is supported by a combination of interactions with glia, pericytes, and nerve cells, 
known together as the neurovascular unit (NVU). A number of in vitro studies show that co-
culturing endothelial cells with astrocytes and pericytes, as well as nerve tissue is capable of 
expressing tight junction proteins and a tight endothelial barrier, suggesting that cell-cell 
interactions and production of essential factors such as FGF and TGF-β are involved in BBB 
maintenance.     
Disruption of the BBB is often associated with brain injury and considered to be detrimental to 
the recovery process. Although the mechanisms are poorly understood, breakdown of the BBB 
has been suggested to be due to production of matrix-metalloproteinases, growth factors and 
cytokines. Inflammatory mediators have been well known to modulate BBB permeability. Since 
inflammation typically follows excitotoxicity in the ischemic cascade to cell death, BBB disruption 
may be secondary in the injury process. Whether the vascular damage is precipitated by 
neurodegeneration is unclear. Understanding how the neurovasculature might be affected is 
important for prevention and treatment of neurovascular diseases, such as stroke or neonatal 
asphyxia since neuroprotectants, except for therapeutic mild-hypothermia, have failed in the 
clinics. 
Cooling of the head or body down to about 33°C for up to 3 days has so far been the most 
effective neuroprotective strategy for treating cerebral ischemia observed in stroke or perinatal 
asphyxia. Along with reducing energy demand and energy consumption, mild hypothermia 
seems to affect many aspects of cellular injury but overall is very efficient at stopping cell death. 
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A small group of proteins are expressed during mild-hypothermia. One of them is the RNA 
binding motif protein 3 (RBM3) and based on in vitro studies it is involved in cell proliferation 
and survival. Whether RBM3 is involved in hypothermia-induced neuroprotection deserves 
investigation as it may provide some hints into the mechanisms of how hypothermia prevents 
cell death. 
A useful in vitro system to study aspects of neurodegeneration that is close to the in vivo 
situation is the organotypic slice culture system, which has been very well established for 
cortical, hippocampal, and cerebellar tissue. Previously our lab has established an in vitro BBB 
model utilizing the cortical organotypic slice culture system, which preserves tight junction 
proteins for more than a week under the presence of FGF2. The main objective of my PhD 
thesis was to analyze the expression of the neuronal and vascular elements of the blood-brain 
barrier (BBB) under normal and stressed conditions and to study the cell-cell interaction at the 
biochemical and cellular level utilizing the organotypic slice culture system established in our 
laboratory. In the first project we have studied the expression of transporter proteins in cortical 
organotypic slice cultures (COSCs). We could show that transporters such as glucose 
transporter 1 (GLUT-1) and the ATP-binding cassette (ABC) transporter, P-glycoprotein (P-gp) 
were present and functional in the blood vessels of COSCs. In the second project we used 
entorhino-hippocampal organotypic slice cultures (EHOSCs) derived from newborn mice to 
study the effect of oxygen-glucose deprivation (OGD) as well as excitotoxicity on 
neurodegeneration and accompanying neurovascular changes. We could show that changes in 
BBB integrity and vascular remodeling were linked to neurodegeneration. Selective loss of the 
neurovasculature in CA1 of the hippocampus was preceded by neuronal death indicating that 
not OGD by itself, but the OGD-induced neurodegeneration was responsible for the loss of local 
blood vessels.  Finally, in the third project we have explored a potential function of the cold-
inducible RNA binding motif protein 3 as a neuroprotectant in response to mild hypothermia that 
is employed after neonatal asphyxia. We could show that RBM3 expression was strongly 
induced in COSCs upon hypothermia and was required and sufficient for neuroprotection of 
dissociated PC12 cells from induced apoptosis.  
 
 
 
 
 
 
8 
 
ABBREVIATIONS 
ABC ATP-binding cassette 
AD Alzheimer’s disease 
AED  Anti-epileptic drug 
AF-6  All-1 fusion partner from 
chromosome-6 
AJ adherens junction 
ALS Amyotrophic Lateral Sclerosis 
AMPA (RS)-α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid 
AMT adsorptive-mediated transport 
ANG angiopoietin 
AQP4 aquaporin-4 
ATP adenosine-5’-triphosphate 
BBB  blood-brain barrier 
BCRP  breast cancer resistance protein 
BCSFB blood-cerebrospinal fluid barrier 
BDNF  brain derived neurotrophic factor 
CA cornu Ammonis 
CIRP cold-inducible RNA-binding protein 
Cld5 claudin-5 
CNQX 6-cyano-7-nitroquinoxaline-2, 3-
dione 
CNS central nervous system 
COSC  cortical organotypic slice culture 
CSF cerebrospinal fluid 
CSP cold shock protein 
CS-RBD consensus sequence RNA-binding 
domain 
DCC Delected in Colorectal Cancer 
DCX doublecortin 
DG dentate gyrus 
DIV days in vitro 
DNA deoxyribonucleic acid 
DND delayed neuronal death 
E embryonic day 
EAAT excitatory amino acid transporter 
EC entorhinal cortex 
ECM extracellular matrix 
EGL external granular layer 
EHOSC entorhino-hippocampal 
organotypic slice cultures 
Eph ephrin receptor 
FDA Food and Drug Adminstration 
FFA free fatty acid 
FGF fibroblast growth factor 
FVIII Factor-8 
GABA γ-aminobutyric acid 
GDNF glial derived neurotrophic factor 
GFAP glial fibrillary acidic protein 
GluR glutamate receptor 
GLUT1 glucose transporter-1 
GRP glycine-rich RNA-binding protein 
GUK guanyl-kinase-like domain 
9 
 
HIF hypoxia-inducible factor 
HIE hypoxia-ischemia encephalopathy 
hnRNP heterogeneous ribonucleoprotein 
IgG immunoglobulin G 
IGL internal granular layer 
IL interleukin 
JAM junctional adhesion molecule 
KA kainic acid 
KA1 kainate receptor-1 
LAM laminin 
MAGUK membrane-associated guanylate 
kinase-like-protein 
MCAO middle cerebral artery occlusion 
MDR multidrug resistance  
mGluR metabotropic glutamate receptor 
miRNA micro-RNA 
ML  molecular layer 
mRNA  messenger RNA 
MRP multidrug resistance-associated 
protein 
MS Multiple Sclerosis 
NeuN neuronal nuclear 
NG2 chondroitin sulfate proteoglycan 
NGF nerve growth factor 
NMDA N-methyl-D-aspartate 
NO  nitric oxide 
NR NMDA receptor 
NT-3 neurotrophin-3 
NVU neurovascular unit 
OGD oxygen-glucose deprivation 
OHC organotypic hippocampal slice 
culture 
P postnatal age 
p75NGFR  p75 nerve growth factor receptor 
PC12 pheochromocytoma-12 cell line of 
rat adrenal medulla 
PD  Parkinsin’s Disease 
PDGF platelet derived growth factor 
P-gp P-glycoprotein 
PI propidium iodide 
PI3K    phosphoinositide 3-OH-kinase 
RBD RNA binding domain 
RBM3 RNA binding protein motif 3 
RG arginine-glycine 
RMT receptor-mediated transport 
RNA ribonucleic acid 
RNP ribonucleoprotein 
Robo round about 
RRM RNA recognition motif 
SE status epilepticus 
SGZ subgranular zone 
siRNA small interfering RNA 
SLC solute carrier 
STS staurosporine 
10 
 
SVZ subventricular zone 
TBI traumatic brain injury 
TEER   transendothelial electrical resistance 
TGF transforming growth factor 
TIA transient ischemic attack 
TJ tight junction 
TLE temporal lobe epilepsy 
TNF tumor necrosis factor 
t-PA tissue-type plasminogen activator 
TTX tetrodotoxin 
Unc5 Uncoordinated-5 
VE vascular endothelial 
VEGF vascular endothelial growth factor 
vWF von Willebrand Factor 
WHO World Health Organization 
Wnt Wingless-type 
ZO zonula occluden 
 
 
 
 
11 
 
CHAPTER I:  NERVOUS AND VASCULAR NETWORKS AND PATHOLOGY 
1.1   SIMILARITIES BETWEEN NERVES AND VESSELS 
 
The anatomical patterning of nerves and vessels and their intimate contacts with one another in 
the human body have been recognized since the late 1800’s, as illustrated by the Belgian 
anatomist, Andreas Vesalius (Larrivée et al., 2009). From veins to arteries to capillaries the 
vascular network is strikingly complex with numerous interconnected branches extending in 
various directions to deliver and exchange blood borne substances throughout the body. 
Similarly, neuronal networks are arranged in a complex fashion in order to connect information 
from various parts of the brain to the periphery. These commonalities at the anatomical level 
imply that nerves and vessels may require similar instructions for patterning of branches. 
Indeed, it has been known for a while that nerves and vessels utilize the same routes and 
modes of migration (Speidel, 1933; Martin and Lewis, 1989). More recent and elegant genetic 
studies in mice and zebrafish have only deepened this relationship at the cellular and molecular 
level revealing similarities in chemical cues and in sensing mechanisms (Carmeliet, 2003; Tam 
and Watts, 2010). The frequent alignment of blood vessels and nerve fibers of peripheral tissue 
suggest that cell-cell interactions may also be necessary in determining their patterning 
(Larrivée et al., 2009). In the skin, growth factor released by Schwann cells may determine 
vessel branching along nerves (Mukouyama et al., 2002). The patterning of sympathetic 
neurons is dependent on artemin released by blood vessels (Honma et al., 2002). In 
development, the co-occurrence of vascular and neuronal formation in branching, coupling, and 
guidance within target tissues have also suggested that neurons and endothelial cells build their 
systems in coordination to achieve a working neurovascular system (Park et al., 2003). In the 
adult brain angiogenesis and neurogenesis continue to take place in neurogenic zones further 
supporting this cellular coordination (Palmer et al., 2000). Indeed, a number of growth factors 
and guidance molecules are shared by both the nervous and vascular systems (Table 1; Ward 
and LaManna, 2004: Park et al., 2003). For example vascular endothelial growth factor (VEGF), 
a well known angiogenic factor that induces angiogenesis and vasculogenesis, is also important 
for neuronal development, patterning, and growth (Ferrara, 2000; Carmeliet and Storkebaum, 
2002; Jin et al., 2002). In addition to these structural parallels, both networks communicate 
bidirectionally, where information via electrical impulses in nerves is sent back and forth along 
axons and dendrites, while oxygen and nutrients carried by blood flow are exchanged between 
veins and arteries.  Furthermore, analogous to the glia of the nervous system, which aid in 
neural function, the mural cells of the vascular system aid in vessel stability (Shima and 
Mailhos, 2000; Ward and LaManna, 2004). Despite these commonalities existing between 
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nerves and vessels little is known about the coordination and interaction between the two 
systems, especially at the interface between the vascular and nervous systems of the 
neurovascular unit (NVU). The physiologic interactions between nerves and vessels may offer 
insights into endogenous protective responses that the brain activates once an injury occurs.    
___________________________________________________________________________    
Table 1.1: Effects of growth factors and guidance molecules on nervous and vascular systems 
(adapted and modified from Ward and LaManna, 2004; Park et al., 2003) 
      Nervous System                     Vascular System                       Refs 
Growth factor: 
VEGF         neurogenic           vasculogenesis              Ward and LaManna, 2004 
         neuroprotective         angiogenesis   
         neuron/ axon growth         EC cell survival/ proliferation/ 
             migration 
bFGF         neurogenesis            angiogenesis              Marchal et al., 2009; 
                                                                                                                                Murakami and Simons, 2008 
Angiopoetins               neurite outgrowth         EC cell survival/ migration       Ward and LaManna, 2004  
                                    neurite patterning                pericyte recruitment              Park et al., 2003 
                                    neuroprotection                   anti-permeability      
PDGF                          oligodendroglial/                  angiogenesis              Raff et al., 1988; 
         neuronal development         vessel stability              Williams et al., 1997; 
         neuroprotection          pericyte recruitment/              Winkler et al., 2010 
                                                                                migration/ proliferation 
TGF-β                           neurogenesis                        vasculogenesis              Choi and Bellermann, 1995; 
                  angiogenesis                           Dünker and Kriegelstein, 2000; 
                       
          
Erythropoietin              neurogenesis                      endothelial growth factor         Park et al., 2003   
                                    neuroprotection        
GDNF         neuroprotection         BBB formation              Park et al., 2003 
Artermin                      GDNF family member          vascular guidance  of              Park et al., 2003 
             sympathetic nerves 
BDNF         neuronal survival          EC cell survival              Ward and LaManna, 2004 
             vessel stabilization 
             secreted by EC 
NGF         neuronal survival/         angiogenic               Ward and LaManna, 2004 
         differentiation 
         neurite outgrowth 
NT-3         neuronal survival/         angiogenic               Ward and LaManna, 2004 
         differentiation  
p75NGFR                co-receptor for           vascular tone/               Ward and LaManna, 2004 
         high affinity            smooth muscle cell  
         Neurotrophin binding           apoptosis 
         to Trk 
Nogo         inhibitor of axon                   EC migration              Ward and LaManna, 2004 
         regeneration                       inhibition of SMCs   
Guidance molecule: 
Semaphorin/Plexin/    axon guidance        coronary vessel EC marker      Ward and LaManna, 2004 
Neuropilin        attraction/ repulsion        VEGF164/5 receptor 
         repulsive growth cone 
         guidance  
Ephrin/Eph        guidance cues for          angiogenesis                           Ward and LaManna, 2004 
         growing axons         arterial versus venous identity 
         migration of neural 
         crest cells 
Robo/Slits        axon guidance         vessel stability               Wang et al., 1999;  
                                                                                                                                 Jones et al., 2009 
Netrin/Unc5/DCC        axon guidance         vessel tip cell repulsion            Dickson et al., 2002; 
              Larrivée et al., 2007    
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1.2   HIPPOCAMPUS 
The hippocampus is located in the temporal lobe and is one of the most extensively studied 
regions of the brain. Mainly, due to its single layer of principle cells (pyramidal neurons) and the 
laminated organization of synaptic inputs to well defined dendrites, the hippocampus has been 
an attractive model to study general neuronal and systems properties of the brain. The simplicity 
in architecture has made identifying neuronal cell bodies and dendrites of mammalian origin 
possible and their synaptic inputs and population discharges recordable.  Methods for growing 
hippocampal neurons in culture (Banker and Cowan, 1977) and organotypic slices (Li and 
McIlwain, 1957; Gähwiler, 1981), in particular transverse hippocampal slices (Zimmer and 
Gähwiler, 1984), have helped to advance progress in neurobiology. Although hippocampal cells 
in culture can be individually identified, easily manipulated, and recorded, hippocampal slices 
provide the cytoarchitecture of the characteristic laminated synaptic inputs and their dendrites. 
Field potential recordings are easily performed and assessed in the slices, just as well as in 
freely moving animals (Bliss and Richards, 1971; Anderson et al., 1972). In addition to the 
special hippocampal anatomy, the hippocampus is involved in learning and memory and 
selectively vulnerable to certain types of neurological disorders (e.g Alzheimer’s disease, 
epilepsy and stroke). 
 
1.2.1 STRUCTURE AND FUNCTION 
The hippocampal formation is composed of the entorhinal cortex (EC), hippocampus proper, 
and subiculum. Cornu Ammonis1 (CA1), CA2, and CA3 pyramidal neurons, and the dentate 
gyrus (DG) granule cells, that are organized respectively into a laminated structure of stratum 
pyramidale and stratum granulosum, make up the subfields of the hippocampus proper (Fig. 1A; 
Cajal, 1901). In the mammalian brain glutamate is the major excitatory neurotransmitter, while γ-
aminobutyric acid (GABA) is the main inhibitory neurotransmitter. Pyramidal and granule cells 
make up 90% of glutamatergic hippocampal neurons and GABAergic interneurons make up the 
remaining 10% in the hippocampus (Fritschy et al., 1998). Two types of glutamate receptors 
exist, ionotropic, which are ligand-gated ion channels, and metabotropic, which are G-protein 
coupled receptors that modulate glutamate release as well as GABA release (de Blas et al., 
1988). The most prominent ionotropic receptors in the adult hippocampus are NMDA receptors: 
NR1 and NR2A/B subunits, AMPA receptors: GluR1 and GluR2 subunits, and kainate receptors 
(GluR5,-6,-7, KA1 and KA2). There are 8 metabotropic receptor subtypes, mGluR1-8, and all 
are expressed in the hippocampus except for mGluR6 (Shigemoto et al., 1997). Other receptors 
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such as acetylcholine nicotinic receptors, noradrenaline receptors, and serotonin receptors are 
also present in CA1; therefore other neurotransmitters are present as well  (Vizi and Kiss, 
1998).  
The hippocampus is part of the limbic system and has many important functions including 
memory formation, navigation, emotional response, and spatial orientation. Injury to the 
hippocampus proper and EC seems to be associated with anterograde and retrograde amnesia, 
while only loss of CA1 pyramidal neurons occurs in anterograde amnesia (Alvarez and Squire, 
1994). Unlike most of the neuronal circuitry within the neocortex, which is bidirectional, the 
circuitry of the hippocampal formation is unidirectional. The pathway of input to the 
hippocampus comes from the major glutamatergic afferents of neuronal projections from the 
EC. The axons of EC project to CA1 or along towards the so-called perforant path, which project 
to dendrites of DG granule cells. The mossy fibers, which are the axonal projections of DG 
granule cells, interact with dendrites of pyramidal cells of the CA3 region. From there, the 
Schaffer collateral axons of CA3 pyramidal cells project to the dendrites of CA1 subfield. The 
final and major excitatory output is then made by the efferent projections of CA1 to the 
subiculum or to the EC, where the hippocampal processing loop ends and the information is 
sent to other cortical regions (Amaral and Witter, 1989).  
The transverse hippocampal arteries, of the longitudinal hippocampal artery, which branches 
from the posterior cerebral artery, supply the blood to the hippocampus in rat (Fig.1B; Coyle, 
1976). Arteries in CA1 have been reported to be smaller in diameter, shorter, and fewer in major 
branches than the internal transverse arteries of CA3 (Coyle, 1976). Of the transverse 
hippocampal veins, the internal transversal hippocampal veins are the longest and most 
abundant (Fig.1C; Coyle, 1976). Based on the observation of segmentally arranged and an 
alternating pattern of transverse arteries and veins within CA3, the transversely directed 
hippocampal vessels have been postulated to be involved in hippocampal lamellar neuronal 
organization (Coyle, 1976). Unfortunately, no follow-up studies investigating this theory have 
been reported, to date. Nevertheless, differences in hippocampal vascularity have been 
observed (Imdahl and Hossmann, 1986; Gerhart et al., 1991). Capillary density within stratum 
pyramidale of CA1 has been reported to be reduced and shown to be selectively decreased 
following cerebral ischemia (Imdahl and Hossmann, 1986; Jingtao et al., 1999). This uniquely 
low density of the vascular network and possibly low blood supply to CA1 suggests for regional 
differences in requirement of blood supply (Lokkegaard et al., 2001). Additionally, differences in 
density of perfused capillaries along the septotemporal axis of rat hippocampus have been 
observed (Fig.1D-E; Grivas et al., 2003).  
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        A.               B.          C. 
            
D.       E. 
 
Figure 1. Structure of nerves and vessels of rodent hippocampus. The hippocampal formation and 
neuronal network (A), major hippocampal arteries (B), major hippocampal veins (C), dorsal 
hippocampal vasculature (D) and ventral hippocampal vasculature (E).  (Cajal, 1901; Coyle, 1976; 
Grivas et al., 2003) 
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1.2.2 NEUROVASCULAR NICHE  
The hippocampus also contains a neurogenic region in the dentate gyrus. There are two 
neurogenic zones in the adult brain, the subventricular zone which produces new interneurons 
in the olfactory bulb and the subgranular zone (SGZ), which generates new granule cells within 
dentate gyrus of the hippocampus (Palmer et al., 2000). It is not completely understood why 
adult neurogenesis is restricted to these two regions. Interestingly, in the SGZ, 37% of the cells 
proliferating are endothelial precursor cells. Because angiogenesis is also present, these zones 
have been termed as ‘neurovascular niches’ (Palmer et al., 2000; Louissaint et al., 2002). The 
blood vessels and neuroprogenitor cells appear in close proximity to each other (Palmer et al., 
2002), which is reminiscent of neuronal and endothelial precursors that are found together 
during embryogenesis and postnatal neurogenesis.  Since the two events are temporally 
associated, the coordinated interactions between neurogenesis and angiogenesis have been 
suggested to influence development and responses to the environment and following injury 
(Ward and LaManna, 2003; Park et al., 2003). Interestingly, angiogenic factors have been 
reported to induce and sustain neural stem cells, suggesting the importance of angiogenesis in 
maintaining a neurogenic environment (Shen et al., 2004). As previously mentioned, during 
development neural cells and endothelial cells respond by production of growth factors and their 
receptors. Regional production of VEGF in the neurovascular niche attract growth and migration 
of vessels as well as stimulate neurogenesis in part by activating endothelial cells to express 
brain derived neurotrophic factor (BDNF; Louissant et al., 2002; Barami, 2008; Shen et al., 
2004). Thus, VEGF has been considered as a potent inducer of both neuronal and endothelial 
proliferation and differentiation (Jin et al., 2002; Schänzer et al., 2004; Sun et al., 2006; Segi-
Nishida et al., 2008). This functional overlap of growth factors and receptors suggest that 
neurogenesis and angiogenesis are coordinated in a co-dependent manner sharing common 
molecular triggers and signaling pathways (Park et al., 2003).  Whether the production of growth 
factors are shared between nerves and vessels (paracrine signaling) or utilized separately 
within their respective compartments (autocrine signaling) remains to be determined.  
1.3   NEUROVASCULAR DISEASES  
Neurovascular diseases involve damage to blood vessels that supply blood to the brain or 
spinal cord, such as stroke. Abnormalities to the blood vessels include narrowing of arteries, 
which reduces blood flow, or weakening of arteries, which leads to brain aneurysms and 
hemorrhaging, but ironically, most of the research on neurovascular diseases has been focused 
on understanding molecular processes of neuronal excitotoxicity, oxidative stress, and cell 
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death. Yet neuron-targeted therapeutic approaches have been mostly unhelpful in clinical trials. 
Due to this neurocentric view, less has been reported on the impact of non-neuronal cells, in 
particular endothelial cells. Previously endothelial cells were viewed as quiescent cells which 
simply make up blood vessels mainly to supply the brain with oxygen and nutrients. However, 
with advancements in vascular biology, endothelial cells have shown to be metabolically active, 
involved in wound healing, vascular tone, blood coagulation, inflammatory responses, immune 
surveillance, and endocrine processes, all of which are necessary in maintaining a balanced 
homeostatic microenvironment (Nachman and Jaffe, 2004). Today, neurological disorders that 
were previously viewed as soley due to neuronal dysfunction have been included as 
neurovascular diseases caused by or associated with cerebral endothelial dysfunction. For 
example, observations of reduced endothelial glucose transport capacity (Kalaria and Harik, 
1989) and regulation of Aβ trafficking, by influx and efflux transporters at the blood-brain barrier 
(Deane et al., 2004) suggests a pathological status of the endothelium to contribute to initiation 
or progression of AD. Indeed, the number of neurodegenerative diseases which are 
accompanied by vascular abnormalities have grown, some of which include Parkinson’s disease 
(PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), 
neuro-AIDS and different types of brain tumors (Abbott et al., 2006). As either a precipitating or 
secondary event of injury, it may well be that cerebral endothelial dysfunction is associated with 
most, if not all diseases (Aird, 2005).  
1.3.1 STROKE AND CEREBRAL ISCHEMIA 
The brain utilizes about 20% of oxygen and receives about 15% of blood pumped by the heart 
(Rolfe and Brown, 1997). The blood supply to the brain is physiologically demanding. Since 
neurons have such a high rate of metabolism a reduction in oxygen and glucose, from a 
disruption in blood supplied by arteries and capillaries would cause neuronal dysfunction, as in 
stroke. Stroke or transient ischemic attack (TIA) involves impairment of blood vessels either by 
a vessel occlusion (85% of stroke cases are cerebral ischemia) or cerebral bleeding. Embolisms 
account for 75% of vessel occlusions and are mainly caused by focally-obstructed blood flow 
within the brain (Mergenthaler et al., 2004). Stroke is the second leading cause of mortality with 
about 6 million deaths worldwide each year and some of the risk factors for stroke include 
smoking, diabetes, hypertension, high cholesterol, and a sedentary lifestyle (WHO Global 
Infobase; Moskowitz et al., 2010; Woodruff et al., 2011).  
Stroke is a vascular disorder with neurological consequences. Brain lesions followed by cerebral 
ischemia is variable depending on the brain region that is affected. White matter appears to be 
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more resistant than gray matter to ischemic cell damage (Mattson et al., 2001). Also, in certain 
neuronal populations some are selectively vulnerable to ischemic cell death while others are 
not, such as CA1 pyramidal neurons and dentate granule neurons of the hippocampus, 
respectively (Mattson et al., 2001). Additionally, following cerebral ischemia, alterations in the 
cerebral vasculature occur, which include blood-brain barrier breakdown, upregulation of 
endothelial adhesion molecules, apoptosis and angiogenesis (Moskowitz et al., 2010). Although 
stroke causes ischemic cell death it also triggers a regenerative response in the penumbra, 
which is the area adjacent to the injured cells that belong to the ischemic core. Cell death 
ensues in the ischemic core because of severe loss of blood flow, reduction in ATP levels and 
energy stores, ionic imbalance and metabolic failure.  The ischemic penumbra zone is defined 
by an area of reduced blood flow from collateral blood vessels but with brain tissue surviving for 
a few hours as a consequence of milder insults (Astrup et al., 1981). If the blood flow is not 
restored within this short time frame, the penumbra becomes a part of the ischemic core (Green 
et al., 2003; Durukan and Tatlisumak 2007). In response to low oxygen levels, endothelial cells 
proliferate and angiogenesis occurs primarily in the penumbra. The growth of new blood vessels 
is thought to act as a natural defense mechanism in restoring oxygen and nutrient supply to the 
damaged site (Beck and Plate, 2009). A greater density of microvessels in the penumbra has 
shown to be correlated with longer survival in stroke patients (Krupinski et al., 1994). The 
simultaneous neuronal and vascular responses in the ischemic region has been suggested to 
occur as coordinated events as was proposed during embryogenesis and postnatal 
development (del Zoppo, 2009; Park et al., 2003). 
 
1.3.1.1 Developing brain 
Neonatal asphyxia affects about 1 to 3 out of 1000 live births (Ferriero, 2004). Asphyxia is lack 
of oxygen (hypoxia) or perfusion (ischemia), which predominantly affects newborn infants 
however it can arise from anytime before, during, or after birth. It is due to a disruption in 
maternal oxygenation, placental blood flow or impairment in pulmonary gas exchange leading to 
poor oxygenation and eventually perinatal brain injury (Badawi et al., 1998; Ferriero, 2004). 
Infants born prematurely with very low birth weight usually exhibit abnormal or underdeveloped 
lungs and heart; therefore suffer from chronic hypoxia. As a consequence of the lack of oxygen 
or perfusion, various organs are damaged and most vulnerable to injury is the brain which can 
lead to hypoxia-ischemia encephalopathy (HIE). Lesions in the basal ganglia and thalamus are 
frequently observed (Ferriero, 2004). Neonatal encephalopathy is a very devastating condition 
of which 20% result in fatality before age 1 and 25% that survive are neurologically impaired 
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including mental disabilities, cerebral palsy, motor and vision problems, and epilepsy (Finer et 
al.1981; Vannucci and Perlman, 1997; Ferriero, 2004).   
 
1.3.1.2 Animal models 
Knowledge about stroke pathophysiology has been gained through studying various 
experimental animal models, mostly in rodents. In vivo models of stroke are of three types: focal 
cerebral ischemia, global cerebral ischemia, and hypoxia/ischemia as a model used in young 
animals combining vessel occlusion and hypoxic breathing (Cimino et al., 2005).  Within these 
stroke models there is also a permanent or transient form of ischemia, where reperfusion can be 
studied in the latter. Focal cerebral ischemia is usually induced by middle cerebral artery 
occlusion (MCAO). MCAO has been developed because it closely mimics ischemic stroke 
patients which exhibit a thrombotic or embolic occlusion in a large cerebral artery such as the 
middle cerebral artery (del Zoppo et al., 1992; Durukan and Tatlisumak, 2007). Lesions by focal 
cerebral ischemia are complex characterized by an ischemic core of necrotic cells, surrounded 
by an ischemic penumbra of cells that are metabolically compromised, which will eventually die 
by apoptosis and increase the size of the infarct (Durukan and Tatlisumak, 2007). The cells of 
the penumbra are of interest since they would be targeted for therapy. On the other hand, global 
cerebral ischemia is clinically relevant to cardiac arrest and asphyxia in humans. Its duration of 
insult to cause neuronal damage is shorter (5-10 minutes) than in focal cerebral ischemia (90-
120 minutes). Global cerebral ischemia is induced commonly by four-vessel occlusion, bilateral 
arterial occlusion or less commonly, due to high mortality, by cardiac arrest (Woodruff et al., 
2011). Lesions by global cerebral ischemia are associated with delayed neuronal death in the 
hippocampus, in particular CA1 region (Kirino, 1982). The neuronal death has been accepted as 
a consequence of excitotoxicity since inhibitors of glutamate receptors and GABA agonists 
reduce neuronal injury following ischemia (Choi, 1992). Although, experiments conducted to 
prevent and relieve brain injury have successfully been performed on animal models 
unfortunately neuroprotective strategies, except for therapeutic hypothermia, have not been 
successfully translated in the clinics,  
 
1.3.1.3 In-vitro models 
Most in vitro models employ primary cultures of neurons or glia from the cortex, hippocampus or 
cerebellum of newborn rats or mice. Usually, O2 is replaced by N2 gas in a hypoxia chamber, 
and cultures incubated in medium with or without glucose are transferred there. However, the 
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deprivation of oxygen (hypoxia) or oxygen and glucose (ischemia) seems to require a longer 
time to induce neuronal death in vitro than in vivo (Woodruff et al., 2011). Nevertheless, as a 
very simplified system, it can still offer some information on how a particular cell reacts which 
certainly contributes towards identifying possible mechanisms involved in ischemia, 
Another in vitro model for stroke which has been comprehensively studied is the organotypic 
hippocampal slice culture (OHC; Laake et al., 1999; Frantseva et al., 1999; Rytter et al., 2003). 
In addition to the advantages of a preserved neuronal network and contacts to native in vivo 
partners, the duration of OGD-induced neuronal death in slice cultures is shorter (15-30 
minutes) than in dissociated cell cultures. Moreover, neuronal death is localized to CA1 of 
hippocampus which closely resembles the in vivo model of global cerebral ischemia displaying 
NMDA receptor mediated cell death (Rytter et al., 2003). Whether non-NMDA ionic glutamate 
receptors are involved in OGD induced neuronal death is not as clear but 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX), an AMPA antagonist seems to suggest that they contribute 
to neuronal death induced by mild OGD (Noraberg et al., 2005). A notable difference that is 
observed in OHCs is that the kinetics of delayed neuronal death seems more accelerated in 
slice cultures (24-48 hours) than in vivo (48-96 hours; Noraberg et al., 2005). Cellular uptake of 
the fluorescent dye propidium iodide (PI) is often used to measure cell death in the slice 
cultures. Although a number of mechanisms are elicited by OGD, excitotoxicity has been the 
most popular to study using OHCs.     
 
1.3.2 EPILEPSY 
Another sequela of brain injury by excitotoxicity is epilepsy. It is a very serious common 
neurological disorder that affects approximately 1% of the population (Pitkänen and Sutula, 
2002). Epilepsy is characterized by the generation of seizures due to a long-term predisposition 
and co-morbidity of neurobiological, psychological, cognitive, and social deficits (Fisher et al., 
2005). Epileptic seizures are abnormal patterns of neuronal activity, altering neuronal excitability 
which can induce plastic changes in the cortical circuitry (Pitkänen and Lukasiuk, 2011). Status 
epilepticus (SE) is characterized by a recurrence of seizures in the brain. The etiology of 
epilepsy is unknown, but it is frequently acquired after a primary injury to the brain (i.e. trauma, 
infection, tumor, stroke, etc.). Temporal lobe epilepsy (TLE) is the most common form of focal 
epilepsy and is characterized by hippocampal sclerosis and vascular malformation (Weissberg 
et al., 2011). Stroke appears to be a major cause of TLE suggesting a neurovascular role in the 
etiology of epilepsy (Hauser et al., 1996).   
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Unfortunately, there is no cure for epilepsy.  Although, there are anti-epileptic drugs (AEDs) 
designed to inhibit seizures by enhancing the inhibitory neurotransmitter GABA or by inhibiting 
activation of Na+ channels to lower firing of action potentials. Most AEDs, however, are not very 
effective because they are prevented from gaining access to or remaining in the CNS by blood-
brain barrier transporters, mainly P-glycoprotein, a multi-drug resistant transporter which is 
specialized in drug efflux (Löscher and Potschka, 2005a, b; Bauer et al., 2008). In rare cases is 
resection of the epileptic region performed and even then patients still depend on AEDs.  
       
1.3.2.1 Developing brain 
The incidence of seizures is higher in the developing brain than the adult brain (Holmes and 
Ben-Ari, 2001). CNS disorders such as HIE, trauma, infection, congenital defects in cortical 
growth, neurovascular malformation, or a previous episode of febrile seizures are some causes 
of epilepsy in the infant and it seems that any disturbances in the development of the immature 
brain, such as abnormal neuronal migration or synaptic maturation may give rise to epilepsy 
(Ben-Ari and Holmes, 2006). Interestingly, the immature brain appears to be more resistant than 
the mature brain to seizure-induced neuronal injury (Ben-Ari and Holmes, 2006), which has 
been also observed in SE models of younger animals less than 2 weeks of age (Holopainen, 
2008).  
1.3.2.2 Animal models 
Rodent models have contributed a great deal to understanding the mechanisms underlying the 
formation of seizure-generating neuronal circuits (Pitkänen and Lukasiuk, 2011). The two most 
common models are the poststatus epilepticus model and kindling model. The poststatus 
epilepticus model induces seizures by exposing systemically or intracerebrally to excitotoxic 
agents, such as kainic acid or pilocarpine (Walker et al., 2002). The kindling model uses 
repeated weak electrical stimulation to excite neurons by implanting electrodes to certain brain 
regions such as the amygdala or hippocampus (Sayin et al., 2003). Eventually, the 
administration of kainic acid or pilocarpine or the weak electrical stimulations alter the neuronal 
activity and are able to produce spontaneous seizures that later result in neuronal loss in the 
hippocampus. The neuronal loss in CA1, CA3, and hilus of hippocampus of the poststatus 
epilepticus model in adult animals is similar to the human form of disease (Gorter et al., 2003) 
and therefore is a common animal model of TLE. Recently, angiogenesis and BBB disruption 
have been observed in a pilocarpine-induced SE rodent model (Rigau et al., 2007; van Vliet et 
al., 2007).  
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1.3.2.3 In-vitro models  
Organotypic slice cultures have been also used as in vitro models of epilepsy. Since the 
hippocampal lesions are often associated with epilepsy, such as TLE, OHCs have been 
preferred. Glutamate and its analogues such as NMDA, KA, and AMPA have been used to 
induce neural excitotoxicity and neuronal death in OHCs derived from 6-7 day old postnatal 
animals (Noraberg et al., 2005).  Frequently, KA is used to induce neuronal damage in OHCs 
since the regional specific neuronal death (CA1 and CA3) and reorganization of the 
hippocampal circuitry are reported to be similar to epileptic models of SE (Scharfman, 1994; 
Okazaki et al., 1999; Holopainen et al., 2004). More recently, angiogenesis and absence of 
blood-brain barrier tight junction protein, ZO-1 have been reported in OHCs exposed to KA 
(Morin-Brureau et al., 2011).   
     
1.4   NEURONAL DEATH 
The evolution of injury and cell death in part depends on the brain region, the cellular 
constituents, and the extent of insult. In hypoxia-ischemia as well as in status epilepticus, 
neuronal death occurs. In ischemia, the physiological disruption by oxygen and glucose 
deprivation does contribute to cell death but the cascade of neuronal damage begins at the 
onset of excitotoxicity which is mediated by activation of glutamate receptors (Fig.2; Dirnagl et 
al., 1999). Cell dysfunction and a majority of neuronal damage is due to accumulation of 
glutamate in the extracellular matrix that activates glutamate receptors (NMDA, AMPA, and KA) 
allowing toxic increases in intracellular calcium in the CNS (Choi, 1992).  The ionic imbalance in 
calcium and activation of AMPA receptors result in high intracellular levels of sodium which is 
detrimental as it can impair cell function and induce cell death at earlier time points after 
ischemia (Won et al., 2002).  Multiple signaling pathways however can be activated by calcium 
or by activation of calcium dependent enzymes which may signal release of free radicals 
leading up to cell death (Wang et al., 2005). This variation in type of cell death suggests that the 
consequences of cerebral ischemia are complex. In fact, the events leading up to cell death 
trigger a fairly well-defined spatio-temporal pattern of pathophysiologic events, known as the 
ischemic cascade, which begins with and not strictly in order but overlapping, excitotoxicity, 
spreading depression, formation of oxygen free radicals, tissue acidosis, followed by 
inflammation and cell death by apoptosis (Dirnagl et al., 1999; Durukan and Tatlisumak, 2007).     
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Figure 2. Ischemic Cascade. A number of mechanisms occur in ischemia leading up to cell death 
including excitotoxicity, depolarization, calcium overload, production of free radicals, tissue 
acidosis, mitochondrial dysfunction, microglial activation, and inflammation (A). The ischemic 
cascade is spatio-temporal occurring from hours-to-days (B) (Dirnagl et al., 1999)    
 
1.4.1 NECROSIS AND APOPTOSIS 
Ischemic cell death may arise in two forms: necrosis and apoptosis. Depending on the extent 
and duration of injury the cells will not only suffer a functional but also a structural breakdown. 
Disturbances in ion homeostasis can be accompanied by water influx which creates an 
imbalance in the cell volume and forces the cell to swell and lyse, undergoing necrosis. 
Apoptosis is a physiological mechanism of which cell death is programmed to respond to a 
A. 
B. 
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particular insult and can be triggered by a number of processes, including excitotoxicity, free-
radical formation, inflammation, mitochondrial and DNA damage, and cytochrome c release 
from mitochondria (Fisher and Schaebitz, 2000; Mergenthaler et al., 2004; Sugawara et al., 
2004). In apoptosis, cell membranes and organelles remain intact, while the cell shrinks along 
with chromatin condensation, DNA fragmentation, and cleavage into small membrane bound 
bodies (Love, 2003; Mergenthaler et al., 2004). Ischemia-induced neuronal death has been 
characterized by a mixture of necrosis and apoptosis, however, in focal cerebral ischemia 
necrosis is predominant in the ischemic core while apoptosis is found in the penumbra (Smith, 
2004). Increasing morphological and biochemical data have indicated that in the ischemic brain 
both apoptosis and necrosis may occur simultaneously and since both processes may not 
always be mutually exclusive a hybrid term for the continuum of the two forms of cell death 
‘aponecrosis’ has been proposed (MacManus and Buchan, 2000; Unal-Cevik et al., 2004).  
1.4.2 DELAYED NEURONAL DEATH 
Depending on the type of insult certain subfields of the hippocampus is particularly prone to 
damage. Pyramidal neurons in the hippocampal CA1 subfield have been extensively studied 
and found to be selectively vulnerable to injury by ischemia in experimental animals and in 
humans after ischemic injury (Ito et al., 1975; Kirino, 1982; Petito et al., 1987). Although, the 
selective CA1 vulnerability to ischemia has not been completely understood, intrinsic differences 
between the hippocampal subfields have been proposed to be involved (Kirino et al., 1984). 
However, CA1 cell death does not immediately appear following brief ischemia but develops 
slowly, taking at least 2 days to occur (Kirino, 1982; Kirino and Sano, 1984). Furthermore, 
energy metabolism (Arai et al., 1986) and electrical activities (Suzuki et al., 1983) in neurons 
appear normal and unaffected up to 24 hours. However, between 2 and 4 days after ischemia 
the cell undergoes an irreversible change which does not allow it to be rescued by reperfusion 
and therefore dies. As a result, this slow development in CA1 cell death has been labeled as 
delayed neuronal death or DND (Kirino and Sano, 1984). This type of cell death has been 
characterized as apoptotic (Nitatori et al., 1995).      
         
1.5   BLOOD-BRAIN BARRIER 
The blood-brain barrier (BBB) is vitally important to the CNS. Analogous to the function of a cell 
membrane which maintains and balances the composition of the intracellular fluid, the BBB 
maintains and balances the extracellular milieu of the nervous system. The BBB includes the 
blood-cerebrospinal fluid barrier (BCSFB), blood-retinal barrier, and blood-spinal cord barrier. 
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Other barriers interfaces that separate the blood from the CNS are located in the arachnoid 
epithelium and the choroid plexus epithelium. There is no BBB in the circumventricular organs 
(neurosecretory or chemosecretory sites) but the ependyma and the surrounding glia contain 
tight junctions that prevent leakage into the brain or CSF (Abbott, 2005).  
Experiments performed by Paul Ehrlich in 1885 were the first to show that a barrier existed 
between the blood and the brain in the CNS. Evans blue dye was intravenously injected in rats 
which demonstrated all regions except the brain to be infused with the dye (Ehrlich, 1904). 
However, not until 1913, when his graduate student Edwin E. Goldmann injected the dye in the 
cerebrospinal fluid (CSF) and showed the opposite effect where only the CNS was infused with 
the dye and not the blood vessels that his hypothesis for a BBB existing was truly corroborated. 
But it was in 1898 that Lewandowsky introduced the term ‘blood-brain barrier’ after he and 
colleagues observed neurotoxic compounds to selectively affect the CNS by intracerebral 
injection and not by intravenous administration. Remarkably, it was not until over half a century 
later in 1967 that Reese and Karnovsky identified by electron microscopy that the endothelium 
was the main component making up the BBB. The endothelium of the CNS is unlike the one of 
the periphery because it lacks fenestrations and contains tight junction proteins (Bauer et al., 
1993; Stewart and Hayakawa, 1994).  
Importantly, the BBB functions to protect the CNS from toxins and blood-borne pathogens that 
may travel by way of the vascular system. It contains both transcellular and paracellular 
pathways for non-permeable substances to pass through the brain but allows only essential 
molecules, such as oxygen and glucose to enter the brain, as well as maintaining ion 
homeostasis in the CNS (Fig. 3). In addition the BBB prevents neurotransmitters from escaping 
the brain (synaptic regions are highly vascularized) and regulates immune surveillance with 
reduced inflammation and cell damage (Abbott, 2005). 
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Figure 3. Paracellular and Transcellular pathways of the Blood-brain barrier. The BBB protects the 
brain by regulating the accessibility of molecules to the CNS. The paracellular pathway is 
regulated by tight junction proteins that allow passage of certain water soluble molecules (a). The 
transcellular pathway is regulated by various transporters and receptor-mediated and adsorptive-
mediated systems, which control the passage of other essential molecules that support to 
maintain an optimal environment for cerebral functions (b, c, d, and e) (Abbott et al., 2006) 
1.5.1 BBB INDUCTION 
As mentioned previously, the endothelial cells of BBB lack fenestrations and additionally they 
have low pinocytotic vesicles, and contain more mitochondria than endothelial cells of the 
periphery (Fenstermacher et al., 1988; Sedlakova et al., 1999; Oldendorf et al., 1977). Grafting 
experiments of embryonic quail tissue revealed that induction of capillaries in non-vascularized 
brain tissue transplanted to the coelomic cavity possessed lower pinocytotic vesicles and higher 
mitochondrial content compared to somite grafts of dorsal mesoderm transplanted to the 
cerebral ventricles, suggesting that the origin of the BBB is neuronal (Stewart and Wiley, 1981). 
Recently, the induction and specialization of the CNS vascular system and BBB has been 
shown to be controlled by the signaling between the neuroepithelium and the vascular 
endothelium via the canonical wingless-type protein (Wnt) and β-catenin pathway (Stenman et 
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al., 2008; Liebner et al., 2008; Daneman et al., 2009; Liebner and Plate, 2010). Mice generated 
to develop without wnt7a/wnt7b expressed in the neuroepithelium or beta-cateninin in 
endothelial cells displayed CNS specific abnormal angiogenesis. The mice died around E12.5 
with severe CNS hemorraging. The endothelial and pericytes were strongly decreased in 
number and the vascular morphology was malformed. BBB formation with respect to the 
expression of GLUT1 and tight junction proteins were also reduced.  The fact that Wnt signaling 
is critical for the proper development and function of the CNS; that it also modulates the 
formation of blood vessels and the specialization of BBB further underlines the importance of 
the relationship between then nervous and vascular systems (Stewart and Wiley, 1981).       
1.5.2 BBB COMPOSITION 
The endothelial cells that make up the inner lining of the vasculature express tight junction 
proteins (e.g. occludin, claudin 1/3 and 5, and zonula occluden-1 to 3) and transporter proteins 
such as glucose transporter 1 and P-glycoprotein allow close inter-endothelial cell connections 
and regulate transport across the endothelium, respectively (Gonzalez-Mariscal et al., 2003; 
Guo et al., 2005: Schinkel et al., 1999). The molecular composition of the BBB, in particular the 
tight junctions (TJs) and adherens junctions (AJs) have been sought after for over a decade 
(Furuse et al., 1993, 1998a, b; Ando-Akatsuka et al., 1996; Morita et al., 1999; Balda and 
Matter, 2000; Tsukita and Furuse, 1999, 2000; Heiskala et al., 2001; Fig. 4).  Most of the 
findings have been based on epithelial and endothelial cells of non-neuronal origin. In freeze-
fracture replicas, the TJ particles appear similar to connexons of gap junctions (Wolburg and 
Lippoldt, 2002). The assembly of TJs occurs along the outer leaflet between adjacent 
endothelial membranes, where the extracellular domains of TJs form homo- and heterodimers 
interconnecting the plasma membranes merging into “kiss” points (Kniesel et al., 1996).  In 
freeze fracture replicas, the outer leaflet is referred to as the protoplasmic fracture face (P-face) 
and the inner leaflet is the exo-cytoplasmic fracture face (E-Face) of endothelial or epithelial 
cells. The P-face has been associated with a more mature endothelial barrier with a high 
transendothelial electrical resistance (TEER) than the E-face (Butt et al., 1990). Therefore, the 
complexity of strands and their association with the P-face or E-face have been considered as 
parameters in determining the functional quality of tight junction proteins (Wolburg and Lippoldt, 
2002). Depending on the vascular bed, peripheral endothelial cells possess a lower level of P-
face strands than epithelial cells, whereas brain endothelial cells have the highest P-face 
association (Wolburg and Lippoldt, 2002). Despite the large amount of research that has been 
conducted on elucidating the structural components involved in formation and maintenance of 
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the BBB, the cellular and molecular mechanisms controlling its maintenance are still poorly 
understood.                    
1.5.2.1 Tight junctions 
With the exception of small (< 400 Da) and lipophilic molecules, endothelial cells of brain 
capillaries are able to restrict movement of blood borne solutes to the brain due to TJs. Indeed 
TJs represent one of the main constituents that distinguish the endothelium in the CNS from the 
periphery as it is 50-100 times tighter (Rubin and Staddon, 1999; Abbott et al., 2006). TJ 
proteins are considered to regulate the permeability of the BBB and maintain endothelial cell 
polarity, known as the “barrier” and “fence” functions, respectively (Bazzoni and Dejana, 2004). 
The cell-cell juncture is complexed with other transmembrane proteins, such as adherens 
junctions (AJ), gap junctions, and desmosomes, but TJs are the most apical. The carboxy 
termini of the junctional proteins are linked to cytoplasmic accessory proteins which recruit the 
actin filaments of the endothelial cells forming a continuous capillary structure (Fig. 4).  
Occludin is a 65 kDa phosphoprotein with 4 transmembrane spanning domains, 2 extracellular 
and 1 intracellular loops and a cytoplasmic amino and carboxyl terminus. It was the first tight 
junction protein to be identified (Furuse et al., 1993). The function of occludin in the paracellular 
seal has not been determined but appears to have a minor role as barrier formation was normal 
in occludin-deficient mice (Saitou et al., 2000), although, in some diseases, BBB dysfunction 
has been associated with reduced occludin expression (Bolton et al., 1998; Huber et al., 2002; 
Brown and Davis, 2005). Claudins are 20-27 kDa proteins with two extracellular and intracellular 
loops (Mitic et al., 2000). Claudin-1/3, 5, and 12 have been reported to be associated with the 
BBB (Morita et al., 1999; Liebner et al., 2000; Lippoldt et al., 2000). Claudin-5 deficient mice die 
within 10 hours after birth from fatal hemorrhage, suggesting that it necessary for BBB formation 
(Nitta et al., 2003). Zonula occludens (ZO-1, -2, and -3) are membrane-associated guanylate 
kinase-like-protein (MAGUKs) with 3 PDZ domains, 1 SH3 domain, 1 guanyl kinase-like domain 
(GUK), which are all important for protein binding. They are the third major type of BBB TJs and 
are the largest in size between130-220 kDa (Haskins et al., 1998).They are phosphoproteins 
expressed in endothelial, epithelial and astroglial cells (Howarth et al., 1992). The TJs are linked 
to the actin cytoskeleton by ZO-1 (Fanning et al., 1998). ZO-1 is 220 kDa and functions also as 
a signaling molecule conveying information about the TJs to the interior of the cell (Hawkins and 
Davis, 2005). ZO-2 is 160 kDa, similar in sequence to ZO-1 and can functionally substitute ZO-
1, in vitro (Gumbiner et al., 1991; Umeda et al., 2004). Under stress conditions and cell 
proliferation both ZO-1 and -2 translocate into the nucleus, in vitro (Gottardi et al., 1996; Islas et 
al., 2002). ZO-3 is 130 kDa and binds to claudins, but less is known of its expression at the BBB 
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(Itoh et al., 1999).  Additional accessory proteins include cingulin, which is a myosin-like protein 
and binds to ZO-1, junctional adhesion molecule 1 (JAM-1), and myosin at the globular domain 
and to other cingulin proteins and actin at the tail (Citi et al., 1989). Less well known accessory 
proteins but are part of the TJ complex are AF-6 and 7H6 (Yamamoto et al., 1999; Zhong et al., 
1994)              
1.5.2.2 Adherens junctions 
Along the blood vessels at the junctional zone are also present, the adherens junctions. The 
adherens junctions assist in stabilizing the cell-cell contact. They are formed by cadherins, 
which are transmembrane adhesion proteins. In general the cadherins bind to catenins with 
their carboxy-terminal domain to link on with anchoring proteins that bind to actin. It was shown 
that in order for tight junction proteins to develop and be organized at the cell-cell juncture, the 
formation of adherens junctions was a prerequisite (Dejana, 2004). Vascular endothelial (VE) 
cadherin and cadherin-10 are Ca2+ regulated proteins that mediate cell-cell adhesion and have 
been shown to be involved in development and maintenance of BBB and BCSFB (Williams et 
al., 2005; Taddei et al. 2008). The cadherins maintain vessel integrity through activation of 
phosphoinositide 3-kinase (PI3K) which signals actin cytoskeletal rearrangement or by 
complexing with VEGFR2 to signal VEGF expression (Lampugnani et al., 2002; Carmeliet and 
Collen, 1999). Disruption of AJs can lead to BBB permeability (Abbruscato and Davis, 1999), 
but TJs are more involved in restricting the paracellular route (Romero et al., 2003). 
                                
Figure 4. Tight junction proteins of the Blood-Brain Barrier.  A tight endothelial barrier is due to 
the homo- and heterodimerization of TJs (occludin, claudin 3/5, JAM) forming a junctional 
complex linked to the actin cytoskeletal by scaffolding proteins (ZO1-3 and cingulin) (Hawkins and 
Davis, 2005).    
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1.5.2.3 Transporters 
Since tight junctions and adherens junctions keep molecules from passing through the BBB 
paracellularly, possible routes for compounds to cross the BBB are through the transcellular 
pathways. As briefly mentioned the BBB consists of a system of transporters that are associated 
with the transcellular pathway (Fig. 5). The transporter proteins are present on the luminal and 
abluminal endothelial membranes and are responsible for regulating the traffic of molecules 
entering and exiting the CNS. A substantial portion of metabolic substrates crossing the BBB 
are hydrophilic (e.g. glucose and amino acids) and are able to pass the BBB by specialized 
Solute Carrier (SLC) transporters, but xenobiotics such as drugs and toxins are pumped out by 
the ATP-binding cassette (ABC) transporter systems. However, lipophilic and hydrophobic 
compounds of less than 400 Da (e.g. ethanol, caffeine, and nicotine) are able to efficiently cross 
the BBB by lipid-mediated transport which is passive diffusion (Pardridge, 1999). Some 
macromolecules (peptides and proteins) cross the BBB by receptor or adsorptive-mediated 
transcytosis (Abbott et al., 2006).   
There are a number of BBB SLC transporters since many solutes and nutrients are polar 
molecules (e.g. glucose, amino acids, nucleosides, and monocarboxylic acids) that cannot cross 
cell membranes by passive diffusion (Abbott et al., 2010). For example, the transport of glucose 
across the BBB is mediated by the endothelial transporter GLUT-1 through facilitated diffusion 
(Fig. 5). Dick et al. (1984) were the first to identify GLUT1 in the BBB of rats. GLUT1 is a 
member of the SLC2 gene family which consists of 13 members and is a uni-porter which only 
carries glucose. The 55 kDa isoform of GLUT1 is found in the BBB and is more glycosylated 
than the 45 kDa GLUT1 isoform expressed in astrocytes (Simpson et al., 2007). The expression 
of GLUT1 is vital for brain and vascular development (Stenman et al., 2008; Liebner et al., 
2008). It has been demonstrated that changes in GLUT1 activity in endothelial cells can be 
activated by signals released from neuronal cells in rats that have been seizure-induced 
(Cornford et al., 2000). The increased transporter expression in the endothelial plasma 
membrane is a result of increased stability of the GLUT-1 mRNA or by translocation of 
transporters from the intracellular pool (Farrell and Pardridge, 1991; Simpson et al., 2001). The 
transport of glucose across the BBB is passive and not rate limiting under physiologic 
conditions. However, under pathological conditions such as after hypoxia or ischemia, transport 
capacity of GLUT1 can be modulated (Simpson et al., 2007; Boado and Pardridge, 2002). Also, 
AD neurodegeneration has been proposed to be associated with GLUT1 downregulation 
(Kalaria and Harik, 1989). Examples of other solute carriers are provided by Abbott et al. (2010).   
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Some transporters may not always be symmetrically distributed on the plasma membranes of 
endothelial cells. Efflux transporters are generally located on the luminal (apical or blood) side of 
cerebral endothelial cells. Due to this polarization of transporters along the endothelium, the 
uptake of xenobiotics in the brain is thought to be hindered. The major efflux transporters of the 
BBB are P-glycoprotein (P-gp), members of multidrug resistance-associated protein (MRP1-6) 
family, and breast cancer resistance protein (BCRP) (Begley, 2004; Löscher and Potschka, 
2005b, Dauchy et al., 2008). They belong to the ABC family because they contain an ATP 
binding domain allowing them to bind and hydrolyze ATP for energy to pump out compounds 
against a concentration gradient. They are endogenously expressed in normal cells and 
overexpressed in tumor cells. Therefore anti-cancer or tumor agents have not been able to work 
effectively, hence the names of the efflux transporters, “multidrug” and “breast cancer” 
resistance proteins. Constitutive expression of P-gp seems necessary to protect the brain from 
potential toxic compounds since P-gp deficient mice show an increase in neurotoxicity of 
various drugs (Schinkel et al., 1994).  Furthermore, P-gp inhibitors appear to improve drug 
penetration and seem promising to overcome drug resistance however more studies are 
necessary before being clinically relevant (Löscher and Potschka, 2005b). Other BBB 
transporters include the excitatory amino acid transporters (EAAT1-3), which remove glutamate 
out of the brain, but for more information on other BBB transporters refer to the review by Abbott 
et al., (2010).  
 
1.5.2.4 Enzymes 
The BBB also contains a variety of intracellular and extracellular enzymes that neutralize drugs 
and nutrients, supporting a ‘metabolic barrier’. For example, peptidases and nucleotidases, 
which are ecto-enzymes metabolize peptides and ATP, respectively and monoamine oxidase 
and cytochrome P450 which are intracellular enzymes inhibit neuroactive and toxic compounds 
(Abbott et al., 2006). Also, some enzymes are located on the luminal surface (e.g. alkaline 
phosphatase and γ-glutamyl transpeptidase) and some on the abluminal surface (e.g. Na+-K+ 
ATPase and sodium-dependent neutral amino acid transporter) thus are also responsible for 
maintaining the polarity of the endothelial membrane. Overall, this enzymatic barrier functions to 
prevent harmful substances from entering the CNS (Abbott et al., 2006).  
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Figure 5. Transporters at the Blood-Brain Barrier. The transcellular pathways of the BBB include 
(a) passive diffusion (b) ABC transport efflux (c) solute carrier mediated transport (d) receptor 
mediated (RMT) and adsorptive mediated transport (AMT) and (e) monocyte transmigration. A list 
of molecules is given below each transport system. Arrows indicate the direction of transport. 
(Abbott et al., 2010)    
1.6   NEUROVASCULAR UNIT  
The term neurovascular unit (NVU) was introduced in 2001 as a physiological unit made up of 
neurons, non-neuronal cells (e.g. astrocytes and microglia) and the endothelium (Lo et al., 
2003; Iadecola, 2004; Hawkins and Davis, 2005). It is a conceptual framework that connects 
neuronal function with the vasculature as a structural unit linked by astrocytes (Fig. 6; del 
Zoppo, 2012). The NVU includes the endothelium attached by pericytes to the abluminal 
membrane ensheathed by the basal lamina that is surrounded by astrocytic end-feets which 
wrap around the cerebral capillaries (Hawkins and Davis, 2005). It has been known for a while 
that soluble factors released by astrocytes and by contact-mediated mechanisms support 
formation and maintenance of the BBB (Rubin et al., 1991; Tao-Cheng et al., 1987). Less is 
known regarding pericytes, neurons, and perivascular microglial cells but they have been 
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suggested to be involved in changing vascular properties and function (Hawkins and Davis, 
2005).  
 
Figure 6. The Neurovascular Unit at the Blood-Brain Barrier. The cerebral capillary endothelium of 
the BBB is supported by a basal lamina of extracellular matrix proteins and is in constant 
interaction with astrocytes, pericytes, neurons and perivascular microglia that release factors 
involved in maintaining a tight endothelial barrier (Abbott et al., 2006).   
1.6.1 STRUCTURE: CELL-CELL INTERACTION 
Camillo Golgi was the first to observe that glial cells were in contact with blood vessels. The 
close distance between astrocytic endfeets and cerebral endothelial cells strongly suggest 
astrocytes to have a major influence in BBB function. Many in vitro studies have indicated the 
importance of astrocytes in formation and maintenance of tight junction proteins (Bauer and 
Bauer, 2000). They have been shown to release many kinds of growth factors such as basic 
fibroblast growth factor (bFGF/FGF2), transforming growth factor-beta (TGF-β), glial derived 
neurotrophic factor (GDNF), and angiopoietin 1 (ANG-1) that are effective in modulating the 
endothelium as well as regulating the permeability of the BBB (Abbott et al., 2006). Since 
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astrocytes arise after birth when angiogenesis is finished, they are considered to be not 
essential for angiogenesis but rather important for BBB formation and maintenance (Bauer and 
Bauer, 2000). The fact that astrocytes can communicate with nerves and vessels also indicates 
that they function in mediating signals between the nervous and vascular systems. Furthermore, 
astrocytes have water channels known as aquaporin4 (AQP4), which are involved in regulating 
the water content in the brain. They are found along specialized membrane domains, such as 
the astrocytic endfeets that are in contact with blood vessels or astrocytic membranes that 
ensheathe glutamatergic synapses (Nielsen et al., 1997; Nagelhus et al., 2004).  More recently, 
expression of AQP4 by immunohistochemistry was found along blood vessels and in astrocytes. 
Furthermore, it was expressed in a laminar-specific pattern within the mouse hippocampus (Hsu 
et al., 2011). Interestingly, AQP4 was highly expressed in CA1 and DG subfields suggesting the 
importance of water regulation in these regions (Hsu et al., 2011). Additionally, astrocytes have 
glutamate transporters for neurotransmitter signaling and processing (Rothstein et al., 1996). 
Under pathological conditions they can become reactive known as gliosis and activate an 
inflammatory response by releasing cytokines (Pekny and Nilsson, 2005).     
However, in much closer contact to the cerebral endothelial cells are pericytes. Like astrocytes, 
these cells which were once viewed as bystanders have recently been considered quite 
essential for vessel development and BBB formation. They are referred also to as mural cells 
and are related to vascular smooth muscle cells which function to stabilize the vasculature. The 
precursor cells of pericytes express platelet derived growth factor receptor-beta (PDGFR-β) and 
are recruited to the endothelium by expression of PDGF-β in endothelial cells (Leveen et al., 
1994; Betsholtz et al., 2001). Expression of TGF-β is upregulated once the two cells are in 
contact and the pericyte precursors differentiate into the mature form aiding in the proper 
formation and stabilization of the vasculature (Bergers and Song, 2005). Interestingly, the CNS 
contains the most abundant number of pericytes and this is thought to be important for 
maintaining the BBB. Recently, pericytes were shown involved in the polarization of astrocytic 
endfeets during BBB development (Armulik et al., 2010). Furthermore, PDGF-β knockout mice 
revealed their involvement in regulating blood flow, which was reminiscent of hypoperfusion that 
occurs in AD brains (Bell and Winkler et al., 2010). 
In order to meet the metabolic needs of the nervous system, nerves and vessels must 
communicate in a coordinated fashion to direct blood flow accordingly, although the exact 
mechanisms remain elusive. VEGF released by neurons can act in an autocrine and paracrine 
manner affecting both vascular and neuronal cells (Ogunshola et al., 2002). As mentioned 
previously neuronal signaling can also be transferred via astrocytic endfeets to the endothelial 
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cells. Whether neurons are involved in BBB induction is not known. However, a higher γ-
glutamyl transpeptidase activity which correlates with BBB maturation has been reported in co-
culturing experiments of cerebral endothelial cells with either neurons or neuronal plasma 
membranes than with glial cells (Tontsch and Bauer, 1991).  As mentioned neurons and vessels 
share similar growth factors and guidance molecules in neurogenesis and angiogenesis. In 
neurovascular niches, neuroblasts have been reported to migrate along vessel walls (Palmer et 
al., 2000). Neural stem cells proliferate and self-renew when co-cultured with endothelial cells 
implying that the vessel environment supports neural stem cells (Shen et al., 2004). Indeed, the 
expression of neuroprogenitor cells and endothelial precursor cells together during 
neurogenesis and angiogenesis suggest that they may have an important interaction and this 
will be critical to understand in repair after brain injury. Direct signaling between blood vessels 
and nerves is found in the vaso vasorum and the perivascular autonomic nerve fibers (Kummer 
and Haberberger, 1999; Schratzberger et al., 2000).   
Brain macrophages consist of microglia and perivascular macrophages. They are important in 
CNS defense, in particular with immune surveillance. They can release cytokines which signal 
an immune response to upregulate adhesion molecules in endothelial cells for recruitment of 
leukocytes from the blood into the CNS (Zlokovic, 2008).   
Cell-cell contacts of the NVU are maintained by the extracellular matrix (ECM) of the basement 
membrane which is also known as the basal lamina that is composed of mostly collagen type 
IV, laminin, and fibronectin (Wolburg and Lippoldt, 2002; Chen and Shuaib, 2007).  Perlecan, 
nidogen, and other proteoglycans are present to a lesser extent. Integrin receptors of cerebral 
endothelial cells link onto the ECM proteins which anchors the endothelial cells to the basement 
membrane. Thus cell-cell signaling within the NVU is maintained and TJ proteins are preserved 
by the basal lamina (Hawkins and Davis, 2005). Heparin sulfate proteoglycan agrin has been 
shown to be important in maintenance of BBB (Barber and Lieth, 1997). Absence of collagen 
type IV, laminin, and fibronectin as observed in focal cerebral ischemia/reperfusion results in 
BBB permeability leading to cerebral hemorrhage (Hamann et al., 1995).  Also, present in the 
ECM are noncellular proteolytic systems including plasmin, cathepsins, and matrix 
metalloproteinases (MMPs) secreted by cells of the NVU which appear involved in degrading 
the basal lamina and remodeling of the vasculature during ischemia (Chen and Shuaib, 2007; 
Zlokovic, 2006).  Impairment of the NVU and BBB breakdown is thought to be associated with 
these proteases (Fig. 7; Lo et al., 2003).  
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1.6.2 FUNCTION 
The NVU is involved in regulating many processes including hemodynamic neurovascular 
coupling, microvascular permeability, matrix interactions, neurotransmitter inactivation, 
neurotrophic coupling, and angiogenic / neurogenic coupling.  The execution of these activities 
seems dependent on the paracrine signaling between the different cell types of the NVU 
(Zlokovic, 2008). The signaling mechanisms between the various cells will be important to 
elucidate as well as the roles that each play during development, maturation, maintenance, and 
disease. As cell-cell signaling is important for the preservation of the NVU any disruption of the 
cellular interaction leads to vascular damage and BBB breakdown.        
1.7   BLOOD-BRAIN BARRIER DISRUPTION 
Under physiological conditions the BBB is rather impermeable to many physical and chemical 
insults. In contrast, BBB dysfunction is characterized by increased permeability of cerebral 
vessels, disassembly of junctional protein complexes, and alterations in matrix adhesion 
receptors (Hawkins and Davis, 2005; Sandoval and Witt, 2008; Milner et al., 2008). Depending 
on the type of brain injury, BBB permeability has been conjectured to occur as a primary event 
such as with multiple sclerosis (Floris et al., 2004) or as a consequence of the pathology as in 
ischemic stroke (Ilzecka, 1996; Albayrak et al., 1997) and traumatic brain injury (Morganti-
Kossmann et al., 2002) or even independent of excitotoxic nerve damage (Chen et al., 1999). 
Although, the mechanisms of BBB dysfunction are not completely understood, the 
accompaniment of BBB breakdown with CNS injuries suggests that the endothelial barrier plays 
an important role that exacerbates disease or may contribute to development of other disorders 
(Oby and Janigro, 2006). BBB impairment results in decrease of nutrients, increase of toxins, 
ionic imbalance and inflammation in the CNS. In an in vitro model of ischemia, an upregulation 
of matrix proteases have been reported to alter the integrity of BBB by breaking down matrix 
adhesion receptors and inducing loss of cell-cell interactions between endothelial cells and 
astrocytes (Milner et al., 2008). Interestingly, endothelial cells can release permeabilizing factors 
such as nitric oxide (NO) and ATP, which can act on their associated endothelial receptors in an 
autocrine manner (Abbott et al., 2006; 2005).  Disturbances in BBB TJs (Abbruscato and Davis, 
1999) and increased permeability through the transcellular route (Plateel et al., 1997; Cipolla et 
al., 2004) have also been reported following hypoxia and hypoxia/reperfusion. Activation of 
transcription factors, nuclear factor-kappaB and hypoxia-inducible factor-1 (Witt et al., 2005) and 
upregulation of growth factors such as VEGF induce BBB permeability, in vivo (van Bruggen et 
al., 1999). Inflammatory mediators have been well known for modulating BBB permeability 
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(Abbott, 2005). However, the CNS is an immune privileged site and cytokines produced in 
response to peripheral damage are not able to enter the CNS unless it has been compromised 
by a primary injury or infection. As part of BBB immune surveillance, astrocytes and microglia 
may respond by releasing inflammatory cytokines, such as IL-1β, TNF-α, IL-6 and 
cycloxygenase-2 that affect TJ stability (Abbott, 2005). The BBB disruption may allow immune 
cells to enter as part of the inflammatory response through monocyte transmigration (Persidsky 
et al., 2006) as well as making the CNS vulnerable to toxins and pathogens that do further 
harm. As cells of the NVU are exposed to activated macrophages, the inflammatory response 
persists and BBB disruption continues (Persidsky et al., 1999). In experimental models of MS, T 
cells and monocytes appear to cause BBB disruption (Seeldrayer et al., 1993). Thus depending 
on the disease as in MS, the impairment of BBB may occur as an early event (Floris et al., 
2004). Nonetheless, the preservation of junctional complexes and the cells of the NVU are 
integral to BBB function (Fig. 7) and suggest that promising therapies should be targeted to 
protecting all these components for treatment and prevention of neurological diseases.  
 
                        
 
                     Figure 7. Contributing factors to loss of NVU and BBB dysfunction (Lo, 2003) 
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1.8   INTERVENTIONS FOR CEREBRAL ISCHEMIA 
The aim of most interventions for cerebral ischemia is mainly neuroprotection. There are a 
number of ways to promote neuronal survival which is to reduce the infarct volume and death of 
vulnerable cells. Following cerebral ischemia, the cascade of pathophysiological events leading 
to cell death is complex. As discussed depolarization and activation of voltage-gated calcium 
channels and release of excitatory amino acids, such as glutamate occur, followed by activation 
of glutamate receptors that continue increasing intracellular calcium leading to release of 
enzymes producing free radicals and eventually neuronal death (Dirnagl et al., 1999). 
Therefore, inhibiting intracellular calcium, activation of enzymes and reducing glutamate 
excitotoxicity have all been a predominant focus in designing therapies for cerebral ischemia. 
However, successful experiments carried out in animal models have not been able to yield 
promising outcomes in the clinics.         
1.8.1 ANTI-THROMBOTICS 
In acute ischemic stroke, early restoration of blood flow accompanied by anti-thrombotics is a 
common treatment. During the 1960’s, complications with brain hemorrhaging occurred with 
thrombolytic drugs, such as streptokinase, which was discouraging (Wahlgren and Ahmed, 
2004). However, tissue-type plasminogen activator (t-PA), a protein that is naturally produced 
and dissolves blood clots is currently the only approved anti-thrombotic therapy by the Food and 
Drug Administration (FDA) for acute ischemic stroke (NINDS, 1995). Restoring blood flow by 
tPA is critical for survival when given within 3 hours after stroke onset but is associated with a 
high risk of hemorrhage into the ischemic tissue if the treatment is provided after this time 
window, suggesting the primary importance of rescuing the cerebral vasculature by re-
establishing blood flow in limiting ischemia. Currently about 2-5 % of stroke patients are eligible 
for this thrombolytic therapy (Donnan et al., 2011). In experimental models tPA may induce 
excitotoxicity (Nicole et al., 2001) or blood-brain barrier disruption by activating matrix 
metalloproteinases (Wang et al., 2003). Combination therapies have been considered to 
lengthen the tPA therapeutic window while reducing adverse effects of reperfusion and 
plasminogen activation (Liu et al., 2004; Cheng et al., 2006).  
1.8.2 NEUROPROTECTANTS  
Since anti-thrombotics are mainly effective during acute ischemic injury other interventions are 
necessary for those stroke patients which are uneligible for tPA therapy. Furthermore, the 
evolution of brain injury in a majority of stroke patients is rather slow occurring over a period of 
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hours-to-days following an attack.  As previously eluded, neurons of the ischemic core are 
necrotic, and neurons of the penumbral region can be protected if blood flow and oxygenation 
are resupplied in time (Green et al., 2003; Durukan and Tatlisumak 2007). Therefore, these 
neurons of the penumbral region are of interest for designing neuroprotective agents (Ginsberg 
et al., 1999). Many experimental studies have been conducted in various animal models of 
stroke showing incontrovertible positive effects in reduced infarct size and mortality rate with 
different types of pharmacological agents yet disappointingly have been ineffective in clinical 
trials (Ginsberg, 2008). If in vivo models are suppose to provide the proof-of-principle then why 
should the treatments not work in humans? There are a number of reasons for this discrepancy. 
Mainly, the treatments given in clinical trials are not comparable to controlled animal studies. 
Timing of administration is a critical issue and for some neuroprotective agents a delay in the 
treatment decreases a drug’s efficacy. Incorrect dosage and slow bioavailability of the drug 
could also account for a poor outcome. Moreover, inadequacies of attaining prognostically 
important baseline variables because of unrandomized techniques and using small sample 
sizes in trials are other possible explanations (Wahlgren and Ahmed, 2004). On the other hand, 
in the laboratory setting the animal models used for studying may not be suitable and 
representative of stroke in humans.  Young and healthy rather than old animals are preferred.  
Also, stroke is not only a disorder due to ischemic damage but involves other co-morbities such 
as atherosclerosis, which is a very important risk factor and animal models typically show one 
type of disorder (Wahlgren and Ahmed, 2004). Unfortunately, in many instances some agents 
have been subjected to clinical trials without even enough solid data from pre-clinical ischemia 
studies (Ginsberg, 2008). Despite these discrepancies, clinical trials are currently still on-going 
for some potential neuroprotective candidates (Table 2. Minnerup et al., 2012). 
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Table 2. Neuroprotective compounds, currently in clinical trials (Minnerup et al., 2012).                      
1.8.3 THERAPEUTIC HYPOTHERMIA 
Other than by pharmacological treatment, a very promising neuroprotective intervention is mild 
therapeutic hypothermia. It has been around since the late 1940’s as a neuroprotective strategy 
for various clinical problems (Hoesch and Geocadin, 2007). Still, it is the most effective 
treatment at preventing brain damage and secondary injury by reperfusion in patients suffering 
from transient global cerebral ischemia (Hypothermia after Cardiac Arrest Study Group; 2002; 
Bernard et al., 2002). Although, the molecular mechanisms underlying the protective effect have 
not been established, mild hypothermia seems to inhibit many aspects of cellular injury along 
with reducing energy demand and energy consumption. Cooling of the head or the body after 
injury lessens cell death by slowing down cellular metabolism, inhibiting glutamate release, by 
disrupting the apoptotic pathway, and even preventing cellular ionic imbalance (Drury et al., 
2010). Furthermore, it has been shown effective at ameliorating reperfusion injury due to 
oxidative stress (Katz et al., 2004) and preventing BBB breakdown and cerebral edema 
(Baumann et al., 2009). The pleiotropic actions of hypothermia suggest that targeting multiple 
rather than individual death pathways provides better protection.  
For hypothermia to be positively effective, however, the timing and duration of administration 
after injury appears critical. The therapeutic time window for hypothermia seems optimally 
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effective when administered early and no later than 6 hours after injury. Moreover, experimental 
evidence show partial or temporary neuroprotection when the duration of hypothermia is less 
than 6 hours, while a longer duration of up to 72 hours offers a better improvement in recovery 
and neurological performance (Drury et al., 2010). The severity of the insult is also another 
important factor that may influence the efficacy of hypothermia in delaying further damage 
(Iwata et al., 2007). Adverse effects are few but include shivering, hypotension, slowing of heart 
rate, pneumonia, and infection (Minnerup, et al., 2012).    
 
1.9   SCOPE OF THESIS 
Brain homeostasis is severely impaired by a decrease in oxygen and/ or glucose resulting in 
disturbances in neuronal activity and function and leading to cell death. Excitotoxicity by 
overactivation of GluRs is a major contributing factor of neurodegeneration induced by hypoxia 
or ischemia (Choi, 1992). Unfortunately, there are no neuroprotectants, except for therapeutic 
hypothermia, that have been clinically effective in treating brain injury after stroke (Gladstone et 
al., 2002). The function of the BBB is to protect the CNS from toxins and pathogens and only 
allow important nutrients to pass. The BBB is made of tight junction and transporter proteins that 
form the paracellular and transcellular pathways, respectively. NVU is a conceptual framework 
that has been proposed to maintain neurovascular properties and BBB function (Lo, 2003; 
Iadecola, 2004). The NVU is composed of neuronal, glial, and vascular elements, which 
together provide the optimal matrix for sustaining BBB function. A number of studies have 
reported BBB disruption followed by brain injury. In vitro data suggest that tight junction proteins 
may be compromised (Hawkins and Davis, 2005). However, few in vitro studies have brought 
together more than two cellular partners (Bendfeldt et al., 2007; Nakagawa et al., 2009; Al 
Ahmad et al., 2011). Interestingly, in animal models of global cerebral ischemia, BBB leakage 
and capillary damage were found in the hippocampus, suggesting the vascular bed to be 
associated with regional vulnerability to ischemic damage (Suzuki et al., 1983; Imdahl and 
Hossmann, 1986, Jingtao et al., 1999, Won et al., 2011).  
The hippocampal organotypic slice culture system is an excellent tool for studying cellular and 
molecular mechanisms of neuronal death and for testing pharmacological compounds that may 
be related to neuronal survival.  Age dependent differences can be analyzed by changing the 
culturing time and preparing slices of different age groups. Furthermore, both physiological and 
pathophysiological factors can be studied. Under such a well controlled system, many aspects 
from development, plasticity, injury, recovery, and to neurogenesis can be studied (Noraberg et 
al., 2005). Functional, morphological, and pharmacological properties can be better understood.   
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In the following studies we have taken advantage of the organotypic slice culture system in 
several ways: first we continued the characterization of COSCs as an in vitro BBB model with 
the objective of determining the presence and function of BBB transporters as they also make 
up the cerebrovascular system and control the influx and efflux of molecules within the brain.  
Second, we studied BBB disruption and neurovascular remodeling after oxygen and glucose-
deprivation seeking evidence for a crosstalk between neurons and endothelial cells. Third, we 
studied potential mechanisms of therapeutic hypothermia induced neuroprotection that has 
been effective in treating neurological injury caused by neonatal asphyxia with a focus on the 
role of the RNA binding protein, RBM3.  
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CHAPTER II:   PRESERVATION OF GLUT1 AND P-GP TRANSPORTERS USING IN-
VITRO BBB MODEL 
2.1   EXPRESSION AND FUNCTION OF GLUT1 AND P-GP  
Two of the best known transporters of the BBB are GLUT1 and P-gp. Since the brain is an 
extremely metabolic organ, a constant glucose supply is essential. GLUT1 is expressed in 
endothelial cells and astrocytes. It is the main glucose transporter of the BBB (Simpson et al., 
2007). The distribution of GLUT1 may determine the status of BBB function (Dermietzel et al., 
1992; Garbuzova-Davis et al., 2007). It is an integral membrane protein which is expressed 
asymmetrically along luminal and abluminal membranes of the endothelium as evidenced by 
immunogold electron microscopy in rat and bovine brains (Farrell and Pardridge, 1991; Simpson 
et al. 2001). In brain capillaries, P-gp carries substrates that have entered the endothelial 
membrane back into the blood. As mentioned previously, hydrophobic molecules < 400 Da 
easily cross the BBB and apparently P-gp accounts for this size restriction. The multidrug 
resistance P-gp is involved in effluxing a variety of drugs including chemotherapeutics, opioids, 
steroids, antibiotics, calcium-channel blockers, immunosuppressants, and etc. (Bauer et al., 
2005).  The ABC transporter typically develops later after the BBB has been established (Qin 
and Sato, 1995; Matsuoka et al., 1999; Schumacher and Mollgard, 1997). Lipophilic substances 
such as narcotics, alcohol, and anticonvulsants are able to pass the BBB, however, most 
pharmacological drugs that are not lipophilic fail because they are not able to cross the BBB due 
to tight junction proteins and/or cannot remain in the CNS due to efflux by P-gp. Generally, 
efflux transporters are located on the luminal membrane which is thought to effectively prevent 
xenobiotics from entering the CNS.  Whether the localization of P-gp on the endothelial 
membrane is preferably luminal or abluminal is not clear from immunolocalization studies, 
although functional analyses of P-gp suggest that it is located on the luminal membrane (Bauer 
et al., 2005). Since the capillary structure is complex, both GLUT1 and P-gp have been studied 
in endothelial cell culture models (El Hafny et al., 1997; Janigro et al., 1999; Bauer and Bauer, 
2000) however have not been previously assessed in organotypic slice cultures.  
 
2.2   BBB MODELS 
As mentioned earlier, BBB is maintained by the NVU, which is composed of several cell types: 
astrocytes, pericytes, nerve cells, and perivascular microglia surrounding the endothelium with 
their processes along with the basal lamina (Abbott et al., 2010; Armulik et al.,  2010). In vivo 
models have the main advantage of preserving the anatomical structure of the neurovascular 
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unit and BBB interface. Furthermore, we can study the regional variation that evidently exists 
within the brain. The study of the BBB has been focused by many on the permeability. Brain 
perfusion techniques and intravenous administration of compounds of different sizes have been 
utilized as tracers for measuring transport and permeability across the BBB (Grant et al., 1998). 
This method is only sufficient to observe BBB disruption. Since the BBB is a dynamic structure 
assessing the kinetics of BBB opening is rather important. Therefore, in vitro models were 
established by isolating and culturing brain endothelial cells with astrocyte conditioned medium 
or by co-culturing methods with astrocytes and more recently with pericytes to establish BBB 
function with a high TEER, to express tight junction proteins, and to display transport properties 
(Grant et al., 1998; Nakagawa et al., 2007; Abbott and Romero, 1996).  The molecular and 
cellular mechanisms responsible for function and maintenance of the BBB under physiological 
or pathophysiological conditions could be studied. Therefore, a lot of BBB research has been 
based on developing in-vitro systems.  
Many utilize transwell tissue culture plates designed for co-culturing. These systems allow the 
endothelial cells to be cultured on a porous membrane with a plastic support that is able to fit 
within a well containing a separate culture of either astrocytes or pericytes. This interaction, 
between endothelial cells and astrocytes in this co-culturing system should mimic the 
organization of BBB at the level of the astrocytic end-feet and the endothelial cell interface. 
Furthermore, the endothelial monolayer facing the cells is considered as the abluminal side and 
the one facing away is the luminal side.  Indeed, this model has helped the BBB field 
tremendously.  The permeability of many compounds can be tested by using this model 
however the specificity of the BBB in transporters and the TEER are often not physiologically 
relevant (Grant et al., 1998). Therefore, translating in-vitro to in-vivo studies has been 
unsatisfactory and the data of many in-vitro BBB studies has been questioned. 
Another important discrepancy between the in-vivo situation and many co-culture systems is 
that dissociated cells do not provide the 3-dimensional aspect of the BBB, composed of a 
vascular lumen with the abluminal side surrounded by pericytes and enclosed by a polarized 
network of astrocytic endfeets linking the communication between the nerves cells and the 
blood vessels. To resolve this disparity between in-vitro and in-vivo BBB systems, our lab 
previously established an alternative BBB model utilizing cortical organotypic slice cultures 
(COSCs) of newborn mouse brains and in the presence of FGF2 BBB tight junction proteins are 
well preserved (Bendfeldt et al., 2007).  
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2.3   BBB PRESERVATION IN COSCs 
This slice culture system allows the study of the different cell types making up the NVU taking in 
to account their 3-dimentional structural connectivity. In the presence of low amounts of FGF2, 
vascular structures can be preserved at 37°C up to 10 days in the absence of blood flow. With 
this tool it is possible to study many components of the BBB in a more realistic in vitro 
environment, with cell-cell interactions between natural in vivo partners. COSCs are derived 
from neonatal mice of postnatal age 3 (P3). In the presence of 5 ng/mL FGF2 the density of 
vessels is higher than in controls without growth factor or in cultures with a higher FGF2 
concentration. Moreover, the expression of BBB markers: occludin, claudin-5, claudin-3, and 
ZO-1 are all retained (Bendfeldt et al., 2007).       
2.4   ARE BBB TRANSPORTERS EXPRESSED IN COSCs? 
Tight junction proteins are not the only ones involved in controlling the permeability of the BBB. 
Other important determinants for BBB function are transporter proteins expressed by endothelial 
cells which modulate and regulate transport across the endothelium. GLUT1 allows for transport 
of glucose and the ABC transporter, P-gp, effluxes drugs across the BBB. Although, we showed 
that in the presence of FGF2 tight junction proteins such as claudin-3,-5, ZO-1, and occludin in 
blood vessels were well preserved (Bendfeldt et al., 2007) we did not examine at that time how 
transporters are expressed in COSCs. Therefore, in a follow up study, we analyzed the 
expression of GLUT-1 and P-gp in slice cultures derived from young and old mice. Furthermore, 
we performed transport studies in order to test the functionality of P-gp. Rhodamine 123, a 
substrate of P-gp, can be seen collected into the lumen of blood vessels in live slices within 2 
hours. The specificity of the transporter was examined by applying an inhibitor of P-gp, 
verapamil, which resulted in the absence of Rhodamine 123 in the lumen of the blood vessels.  
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This study have been published in  
Neuroscience (Camezind and Chip et al., 2010) 
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bstract—A variety of neurological diseases are character-
zed by disturbances of the blood–brain barrier (BBB) and its
ransporters. We recently introduced fibroblast growth factor
reated cortical organotypic slice cultures of mice as a model
or in vitro studies of the blood–brain barrier and have now
urther characterized the maintenance and function of trans-
ort-proteins typically expressed in the endothelium of cere-
ral blood vessels. The glucose transporter GLUT-1 is
resent in blood vessels of slice cultures derived from post-
atal day 4 to 21 mice after 3 days in vitro. The endothelial
ultidrug resistance P-glycoprotein (P-gp) which is involved
n the control of pharmacological substance transport across
he blood–brain barrier is also maintained in blood vessels,
ost prominently in slice cultures derived from postnatal day
4 and 21 mice. To assess P-gp function, we tested rhoda-
ine 123 transport in presence or absence of the P-gp inhib-
tor verapamil. Rhodamine 123-fluorescence accumulated
apidly in the vascular lumen both in acute slices and in
lices cultured for 3 days in vitro. Our results provide evi-
ence that endothelial transporters and their functional prop-
rties can be maintained in organotypic cortical slices cul-
ures, thus making it an attractive model system for the study
f the blood–brain barrier. © 2010 IBRO. Published by
lsevier Ltd. All rights reserved.
ey words: brain vasculature, endothelial cells, P-glycopro-
ein, glucose transporter 1, cortical organotypic slice cul-
ures, mouse.
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361isturbances of the integrity and transport function of the
lood–brain barrier (BBB) are typical for neuropathologies
uch as stroke, Alzheimer’s disease and multiple sclerosis.
he BBB separates the nervous tissue from the general
irculation, thereby ensuring an optimal environment for
erebral functions. The unique BBB phenotype character-
zed by the tightest endothelium is the result of the contin-
ous influence from the surrounding nervous tissue, in-
luding pericytes embedded in the basement membrane,
erivascular microglia, astrocytes that surround the base-
ent membrane with their processes, and the basal lam-
na consisting of type IV collagen; fibronectin and laminin
Abbott, 2002).
To date, useful in vitro BBB models which take the
tructural connectivity of the different BBB elements into
ccount are rare. We recently introduced fibroblast growth
actor (FGF-2) treated cortical organotypic slice cultures
COSCs) of newborn mice as a new model for in vitro
tudies of the BBB (Bendfeldt et al., 2007). In the proposed
odel both the viability and the structural connectivity of
he different brain tissue elements are maintained for sev-
ral days in vitro. In addition, persistence of the tight junc-
ion proteins occludin, zonula occludens protein-1, clau-
in-3 and claudin-5 suggests preservation of BBB integrity
t the level of the tight junction.
BBB function, however, is not only based on physical
estrictions secured by interendothelial tight junctions, but
lso on the function of highly efficient transport proteins
Abbott and Romero, 1996; Begley and Brightman, 2003).
ifferent selective transporters provide for blood to brain
ermeability of certain highly hydrophilic solutes (e.g., glu-
ose and amino acids), or hydrophobic foreign chemicals
Miller et al., 2008). The glucose transporter 1 (GLUT-1) is
xpressed selectively in the capillary endothelium of the
rain (Guo et al., 2005) and the distribution of GLUT-1 is
onsidered a sensitive indicator of normal or abnormal
BB function (Dermietzel et al., 1992; Garbuzova-Davis et
l., 2007).
P-glycoprotein (P-gp), a 170–180 kDa plasma mem-
rane-associated protein, is a product of the multidrug
esistance gene (mdr) (Ling, 1997) and belongs to the
TP-binding cassette (ABC) superfamily (Cordon-Cardo
t al., 1989). Brain capillaries express particularly high
evels of P-gp. Because of its location in the luminal
embrane, its high expression level, as well as its ability
o transport drugs and several endogenous compounds,
-gp is considered as a primary control for penetration
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R. S. Camenzind et al. / Neuroscience 170 (2010) 361–371362f chemical substances across the BBB (Schinkel et al.,
995; Lin and Yamazaki, 2003). Furthermore recent
ata indicate that P-gp is involved in the excretion of
myloid beta, a peptide that is associated with Alzhei-
er’s disease (Cirrito et al., 2005).
The aim of the present study was twofold: to determine
he preservation of the vasculature in COSCs derived from
ore mature mice (postnatal day 8–21) and to search for
he presence of the BBB transporters GLUT-1 and P-gp. In
ddition, here we investigated transport function of P-gp in
lood vessels of acute cortical slices and COSC’s of the
ouse brain.
EXPERIMENTAL PROCEDURES
ulture protocol
OSCs were prepared and cultivated with the classical technique
Stoppini et al., 1991) with slight modifications (Radojevic and
apfhammer, 2004; Bendfeldt et al., 2007). Postnatal day (P) 4,
8, P14 and P21 C57Bl/6 mice were decapitated. After rapidly
emoving the brain, the cortex was dissected together with parts of
he underlying striatum or diencephalon, and 250-m-thick frontal
lices were cut on a tissue chopper. Slices were separated, placed
n Millicell-CM 0.4 m culture plates (six slices per membrane;
illipore, Zug, Switzerland) in six-well dishes and were main-
ained in culture medium at 37 °C in a humidified CO2-enriched
tmosphere for a minimum of one day in vitro (DIV). The medium
onsisted of HEPES-buffered minimal essential medium (50%),
ank’s Balanced Salt Solution (HBSS) (25%), and heat-inacti-
ated horse serum (25%) complemented with glutamax (2 mM;
nvitrogen, Eugene, OR, USA), Glucose (1 g/l) and adjusted to pH
.3. FGF-2 (Peprotech, London, UK) was added to the medium (5
g/mL) and medium was changed every other day. No antibiotics
r antimitotics were used. All animal experiments were performed
ith permission of the local animal care committee and in accor-
ance with international guidelines on handling laboratory animals
nd the present Swiss law.
reparation for immunohistochemistry
he cellular integrity of the slices, the formation of blood ves-
els and the presence of transporters were analyzed by immu-
ofluorescence of relevant marker proteins. Cultures were fixed
or 3 h at room temperature (RT) with 4% paraformaldehyde in
hosphate buffered saline (PBS), rinsed three times with 0.1 M
BS, and incubated in blocking solution (BS) containing Tris–
uffered Saline containing 0.5% Triton X-100 (TBST) and 3%
ormal goat serum for 90 min at RT. Primary antibodies were
iluted in BS as follows: the neuronal marker anti-Neuronal
uclei (mouse anti-NeuN 1:250; Chemicon, Temecula, CA,
SA), the astrocyte marker Glial Fibrillary Acidic Protein (rabbit
nti-GFAP 1:250; Dako, High Wycombe, UK), the glucose
ransporter 1 (rabbit anti-GLUT-1 1:1000; Thermo, Fremont, CA,
SA) and P-glycoprotein (mouse anti-P-gp 1:1000; Calbiochem,
armstadt, Germany). Architecture of blood vessels was visual-
zed by labeling for the basal membrane constituent laminin (rabbit
nti-Lam 1:200 or mouse anti-Lam 1:2000; Sigma, St. Louis, MO,
SA), and the tight junction was visualized by labeling for the
ntegral membrane protein claudin-5 (rabbit anti-Cl-5 1:200 or
ouse anti-Cl-5 1:50; Zymed, San Francisco, CA, USA). Cultures
ere incubated with primary antibodies overnight at 4 °C, rinsed
ith TBST at RT, and incubated with Alexa Fluorochromes (In-
itrogen, Eugene, OR, USA) linked goat-anti-rabbit (1:1000) or
oat-anti-mouse (1:1000) secondary antibodies in BS for 2 h at FT. Unspecific staining was controlled by omitting the primary
ntibody. The slices were mounted on glass slides with Vectash-
eld mounting medium (Vector Laboratories, Burlingame, CA,
SA) and viewed on a Zeiss Axio Imager.Z1 (Zeiss, Oberkochen,
ermany). High magnification imaging was performed using a
aser-scanning confocal microscope, Zeiss LSM 510 Meta, (Carl
eiss AG, Oberkochen, Germany) and then processed by Bit-
lane Imaris (Bitplane AG, Zurich, Switzerland). Recorded images
ere adjusted for brightness and contrast with Photoshop (Adobe,
an Jose, CA, USA) and ImageJ (Rasband W.S., U. S. National
nstitutes of Health, Bethesda, MD, USA).
ransport activity of P-glycoprotein in acute and
ultured slices
issue dissection was the same as described above. Slices were
eparated, placed in 6-well dishes and were maintained in culture
edium, at 37 °C in a humidified CO2-enriched atmosphere for
ither 30 min for the experiments with the acute slices or 3 days
or the experiments with cultured slices. The medium consisted of
BS and heat-inactivated horse serum (2.5%) complemented with
lutamax (2 mM; Invitrogen, Eugene, OR, USA) and glucose (1
/l) and adjusted to pH 7.3. Slices were incubated with 0.5 M of
hodamine 123 (R123; Sigma), a P-gp substrate, up to 120 min
nd to control for specificity of rhodamine uptake by P-gp, slices
ere treated with a P-gp inhibitor, verapamil (100 M; Sigma).
mages were taken with a Zeiss Axio Imager.Z1. For confocal
maging studies organotypic slices of 3 days in vitro were cultured
n porous membranes (Millipore), incubated for 120 min with
ither R123 or R123 and verapamil and then transferred onto
lass bottom dishes (MatTek Corporation, Ashland, MA, USA)
efore imaging was performed on a laser-scanning confocal mi-
roscope (Zeiss, LSM 510 Meta).
onfocal microscopy
he sections were imaged with a Zeiss LSM 510 Meta scanning
onfocal microscope system equipped with an argon ion laser
or the green channel and a helium-laser for the red channel. A
eries of optical sections (63 or 100 magnification) was
cquired at 0.5 m intervals through the entire thickness of the
pecimen (approximately 10–25 m) and then projected into a
ingle-focus image with the Bitplane Imaris (Bitplane AG).
RESULTS
aintenance of blood–brain barrier characteristics in
lice cultures derived from mouse pups up to
ostnatal day 21
n a prior study we concentrated on cultures obtained
rom P3 and P4 mice (Bendfeldt et al., 2007). Here, we
ave studied cultures derived from more mature mice
P8, P14 and P21). Cultures from cortical slices of P4,
8, P14 and P21 mice remained well preserved in the
resence of FGF-2 (Figs. 1 and 2). The neuronal DNA-
inding protein NeuN revealed survival and differentia-
ion of nerve cells in the cultures prepared from brains of
4, P8, P14 and P21 mice (Fig. 1B, D, F, H). GFAP-
taining showed characteristically shaped astrocytes. A
ense network of astrocytic endfeet engulfed the cere-
ral microvasculature (Fig. 2A, B1–4).
Immunolabeling of the extracellular matrix protein lami-
in showed a dense network of blood vessels in cultures
erived from P4, P8, P14 and P21 mice in the presence of
GF-2 (Figs. 1 and 2A). Labeling for the tight junctional
i
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R. S. Camenzind et al. / Neuroscience 170 (2010) 361–371 363ntegral membrane protein claudin-5 indicated the morpho-
ig. 1. Demonstration of cerebral microvessels and neurons in cort
GF-2 treatment. Immunofluorescence images labeled for laminin (g
ng/mL FGF-2 and show survival and complexity of the vascu
ouble-immunolabeling for laminin and the neuronal DNA-binding p
rom P4 (B), P8 (D), P14 (F) and P21 (H) mice.ogical integrity of the BBB at the level of the tight junction m
fter DIV 3 in cultures derived from P4, P8, P14 and P21
notypic slice cultures at DIV 3 from postnatal day 4–21 mice under
ealed the presence of microvessels in COSCs after incubation with
ork in P4 (A, B), P8 (C, D), P14 (E, F) and P21 (G, H) mice.
uN (red) revealed well-differentiated nerve cells in cultures derivedical orga
reen) rev
lar netw
rotein Neice (Fig. 2C–F).
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R. S. Camenzind et al. / Neuroscience 170 (2010) 361–371364he GLUT-1 transporter is specifically expressed in
lood vessels in cortical organotypic slice cultures
erived from various postnatal ages
e have studied the presence of GLUT-1 protein in
OSCs derived from P4, P8, P14 and P21 mice after DIV
. This allowed us to evaluate whether the maturity of the
ortical tissue would affect GLUT-1 expression. A high
ensity of GLUT-1 immunoreactivity was found in slices
rom all age groups (Fig. 3). Cultures from younger mice
P4, P8) showed a more discontinuous pattern of GLUT-1
taining as compared to the older mice (P14, P21). When
LUT-1 was co-stained with laminin, a majority of blood
essels showed colocalization. By confocal microscopy
he GLUT-1 expression in blood vessels of slices from P14
nimals was not as consistent as from P21 animals.
LUT-1 expression could be found along the inner and
ig. 2. Astrocytes and tight junctions in cortical organotypic slice
mmunofluorescence images double labeled for laminin (red) and for G
strocytic endfeet in close apposition to the cerebral microvasculature
f the BBB at the level of the tight junction in cultures derived from Puter walls of small vessels (Fig. 3E–G) in P14 cultures. mLUT-1 expression was more continuous in slices derived
rom P21 mice, where it was present in the wall but not the
umen of the blood vessels consistent with its presence in
he plasma membrane of the laminin labeled vessels (Fig.
H–J). Localization to the vessel wall is confirmed in the
rthogonal view, tracing the lumen of a blood vessel (Fig.
H, right part).
pecific expression of P-glycoprotein in blood
essels of cortical organotypic slice cultures
nother important endothelial transport protein typically
resent in cerebral blood vessels is P-gp, a product of the
dr gene, which is critically involved in the control of drug
enetration into the CNS tissue. Immunostainings were
erformed on cultures derived from P4, P8, P14 and P21
at DIV 3 from postnatal day 4–21 mice under FGF-2 treatment.
een) show normally shaped astrocytes as well as a dense network of
4). Immunolabeling for claudin-5 indicated the morphological integrity
(D), P14 (E) and P21 (F) mice.cultures
FAP (grice (DIV 3).
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R. S. Camenzind et al. / Neuroscience 170 (2010) 361–371 365P-gp immunofluorescencewas confined to endothelial
ells as verified in colocalization studies with laminin (Fig.
) or claudin 5 (not shown) and was much more pro-
ounced in vessels from older mice than in those from
ounger mice (Fig. 4). It was preferentially detected in
ig. 3. Demonstration of the glucose transporter GLUT-1 in brain en
LUT-1 staining was present in the majority of blood vessels and pre
ounger mice (P4, P8) (A, B), GLUT-1 showed a slightly disconti
oublestaining of GLUT-1 (green) and laminin (red) was performed w
lood vessels (E–J). Orthogonal reconstructions of double-labeled m
LUT-1 expression is maintained along the inner and outer borders oapillaries where it appeared rather in patches than con- tinuously along the vessel walls. In P21 cultures, P-gp
taining appeared most intense in capillaries and in the
ndothelium of larger vessels (Fig. 4E, F). In general, the
xpression pattern of P-gp was found to be more variable
ompared to GLUT-1. By confocal microscopy, both cul-
cells of cortical organotypic slice cultures in the presence of FGF-2.
in smaller vessels in a rather homogenous fashion. In cultures from
aining pattern as compared to the older mice (P14, P21) (C, D).
cal microscopy and showed that GLUT-1 was exclusively located in
els as viewed in the x–z (bottom) and y–z (right) planes show that
sels (E, H).dothelial
ferentially
nuous st
ith confo
icrovessures showed P-gp expression either along the inner walls
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R. S. Camenzind et al. / Neuroscience 170 (2010) 361–371366ig. 4. Immunolocalization of the efflux transporter P-gp (green) in vascular endothelial cells of cortical organotypic slice cultures in the presence of
GF-2. In general, P-gp staining was barely detectable in cultures of the younger mice (P8) (A, B) where it appeared rather in patches than
ontinuously along the vessel walls. In older mice P14 (C, D, G–I) and at P21 (E, F, J–L), however, P-gp staining was stronger and rather homogenous
long the vessel wall. A close colocalization of P-gp and laminin (red) staining was preferentially detectable in capillaries. P-gp staining was most
ntense in P21 cultures (E, F, J–L). Orthogonal reconstructions of double-labeled microvessels confirmed that P-gp is localized along the wall (G) and
ithin the borders of the endothelium as stained by laminin (J).
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R. S. Camenzind et al. / Neuroscience 170 (2010) 361–371 367f laminin labeled vessels (Fig. 4G–I) or colocalized with
he plasma membrane (Fig. 4J–L), similar to GLUT-1 ex-
ression. However, unlike GLUT-1, P-gp expression was
ever found along the outer borders of large vessels, but
as located along the inner borders (Fig. 4G).
-glycoprotein mediated transport in acute and
ultured cortical slices of newborn mice
ccumulation of the fluorescent dye R123 on the luminal
ide of brain microvessels is frequently used to deter-
ine the transport capacity of P-gp in cultured endothe-
ial cells and blood vessels. This is the first study that
as investigated R123 transport across blood vessels of
cute and cultured cortical slices either in the absence
r presence of the P-gp inhibiting agent verapamil (Bog-
an et al., 2001).
Uptake of R123 occurred in capillaries and small blood
essels of acute (Fig. 5A) and cultured slices (Fig. 5B–F)
onsistent with the distribution pattern of P-gp in the cul-
ures (Fig. 4). In capillaries, R123 accumulated in the
ascular lumen (Fig. 5A–D). In small vessels and in larger
essels R123 accumulation appeared in patches in the
ndothelial cells (Fig. 5E, F). In acute slices R123 uptake
ccurred in a time dependent manner with more luminal
123 accumulation as the incubation time period in-
reased with a maximum at 120 min (Fig. 5A). With con-
ocal microscopy, a higher magnification than 63 was not
ossible without bleaching out the fluorescence. In DIV 3
ultures of P14 and P21 mice R123 seemed to be present
n the luminal space of small vessels as shown in the
rthogonal views of the confocal images (Fig. 5B–F). Al-
hough background staining was more prominent in cul-
ures as compared to the acute slices they clearly demon-
trate that the transport capacity of P-gp is maintained in
lice cultures for several days. In larger vessels, the accu-
ulation of R123 was found in the luminal space (Fig. 5F)
s well, but also accumulated in the cytoplasm of endo-
helial and smooth muscle cells that encompass the ves-
els (Fig. 5E). The presence of the P-gp inhibitor verapamil
ompletely prevented R123 transport into large and small
etworks of vessels for both acute (Fig. 5G) and cultured
lices (Fig. 5H), indicating the specificity of the transport
unction.
DISCUSSION
ere we studied, in COSCs of different aged mice (P4–
21), in the presence of 5 ng/mL FGF-2 persistence and
unction of vascular networks. Structural integrity of the
BB is shown, in particular the presence of the endothelial
ransport proteins GLUT-1 and P-gp, thereby extending
revious own work focusing on tight junctions (Bendfeldt et
l., 2007). As shown before in 3–4 days old mice, in
ultures prepared from adolescent animals (P21), cerebral
lood vessels maintain BBB associated tight junctions and
ransporters. 1elevance of the model as compared to other
n-vitro systems
he BBB is challenged in a variety of infectious and neu-
odegenerative diseases of the CNS. Drug access to the
rain parenchyma, however, is limited due to the presence
f drug-efflux-proteins, for example, P-gp, in the BBB im-
eding pharmacotherapy of those diseases. To date most
in vitro” models of the BBB rely on monolayers of isolated
ndothelial cells (Huwyler et al., 1996; Gutmann et al.,
999; Török et al., 2003), or use isolated rat brain capil-
aries to study regulation and modulation of BBB transport
unction (Cecchelli et al., 1999; Poller et al., 2010) in order
o gain insight into barrier properties to be able to devise
trategies for improved CNS pharmacotherapy. However,
solated cells are prone to lose some of their in vivo prop-
rties (Colgan et al., 2008) due to loss of regulating factors
rom surrounding astrocytes and glia cells. For in vitro
odels consisting of isolated cells important features of
he intact BBB are lacking which might impair functional
echanistic studies. Isolated capillaries, on the other
and, can be maintained in a physiological saline for up to
h without loss of metabolism-driven, concentrative trans-
ort (Miller et al., 2000; Bauer et al., 2004, 2008), but are
emoved from their natural environment to artificial culture
onditions as well. Thus, to date, “in vivo” studies in animal
odels remain the gold standard for investigations on BBB
isturbances.
Recently, we suggested FGF-2 treated COSCs as a
ew model for reliable in vitro studies of the BBB (Bend-
eldt et al., 2007). Those cultures take the complex envi-
onment of the brain into account, meanwhile maintaining
ight junction proteins critical for BBB structure and func-
ion. Compared with other models, COSCs have the ad-
antage that blood vessels and their membrane compo-
ents remain in situ, thus allowing cell–cell interactions
etween natural in vivo partners.
Although a number of vessels might perish in those
ultures with time because of the absence of intraluminal
lood flow, two early ultrastructural studies in human and
ewborn rat brain tissue (Wolff et al., 1974; Hauw et al.,
975) indicated survival of vessels in explanted brain tis-
ue. Furthermore, more recent immunohistochemical ap-
roaches demonstrated the viability of vessels, for exam-
le, in the presence of vascular endothelial growth factor in
at cortical cultures (Moser et al., 2003).
ocalization of transport proteins
he present study shows for the first time in cultured
ortical brain slices of mice, maintenance of BBB transport
roteins in cerebral blood vessels for several days in vitro.
Firstly, we assessed the presence of GLUT-1 protein in
OSCs. Density of GLUT-1 staining was high in endothe-
ial of COSCs for up to 3 days in vitro in all examined age
roups (P4, P8, P14 and P21). The central dogma of
erebral energy metabolism is that glucose is the obligate
nergetic fuel of the mammalian brain and the only sub-
trate able to completely sustain neural activity (Siesjo,
978). The potential relationship between rates of cerebral
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R. S. Camenzind et al. / Neuroscience 170 (2010) 361–371368ig. 5. Accumulation of rhodamine 123 from the abluminal to the luminal side of brain vessels in cortical organotypic slice cultures at DIV 3 from P8,
14 and P21 mice after 120 min. Slices were incubated with rhodamine 123 in the absence (A–F) or presence of verapamil (G, H) for 120 min.
rthogonal reconstructions of the microvessels as viewed in the x–z and y–z planes showed accumulation of rhodamine 123 in the microvasculature
f capillaries (B–D). Rhodamine 123 accumulation was more pronounced in small vessels (A–D) than in larger vessels (E–F). In the latter, uptake was
lso present in endothelial and smooth muscle cells (E–F). Accumulation appeared in patches both in the endothelial cells and in the vascular
umen. Presence of the P-gp inhibitor verapamil completely prevented rhodamine 123 uptake in the vascular lumen (G) but in few areas of the
lices accumulation of rhodamine was not completely abolished as seen by its occasional presence in the soma of neurons under high
agnification (H).
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R. S. Camenzind et al. / Neuroscience 170 (2010) 361–371 369lucose utilization and the expression of GLUT-1 trans-
orters has been demonstrated in normal adult rat brain
Vannucci et al., 1998). GLUT-1 is expressed selectively at
high level in the capillary endothelium of the BBB, and is
esponsible for glucose transfer across the BBB (Guo et
l., 2005). The 55 kDa form of GLUT-1 is found exclusively
n the microvascular endothelial cells that make up the
BB, where it is present in both the luminal and abluminal
embranes (Dick et al., 1984; Simpson et al., 2007).
In addition to GLUT-1, the current study shows the
resence of the multidrug resistance transporter P-gp in
OSCs. P-gp immunoreactivity was more pronounced in
lices obtained from older mice (P21, P14) than in those
rom younger mice (P4, P8). This is consistent with previ-
us data, where a developmental pattern of enhanced
-gp expression during maturation has been shown in the
ouse (Ying and Thomas, 1995), rat (Yasuji et al., 1999)
nd human BBB (Schumacher and Mollgård, 1997). P-gp
xpression in newborn mouse brain is low, but increases
uring postnatal maturation and by P21 the adult expres-
ion level is reached (Tsai et al., 2002).
There has been some controversy regarding the im-
unolocalization of P-gp in human brain capillaries. While
n some studies P-gp was localized to pericytes (Golden et
l., 1997), other studies have suggested, that it might be
estricted to endothelial cells (Jette et al., 1993; Seeta et
l., 1998). Results for rat and pig are consistent with the
atter, which also suggest that P-gp is expressed on the
asal abluminal surface of the capillary (Miller et al., 2000).
n human and mouse brain (Sugawara et al., 1990; Tatsuta
t al., 1992; Beaulieu et al., 1997; Bendayan et al., 2002),
-gp was shown to be localized on the luminal membrane
f endothelial cells, where an ATP-driven xenobiotic trans-
ort from cell to blood prevents xenobiotic entry into the
NS, and P-gp acts both as an excretory pump and a
arrier to drug entry (Bauer et al., 2005). Double-staining
f P-gp and laminin in our own study also suggest a
uminal localization of P-gp.
-glycoprotein-mediated transport function
n the present study we assessed P-gp mediated transport
cross the BBB by examining the accumulation of the
uorescent dye R123 (Fontaine et al., 1996) into the lumen
f cerebral blood vessels. R123 was administered to the
ulture medium either alone or in the presence of the P-gp
ediated transport inhibiting agent, verapamil (Bogman et
l., 2001).
Although rhodamine is a vital dye for staining mito-
hondria, the uptake of R123 was mostly specific to cere-
ral endothelial cells. R123 appeared in patches both in
ndothelial cells and in the vascular lumen, thereby sup-
orting the hypothesis of P-gp expression on both the
uminal surface and in astrocytic endfeet on the abluminal
urface of mouse brain vessels. R123 appeared both in
ndothelial cells and in the vascular lumen of brain capil-
aries, indicating that P-gp is mainly located on the capillary
ndothelium. In line with our findings are Western blot
tudies that showed strong enrichment of P-gp in the brain
apillary luminal membranes compared to brain capillaries i17-fold) and whole brain membranes (400–500-fold)
Beaulieu et al., 1997).
This is in agreement with results from transport exper-
ments in isolated microvessels of rat brain (Miller et al.,
000). R123 accumulation was reduced after incubation
ith verapamil, consistent with findings from other studies
here transcellular levels of R123 dramatically decreased
pon addition of verapamil in cultured cerebral capillary
ndothelial cells of mice (Hegmann et al., 1992). Our re-
ults indicate functional activity and specific inhibition of
-gp both in acute brain slices and in slice cultures incu-
ated for several days. They show that the slice cultures
re an appropriate model system not only for studying
orphological, but also functional aspects of the blood
rain barrier in vitro.
The BBB contributes to brain homeostasis by protect-
ng the brain from potentially harmful endogenous and
xogenous substances. Both inflammation and altered
arrier function are known to be associated with a number
f neurological diseases as in epilepsy, for example
Tomkins et al., 2007). There, increases in endothelial
-gp expression occur in regions of the brain with seizure
ctivity (Bauer et al., 2008).
P-gp can limit the penetration of drugs into the brain
nd thus modulate effectiveness and CNS toxicity of nu-
erous drugs (Deeley et al., 2006; Girardin, 2006). Con-
equently, CNS disorders are difficult to treat since the
ajority of drugs do not cross the BBB. In effect, BBB
locks delivery of more than 98% of CNS-acting drugs
Taylor, 2002). Adequate BBB penetration is a prerequisite
or the design of both CNS-acting drugs and non-CNS-
cting drugs in advance of clinical usage.
Studies with MDR1 knockout mice have revealed the
mportance of P-gp in preventing the entry of many drugs
nto the brain, indicating that complete knockout of P-gp
eads to an increase in the accumulation of P-gp substrate
n the body (Schinkel et al., 1995; Mealey, 2004). The
unctional similarity in the gene members of human and
ice P-gps makes COSCs or acute slices from mice a
seful model to assess the importance of P-gp in drug
bsorption, distribution and clearance.
CONCLUSION
ur data indicate that the COSC-model is a valuable tool
or BBB studies, in particular for studies of tight junction
egulation or studies on GLUT-1- or P-gp-mediated trans-
ort function. Because of the relative simplicity of the sys-
em, COSCs can be readily manipulated and subjected to
ifferent insults such as hypoxia, glucose deprivation, and
harmacological treatments to assist in understanding
BB disturbances. The present study demonstrates an
ntact cytoarchitecture of the BBB in COSCs derived from
ore mature mice (P21). GLUT-1 and P-gp transport pro-
eins were localized in the cortical vascular system. Fur-
hermore, transport activity of P-gp in slices suggests BBB
unction in vitro. Future studies will show, whether this
ransport activity persists for longer in vitro incubation
ntervals.
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CHAPTER III: SELECTIVE NEURONAL DEATH AND NEUROVASCULAR 
REMODELING FOLLOWED BY OGD AND EXCITOTOXICITY USING IN-VITRO BBB 
MODEL  
3.1  VULNERABILITY OF THE HIPPOCAMPUS TO HYPOXIA AND ISCHEMIA  
In cerebral ischemia, a decrease in the supply of oxygen and glucose to the brain induces 
neuronal impairment and even cell death. The hippocampus is very well known for its structure, 
function, neuronal circuitry, and vulnerability to cell death. A majority of the neuronal 
connections in this brain region are excitatory, responding to glutamate. Pyramidal neurons in 
CA1 of the hippocampus are especially vulnerable.  Humans and animal models of transient 
global brain ischemia all display selective and delayed neuronal death in the hippocampus 
(Petito et al., 1987; Suzuki et al., 1983; Kirino et al., 1984; Nitsch et al., 1989). This selective 
neurodegeneration has been also observed in hippocampal organotypic slice cultures (Laake et 
al., 1999; Rytter et al., 2003) suggesting the in vitro system comparable to in vivo models.    
3.2  NEUROVASCULAR REMODELING AND NEURODEGENERATION  
Neurodegeneration and BBB damage are often associated together after brain injury, but it is 
not clear whether the events are separate or linked. Since endothelial cells make up the 
vasculature of the BBB and maintain the neuronal ‘milieu’, it is not surprising that BBB 
dysfunction and neurodegeneration are found associated with one another. In fact, mounting 
evidence has projected a crucial role of the neurovascular unit in BBB dysfunction in 
neurodegenerative diseases (Zlokovic, 2010; del Zoppo, 2012). Disrupted endothelial tight 
junctions, glia reactivity and neuron death have been associated with excessive glutamate 
levels that arise in CNS disorders (Massieu et al., 2000). Moreover, following hypoxia or 
ischemia, endothelial cells release trophic factors such as VEGF which is involved in processes 
of angiogenesis and inflammation, BBB permeability but also in neuronal survival as it is also a 
neurotrophin (Zhang et al., 2000; Storkebaum et al., 2004; Prat et al., 2002).  Interestingly, in 
temporal lobe epilepsy an increase in vessel density has been reported (Rigau et al., 2007) and 
the overexpression of VEGF  by neurons and astrocytes has been suggested as a mediator for 
BBB damage and vascular remodeling after excitotoxicity (Morin-Brureau et al., 2011). Whether 
the vasculature is remodeled as a direct effect of neurodegeneration is debatable. Therefore, 
we adapted our COSC model to entorhino-hippocampal organotypic slice cultures to study 
vascular remodeling in the presence of neurodegeneration.  
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3.3 NEUROVASCULATURE OF ENTORHINO-HIPPOCAMPAL ORGANOTYPIC 
SLICE CULTURES  
Since CA1 of hippocampus is most vulnerable to neuronal death in ischemic animal models as 
well as in humans (Kirino, 1982; Petito et al., 1987), we were interested in exploring BBB 
disruption and neurovascular remodeling in entorhino-hippocampal organotypic slice cultures 
(EHOSCs). Therefore, we initially had to establish the expression profile of vessels in EHOSCs 
before performing neurodegenerative studies. Both GLUT-1 and Cld-5 along with laminin and 
von Willebrand factor (or FVIII) were ubiquitously expressed, suggesting the presence of an 
intact BBB. Regional vessel densities were quantified and the dentate gyrus contained a higher 
density of vessels than other regions (CA1, CA3, and EC), which was consistent to in vivo data 
of vessels in the rat hippocampus (Ndode-Ekane et al., 2010). Fewer vessels in CA1 than in 
CA3 have been reported in rodents (Imdahl and Hossmann, 1986; Gerhart et al., 1991; 
Shimada et al., 1992) and the nature of this difference in vessel density is unknown but has 
been postulated to be due to differences in glucose utilization as well as cerebral blood flow 
(Gerhart et al., 1991). Although, blood flow was absent in organotypic cultures and oxygen and 
glucose were equally distributed to all areas, the regional differences in vessel density were still 
apparent, suggesting that other factors may be involved. It is plausible that the cellular 
differences between CA1 and CA3 such as Ca2+ load, mitochondrial function, glutamate 
receptor expression, and proteosomal degradation contribute to the differences in vessel 
density.  
3.4  IS THE VASCULATURE SELECTIVELY VULNERABLE?  
Here, we used EHOSCs derived from newborn mice to induce selective neuronal death by OGD 
or excitotoxicity and examined how it may affect the local vasculature. Induced asphyxia by 
OGD was applied on to the slice cultures for 15 minutes. Along with neuronal death, 
components of the BBB and vascular damage were analyzed at 48 hours after injury. In line 
with in vivo studies, OGD induction caused selective cell death in the hippocampal CA1 field 
only. There was a reduction in the density of blood vessels, which was also regionally restricted, 
a finding not previously reported in slice cultures. Exposure to tetrodotoxin (TTX) or to an AMPA 
antagonist (CNQX) to protect the neuronal cells from neurodegeneration prevented reduction of 
blood vessels in the CA1 region. We hypothesized that the vessel reduction was not simply due 
to the OGD insult but dependent on neuronal death. To corroborate our hypothesis we induced 
neuronal death by over activation of AMPA receptors in the slice cultures that is to force 
neuronal excitotoxicity to occur by stimulating the opening of AMPA specific calcium ion 
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channels to allow for accumulation of calcium and release of glutamate. Neuronal death was 
more pronounced in the CA1 region as compared with OGD and had even spread to CA3. 
Vessel loss was induced in the CA1 region but surprisingly, although many neurons also died in 
CA3, the vessels there were not reduced.  On the other hand in DG region, neurons were 
resistant to excitotoxicity and the vessel density was increased. This suggested that a more 
complex interaction between neurons and vessels was taking place such that the fate of the 
vessels was dependent on which region of the hippocampus the vessels were residing in.  
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3.5 SUBFIELD SPECIFIC NEUROVASCULAR REMODELING IN THE ENTORHINO-
HIPPOCAMPAL ORGANOTYPIC SLICE CULTURE AS A RESPONSE TO OXYGEN-
GLUCOSE DEPRIVATION AND EXCITOTOXIC CELL DEATH 
 
This study has been published in  
Journal of Cerebral Blood Flow and Metabolism (Chip et al., 2012) 
 
 
ORIGINAL ARTICLE
Subfield-specific neurovascular remodeling in the
entorhino-hippocampal-organotypic slice culture as a response to
oxygen–glucose deprivation and excitotoxic cell death
Sophorn Chip1,2,3, Cordula Nitsch1, Sven Wellmann2 and Josef P Kapfhammer3
Transient ischemia causes delayed neurodegeneration in selective brain areas, particularly in the CA1 field of the hippocampus. This
is accompanied by neurovascular impairment. It is unknown whether neurodegeneration is the cause or consequence of vascular
changes. In an entorhino-hippocampal-organotypic slice culture system with well-preserved blood vessels, we studied the interplay
between neurodegeneration and neurovasculature. Short-term oxygen and glucose deprivation (OGD) resulted in upregulation of
hypoxic markers and with a delay of 24 to 48 hours in selective nerve cell death in CA1. In parallel, local vessel density decreased as
detected by markers of endothelial cells and of the extracellular matrix. Claudin-5, a tight junction protein and marker of the blood–
brain barrier was reduced. Preventing neuronal death with tetrodotoxin or 6-cyano-7-nitroquinoxaline-2,3-dione rescued blood
vessels, suggesting that vessel loss is not due to OGD per se but a consequence of neuronal death. Induction of excitotoxic
neuronal death with AMPA caused widespread neurodegeneration, but vessel reduction was confined to CA1. In dentate gyrus
without neuronal loss, vessel density increased. We propose that neuronal stress and death influence maintenance, loss and
remodeling of the neurovasculature and that the type of vascular response is in addition determined by local factors within the
hippocampus.
Journal of Cerebral Blood Flow & Metabolism advance online publication, 12 December 2012; doi:10.1038/jcbfm.2012.190
Keywords: angiogenesis; blood–brain barrier; epilepsy; hippocampus; selective neuronal death; transient ischemic attack
INTRODUCTION
The cerebral vasculature supplies oxygen and nutrients to the
brain as well as eliminates and protects the nervous system from
toxins and pathogens. Endothelial cells assembling the inner
lining of the vasculature release trophic factors, support the
maintenance of the blood–brain barrier (BBB), and are involved in
processes of angiogenesis and inflammation.1,2 A decrease in
oxygen and glucose by a dysfunction in the cerebral vasculature
can lead to neuronal impairment and cell death. Unfortunately,
introducing pharmacological neuroprotectants before or after
injury to prevent cell death or secondary damage to the central
nervous system has so far not met clinical expectations. A better
understanding of the proper functioning of the vasculature and its
endothelium might provide new ways on how to preserve or
restore the vasculature as one of the prerequisites for
maintenance of brain activities.
It is a well-known phenomenon that different areas of the brain
react differently to ubiquitously present noxious events as hypoxia
or exposure to toxins. Reasons for selective vulnerability have
been considered to be either due to specific properties of nerve
cells (the special pathoclysis concept of Cecile and Oskar Vogt3) or
to regional differences in vascularization.4 This controversial issue
has not yet been resolved conclusively. The hippocampus with its
different subfields is especially interesting in this context: while
the CA1 area exhibits a high susceptibility to hypoxia/ischemia in
humans5 and in animal models,6–8 the CA3 area together with the
hilus of the dentate gyrus is much more involved in epilepsy-
associated hippocampal sclerosis9 and in animal models of
temporal lobe epilepsy.10
In case of ischemia, the display of transmitter receptors and ion
channels, but also control of oxidative and proteasomal stress11,12
have been proposed as the basis for the differential vulnerability
of regions and/or subpopulations of neurons. In addition, local
characteristics of glial cells13 are considered to play a role in the
regional selectivity of neurodegeneration. Interestingly, capillary
damage and higher susceptibility of BBB leakage in the CA1
region but not the CA3 region in the gerbil and the rat model of
cerebral ischemia–reperfusion have been reported.6,14,15 In the
case of temporal lobe epilepsy, not vascular loss, but angiogenesis
has been described10,16 and the overexpression of vascular
endothelial growth factor (VEGF) by neurons and astrocytes has
been suggested to be the mediator for BBB damage and vascular
remodeling after excitotoxicity.17 Whether the vasculature is
remodeled as a direct effect of neurodegeneration is debatable.
Hippocampal-organotypic slice cultures challenged with oxy-
gen and glucose deprivation (OGD) are in vitro models affording
reproducibility and representing closely to in vivo models by
mimicking cerebral ischemia that occurs after stroke or cardiac
arrest.18,19 Hypoxic conditions in this slice culture system with or
without additional glucose deprivation induce a comparable
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selective neurodegeneration in the CA1 region.19 We have
previously demonstrated the feasibility of the cortical
organotypic slice culture as a BBB model system.20,21 In the
present studies we have adapted this model to entorhino-
hippocampal-organotypic slice cultures (EHOSCs), enabling us to
study vascular effects in the CA1 region elicited by OGD and
neuronal death.
Up to now, little data are available linking neurodegeneration
and neurovascular remodeling. We investigated whether in the
hippocampus, remodeling of the cerebral vasculature after
ischemia is dependent on the selective neurodegeneration in
the CA1 region and whether excitotoxic nerve cell death in other
fields of the hippocampal formation has similar effects. A better
understanding of not only the mechanisms of neuronal damage
but also the diversity in brain regions in their reaction to cerebral
injury as well as of the accompanying vascular damage is
necessary for proper development of therapeutics.
MATERIALS AND METHODS
Preparation of Entorhino-Hippocampal-Organotypic Slice Cultures
All animal experiments were carried out according to the international
guidelines on handling laboratory animals as well as the present Swiss law
for animal experiment and were approved by the animal care committee
of the Canton of Basel. Cultures were prepared as described previously.20,21
Briefly, C57Bl/6CRL mice were decapitated at postnatal day 4 (P4) and the
brains were extracted and placed in ice-cold preparation medium
containing minimal essential medium, 1% glutamax (Life Technologies,
Zug, CH, Switzerland), pH 7.3. Meninges around the cortical hemispheres
were gently removed without disturbing the hippocampus. The
hippocampus together with the entorhinal cortex (EC) was dissected and
400mm transversal hippocampal slices were sectioned using a McIllwain
tissue chopper under aseptic conditions. Slices were carefully separated
and laid over 0.4mmMillicell-CM, 30mm diameter culture inserts (Millipore,
Zug, CH, Switzerland) in six-well plates with 1mL/per well of incubation
medium composed of: HEPES-buffered minimal essential medium
(minimal essential medium, 50%), Hank’s-buffered salt solution (25%),
and heat-inactivated horse serum (25%) supplemented with glutamax (Life
Technologies), glucose (1 g/L), pH 7.3. Plates were stored in a humidified
incubator with 5% CO2 at 371C. The medium was changed the next day
and then every other day up to 1 week.
In Vitro Hypoxia and Oxygen–Glucose Deprivation with
Reperfusion
Entorhino-hippocampal-organotypic slice cultures were cultured for 5 days
(DIV5) before exposure to hypoxia or OGD. Oxygen and glucose deprivation
medium was prepared as detailed by Rytter et al.19 using Neurobasal medium
containing: 2% B27 and 1% glutamax (Life Technologies). Two six-well tissue
culture plates were filled with 1mL/well of OGD medium, perfused with N2 for
1hour in a hypoxic chamber (Billups-Rothenberg, Del Mar, CA, USA) and then
sealed overnight to equilibrate the medium. Anaerobic strips (Sigma-Aldrich,
Buchs, CH, Switzerland) were used as hypoxic indicators when the color of the
strips changed from pink to white. Before the slices were exposed to OGD, the
OGD medium was perfused again with N2 for 30minutes. Propidium iodide
(PI; Sigma-Aldrich, 2mg/mL) was added to the slices for 30minutes and only
healthy slices were selected for experimentation as indicated by low numbers
of PI-positive cells. The schedule of OGD exposure and reperfusion is indicated
in Figure 2A. Briefly, slices were either deprived of oxygen only (hypoxia) or
oxygen and glucose for 15minutes, then replaced with oxygenated
Neurobasal medium and allowed to recover for 3, 24, or 48hours. Propidium
iodide was added before the insult to establish the baseline of cell death and
then added again during the recovery periods.
Pharmacological Interventions
At DIV5, EHOSCs with low number of PI-positive cells were selected for
exposure with several compounds prepared in Neurobasal medium:
100mmol/L (RS)-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA; R&D Systems, Oxford, UK), 100mmol/L 6-cyano-7-nitroquinoxa-
line-2,3-dione (CNQX; R&D Systems), 1 mmol/L tetrodotoxin (TTX; R&D
Figure 1. Preservation of blood vessels in entorhino-hippocampal-organotypic slice cultures (EHOSCs). (A, B) Immunohistochemistry of a
transversal slice of the hippocampus along with the entorhinal cortex (EC) shows the expression of glucose transporter 1 (GLUT1) and claudin-
5 (Cld-5), at DIV7. Scale bar¼ 200 mm. (C) Schematic diagram of an EHOSC, indicating location of the vessel counting grids shown as squares in
the single regions (see Materials and methods). (D) The average vessel density in subfields of the hippocampus (CA1, CA3, DG) and the EC.
Results are mean vessel counts from three independent experiments (n¼ 9) and significance was determined by analysis of variance (ANOVA)
for each group, bars±s.e.m., *Po0.05 as compared with the other three regions.
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Systems) for 30minutes in normoxic slices and then kept for 48 hours until
fixation and immunohistochemistry. Treatment experiments were carried
out with CNQX and TTX during or directly after the insult.
Immunohistochemistry
We used only hippocampal slices of the septal half because they displayed
consistent cell death. Slices were fixed in freshly made 4% paraformaldehyde
overnight at 41C. Paraformaldehyde was removed the following day and the
slices were washed three to four times with phosphate-buffered saline. Slices
were carefully removed from the culture inserts for immunohistochemistry of
free-floating sections. Each slice was placed in a well of a 96-well plate
containing 100mL of blocking buffer: 3% normal goat serum in phosphate-
buffered saline for blocking and 2% Triton-X100 for permeabilization,
respectively. The plates were placed on an orbital shaker and the slices were
incubated in the blocking buffer for 2 hours at room temperature. Primary
antibodies were prepared in phosphate-buffered saline containing 1%
normal goat serum and 0.5% Triton-X100. The primary antibodies used for
detecting blood vessels were: polyclonal laminin (Sigma-Aldrich) 1:200,
polyclonal rabbit anti-human Von Willebrand Factor (Dako, Glostrup,
Denmark) 1:250, polyclonal glucose transporter 1 (Thermo Scientific,
Fremont, CA, USA) 1:1,000, and monoclonal Claudin-5 (Life Technologies)
1:50; and for detecting neurons: microtubule-associated protein 2 (MAP2;
Abcam, Cambridge, UK) 1:500. DAPI (1:500) was occasionally used to verify
the total cell population. Incubation with primary antibodies was for 48hours
at 41C and then washed with 0.5% Triton-X100 for 3 to 4 times. Then, slices
were incubated for 3 hours at room temperature with secondary antibody
prepared in 1% normal goat serum and 0.5% Triton-X100 of either goat anti-
rabbit or goat anti-mouse conjugated to Alexa fluorochromes 350 or 488 (Life
Technologies). Afterwards, slices were washed with tris-buffered saline (TBS)
three times; mounted on glass slides and cover slipped with Mowiol. The
stained slices were viewed by an Olympus AX-70 microscope (Olympus,
Hamburg, Germany) installed with a Spot digital camera. The images were
recorded and adjusted for brightness by Adobe Photoshop (Adobe Systems,
Zurich, Switzerland) or ImageJ (NIH, Bethesda, MD, USA).
Western Blot
Four to five slices of the septal half of the hippocampal region were sonicated
and lysed in 1 RIPA buffer: 50mmol/L Tris–HCl (pH 7.4), 1% NP-40, 0.25%
deoxycholate, 150mmol/L NaCl, 1mmol/L EGTA. In total, 150mg of protein
was boiled for 5minutes in Laemmli buffer and then loaded in an sodium
dodecyl sulfate polyacrylamide gel electrophoresis. The gel was transferred
onto a nitrocellulose membrane. The membrane was incubated at room
Figure 2. Entorhino-hippocampal-organotypic slice cultures (EHOSCs) submitted to either oxygen and glucose deprivation (OGD) or hypoxia.
(A) Treatment schedule for hypoxia or OGD. EHOSCs were cultured for 5 days (DIV5) before being submitted to hypoxia or OGD of 15minutes
duration followed by recovery periods (see Materials and methods). (B) Propidium iodide (PI) (red) and Cld-5 (green) staining after 15minutes
of OGD and 48 h of recovery. The arrow points to the degenerating neurons in CA1. Scale bar¼ 200 mm. (C) Higher magnification of the CA1
region in (B). Scale bar¼ 100 mm. (D) PI and Cld-5 staining after hypoxia and 48 hours of recovery. Scale bar¼ 200 mm. (E) A representative
immunoblot of protein expression of the hypoxic markers vascular endothelial growth factor (VEGF) and GLUT1.ctl, control; hyp, hypoxia.
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temperature on an orbital shaker for 1 hour in blocking solution containing
TBST (TBS and 0.1% Tween20), and 5% bovine serum (Sigma-Aldrich).
After blocking, the membrane was probed with either polyclonal GLUT1
(Thermo Scientific) 1:5,000, polyclonal VEGF 164 (VEGFA; Abcam) 1:1,000, or
monoclonal b-actin (Millipore) 1:8,000 overnight at 41C and washed the next
day for 5 to 10minutes with TBST before incubating in secondary goat anti-
rabbit or goat anti-mouse conjugated to AP (alkaline phosphatase; Jackson
ImmunoResearch Europe, Suffolk, UK ) for 1 hour. Then, the secondary
antibody was washed several times with TBST for 30minutes and the signal
was detected by AP Conjugate Substrate Kit system (Bio-Rad, Cressier, FR,
Switzerland).
Vessel Density and Statistics
The vessel density was quantified based on vessel crossings as described
by Bendfeldt et al.20 Recorded images of  10 magnification were
superimposed with three 6 6 grids, where each grid is equal to
100 100mm per square and a total field of 0.25mm2 over the CA1,
CA3, DG, and EC region (Figure 1C). The average of the crossings from the
three grids for each region was calculated. Countings were based on a
minimum of nine animals (three independent experiments, which each
included data from three animals, each providing three slices). Statistical
analysis was performed by analysis of variance with Bonferroni correction
as post hoc test (Po0.05 was defined as significant).
Figure 3. Oxygen and glucose deprivation (OGD) induces cell death, along with neuronal loss and vessel reduction in the CA1 region of the
hippocampus. (A) A control slice labeled with laminin. (B–D) Higher magnification of the CA1 field labeled with propidium iodide (PI), laminin,
and microtubule-associated protein 2 (MAP2). (E) An OGD-treated slice, after 48 hours of recovery showing reduced laminin-positive vessels,
specific to CA1. (F–H) Higher magnification of CA1 shows increased cell death, reduced vessel density and neuronal disintegration. (I) A
hypoxia-treated slice, after 48 hours of recovery shows less reduction in laminin-positive vessel in CA1 as compared with OGD. (J–L) Higher
magnification of CA1 region shows a mild increase in cell death, reduced vessels, and neuronal loss. (M) Vessel density was determined by
counting vessels immunolabeled with either laminin or (N) von Willebrand factor (FVIII) in the CA1, CA3, DG, and entorhinal cortex (EC) region
of entorhino-hippocampal-organotypic slice cultures (EHOSCs) 48 hours after OGD along with their respective controls (CTL). Results are mean
vessel counts from three independent experiments (n¼ 9) and significance was determined by analysis of variance (ANOVA) for each group,
bars±s.e.m., *Po0.05, **Po0.01. Scale bars¼ 200 mm.
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RESULTS
Blood Vessels and Tight Junction Markers Are Preserved Under
Normal Culture Conditions in Entorhino-Hippocampal-
Organotypic Slice Cultures
Entorhino-hippocampal-organotypic slice cultures prepared of
postnatal day 4 (P4) C57Bl/6CRL mice showed preservation of
local blood vessels, which exhibited a stable expression of glucose
transporter 1 (GLUT1) and claudin-5 (Cld-5) for 1 week (DIV7) in
culture (Figures 1A and 1B). Vessel counts were performed in the
single subfields of the EHOSCs (Figure 1C). Vessel densities as
examined by laminin staining were similar for the CA1, CA3, and
EC region but significantly higher in DG (Figure 1D).
Entorhino-Hippocampal-Organotypic Slice Culture as a Model for
Studying the Blood–Brain Barrier in Short-Term Oxygen and
Glucose Deprivation with 48 hours of Recovery
Since the presence of tight junction proteins and blood vessel
densities remained stable for 41 week in culture, we conducted
all experiments within this time period (Figure 2A). Organotypic
slices were cultured for 4 to 5 days and cell death was assayed in
living slices by PI signal. Only slices with low constitutive PI
staining were selected for experimentation. Oxygen and glucose
deprivation caused cell death along the pyramidal layer of the CA1
sector, where strong PI staining was observed at 48 hours of
recovery (Figures 2B and 2C). In parallel, staining for markers of the
cerebral vasculature as Cld-5 (Figures 2B and 2C), von Willebrand
factor (not shown) and laminin (see Figure 3) was massively
reduced in the CA1 sector only. For all other subfields of the
EHOSCs, the integrity of blood vessels appeared intact and
resistant to short-term OGD. Hypoxia had the same effect on
EHOSC but to a lesser extent: nerve cell death in CA1 was less
pronounced and vessel reduction less severe ( Figure 2D).
The protein expression in the EHOSCs of vascular endothelial
growth factor-A (VEGFA) and the 55-kDa GLUT1 isoform were
upregulated after short-term hypoxia or OGD followed by 48 hours
recovery (Figure 2E). Both proteins are well known to be hypoxia
regulated. Interestingly, the 45-kDa GLUT1 isoform that is
expressed in glial cells was found to be downregulated specifically
after OGD but not after hypoxia (Figure 2E).
Figure 4. Time course of cell death and change in the vessel architecture at 3, 24, and 48 hours after oxygen and glucose deprivation (OGD).
(A) A control slice colabeled with Cld-5 (green) and propidium iodide (PI) (red) for the 3-hour recovery time point. (B) OGD-treated slice
showing vessels labeled with Cld-5. (C) OGD-treated slice with vessels colabeled with Cld-5 and PI. Vessels are highly branched and
continuous with no cell death occurring. (D) A control slice colabeled with Cld-5 (green) and PI (red) for the 24-hour recovery time point
exhibits highly branched vessels with no PI-positive cells. (E, F) In all, 24 hours after OGD, vessels appear disintegrated along with the presence
of PI-positive cells becoming apparent. (G) A control slice colabeled with Cld-5 (green) and PI (red) for 48 hours recovery time point. (H, I) After
48 hours of recovery, Cld-5-stained vessels have greatly diminished and cell death has increased in OGD-treated slices in the CA1 region.
White dotted lines represent the stratum pyramidale of the CA1 area.
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Selective Vessel Loss in the CA1 Region Upon Short-Term Oxygen
and Glucose Deprivation Followed by 48 hours Recovery
Despite the induction of cell death in the CA1 region by OGD or
hypoxia in our model, overall the integrity of blood vessels in
EHOSCs was preserved: the vasculature appeared well branched
as observed by the abundance of Cld-5 or laminin immunolabel-
ing (Figures 2B, 2D, 3A, 3E, and 3I). Solely in the CA1 region, blood
vessels were reduced compared with the control (Figures 3C, 3G,
and 3K). Cell death seen with PI staining was pronounced in CA1
of the OGD or hypoxia-treated samples compared with the control
(Figures 3B, 3F, and 3J) and in parallel pyramidal neurons
exhibited a disintegration of cytoskeleton as visualized with less
MAP2 immunostaining (Figures 3D, 3H, and 3L). These effects in
the CA1 field were milder after hypoxia than OGD (Figures 3J, 3K,
and 3L). Other regions of the EHOSC (CA3, DG, EC) were not
affected, neither PI increase nor MAP2 decrease was found there
after short-term OGD or hypoxia followed by 48 hours recovery.
The quantitation of vessel density for CA1, CA3, DG, and EC
indicated a general decrease in the vessel number for all
hippocampal regions, but the reduction of vessels became
statistically significant only in the CA1 region where B50% of
the vessels were lost 48 hours after short-term OGD (Figures 3M
and 3N). This holds true for the endothelial marker, von Willebrand
factor (FVIII), as well as the extracellular matrix marker of blood
vessels, laminin.
Since short-term OGD did affect vessels specifically in the CA1
region, we performed a time course analysis to see whether the
change in vessel architecture began before, in parallel, or was
preceded by neuronal death. Immunohistochemistry of Cld-5
revealed that at 3 hours of recovery, vascular architecture in CA1
Figure 5. Neuronal cell death and vessel loss are rescued by applying either 1 mmol/L tetrodotoxin (TTX) or 100 mmol/L 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX) during oxygen and glucose deprivation (OGD). (A, B) Laminin and propidium iodide (PI) staining of CA1
region of a control slice culture. (C, D) Laminin was reduced and PI staining was increased after OGD exposure. (E, F) Blockage of neuronal
activity by TTX did not change laminin staining as compared with control. (G, H) Vessel loss and neuronal death induced by OGD was blocked
by TTX. (I, J) CNQX exposure of a control slice had no effect on laminin or PI staining. (K, L) Vessel loss and neuronal death induced by OGD
was blocked by CNQX. (M) Vessel density in CA1 of entorhino-hippocampal-organotypic slice cultures (EHOSCs) treated with or without
1mmol/L TTX or 100 mmol/L CNQX during OGD and after 48 hours of recovery. Results are from three independent experiments (n¼ 9). (N)
Vessel density in CA1 region of EHOSCs treated with only 1mmol/L TTX for 48 hours to silence neuronal activity without inducing neuronal
death. Results are from two independent experiments (n¼ 6) and significance was determined by analysis of variance (ANOVA) for each
group, bars±s.e.m., **Po0.01. Scale bars¼ 200 mm.
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did not differ from controls showing the presence of highly
branched vessels and no PI-stained cells (Figures 4A–4C). As the
recovery period lengthened to 24 hours, cell death became
evident in the OGD-treated slices as PI-positive cells were
appearing and, in parallel, the network of vessels started to
become disintegrated (Figures 4E and 4F). At 48 hours of recovery,
the CA1 region was virtually cleared of vessel coverage (Figures 4H
and 4I). The temporal increase of PI signal from 24 to 48 hours
suggests an inverse relationship occurring between the develop-
ment of cell death and the decrease of vessels. No changes were
evident in the control slices (Figures 4A, 4D, and 4G). These
findings indicate that the vessel changes neither occur before or
after, but rather developed in parallel with a close temporal
correlation to the development of neuronal death.
Protection of Neurons and Vasculature by Tetrodotoxin and CNQX
After Short-Term Oxygen and Glucose Deprivation with 48 hours
of Recovery
Next, we questioned whether the loss of vasculature after OGD is
due to a direct effect of OGD on the vessels or due to the OGD-
induced neurodegeneration. Furthermore, is blockade of neuronal
Figure 6. Entorhino-hippocampal-organotypic slice cultures (EHOSCs) treated with amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) for 30minutes and allowed to recover for 48 hours. (A, B) Microtubule-associated protein 2 (MAP2) and laminin expression of a control
slice. (C) High magnification of blood vessels in CA1 region in (B). (D, E) MAP2 and laminin expression of a slice treated with 100 mmol/L AMPA
for 30minutes with 48 hours of recovery. (F) High magnification of blood vessels in CA1 region in (E). (G) A dose response for the AMPA
agonist. Boxes and circles show mean propidium iodide (PI) intensity in CA1 area with and without the agonist, respectively, bars±s.e.m. (H)
The density of vessels in the CA1 region was significantly reduced in samples of three to six animals, bars±s.e.m. (*Po0.05). Scale
bars¼ 200 mm.
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activity sufficient to induce vessel loss, or must neurodegeneration
take place to cause a disintegration of the vasculature? We tested
this by using the blocker of fast sodium spikes TTX or the AMPA
receptor antagonist CNQX. In control slices with TTX only, with
neuronal activity silenced, vessel architecture was similar to
controls (Figures 5A, 5B, 5E, and 5F). With 1 mmol/L TTX, CA1
neurons were strongly protected from cell death induced by OGD
and the vessel architecture did not change compared with the
OGD only (Figures 5C, 5D, 5G, and 5H). In control slices with CNQX
only, the vessel architecture was also not affected (Figures 5I and 5J).
Very similarly, 100 mmol/L CNQX also protected neurons from
OGD (Figures 5C, 5D, and 5K, and 5L). Quantification of vessel
density clearly established that both neuroprotecting compounds,
TTX and CNQX preserved the blood vessel morphology and
density (Figure 5M). Furthermore, vessel density in CA1 did not
change between controls and slices treated with TTX, where
neuronal activity was blocked for 48 hours (Figure 5N). These
data clearly show that vascular loss after OGD is due to
neurodegeneration.
CA1 Vessel Loss by Short-Term Exposure to AMPA
Since TTX and CNQX could rescue neurons and blood vessels from
OGD-induced cell death and disintegration, we wondered
whether AMPA receptor-triggered excitotoxicity in the absence
of OGD might also induce blood vessel disintegration. Micro-
tubule-associated protein 2 and laminin staining show a well-
preserved appearance of neuronal cytoskeletal and vascular
architecture, respectively, in a control slice culture (Figures 6A
and 6B). A dose response for AMPA indicated strong cell death in
the CA1 region to occur after a 30-minute exposure to 100mmol/L
(Figure 6G). In contrast to hypoxia or OGD, there was no delay in
nerve cell death; it was already present after 3 hours (data not
shown) to a massive degree. A 30-minute exposure to AMPA
followed by a 48-hour recovery period had eliminated the majority
of MAP2-positive neurons in the cornu ammonis (Figures 6A, 6D,
7A, and 7E). At the same time, there was also a clear reduction of
vessel density in CA1, indicating that the AMPA-treatment induced
neurodegeneration was sufficient to provoke vessel loss (Figures
6B, 6C, 6E, 6F, 7B, and 7F). Vessel counts confirmed that excitotoxic
nerve cell death reduced the vessel density in the CA1 region
(Figure 6H). Blocking the AMPA-induced excitotoxicity by
100mmol/L of CNQX partially rescued neurons and preserved
the vessels almost to control levels, even when applied as
posttreatment (Figures 7C, 7D, 7G, and 7H, quantification in
Figure 7I). Taken together, these experiments prove that vessel
loss in the hippocampal CA1 field is due to excitotoxic
neurodegeneration.
Regional Variations in Blood Vessel Plasticity After AMPA-Induced
Excitotoxicity
Neurodegeneration induced by AMPA is not confined to the CA1
region. Microtubule-associated protein 2 staining revealed loss of
neurons in CA3 and survival of neurons in the dentate gyrus
(Figures 7A and 7E). In contrast to CA1, blood vessels were not lost
or were even enriched with more numerous branches in CA3
(Figures 7B and 7F, quantification in Figure 7I). In the DG, there
was a consistent increase in blood vessel density, which could be
blocked by posttreatment with CNQX (Figures 7F and 7H,
quantification in Figure 7I). Thus, nerve cell death is not always
accompanied by vessel loss but rather can induce a variety of
changes in neurovasculature. The actual type of modification is
probably determined by regional features together with the mode
of induction of neurodegeneration.
Figure 7. 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX) applied after
exposure to amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) maintains the vascular architecture and blocks neuronal
death in the hippocampus proper. (A–D) Control slices in the
absence or presence of 100 mmol/L CNQX show similar microtubule-
associated protein 2 (MAP2) and laminin staining. (E, F) In all,
48 hours after recovery from 30minutes of exposure to 100 mmol/L
(RS)-AMPA reduced MAP2 labeling in CA1 and CA3, but the vessel
marker laminin was only reduced in CA1. (G, H) Vessel reduction and
neuronal death are blocked by 100 mmol/L CNQX applied subse-
quently to the 30-minute AMPA insult. (I) The vessel densities were
compared regionally for the respective treatments. Results are from
three independent experiments (n¼ 9) and significance was
determined by analysis of variance (ANOVA), bars *Po0.05,
bars±s.e.m., **Po0.01, ***Po0.001. Scale bar¼ 200 mm.
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DISCUSSION
We have adapted an in vitro neocortical BBB model20,21 to the
hippocampal formation to investigate the effects of ischemia and
recovery on neurovascular integrity in the most vulnerable brain
region, the hippocampal CA1. Entorhino-hippocampal-
organotypic slice cultures behave similar to cortical organotypic
slice cultures with respect to the preservation of blood vessels in
the control situation. Short-term hypoxia or OGD induced a
selective cell death in the CA1 region, delayed by 24 to 48 hours.
This is accompanied by a significant reduction in vessel density.
The blocker of fast sodium spikes TTX or the AMPA receptor
antagonist, CNQX, prevented both, neuronal death and vascular
loss in the CA1 region. Induction of excitotoxicity by AMPA caused
neuronal death in CA1 and CA3 regions. In contrast to a
diminished vasculature in neuron-depleted CA1, in CA3 nerve
cell loss did not reduce vessel density. Nerve cells in the EC and
DG were resistant to excitotoxic cell death and in DG the vessel
density even increased. These contrasting effects could be
prevented by CNQX and TTX. We conclude that neuronal stress
and neuronal death control maintenance, loss and remodeling of
the neurovasculature and that the vascular response is in addition
determined by region-specific factors.
Studying Hypoxia/Ischemia Using Entorhino-Hippocampal-
Organotypic Slice Cultures
Hippocampal-organotypic slice cultures have been used to study
neural development, neural function, neurodegeneration, as well
as neuroprotection.18,19,22 Ischemia induced in in vitro models
produce consistent cell death in specific regions within the
hippocampus.18,19 In our study, we used the OGD medium
proposed by Rytter et al.,19 which caused a delayed and selective
cell death to CA1 without damaging CA3 after 15minutes of OGD
exposure. Septal and temporal regions have been known to
function distinctively from each other.23 Notably, the vulnerability
to cell death appears to be more associated with the septal half, a
phenomenon that we also observed (preliminary data). To avoid a
possible interference from the position of the slice along the
septotemporal axis, we used only hippocampal slices of the septal
half because they displayed consistent cell death in addition to
the reduced vessel density.
In models of hypoxia or ischemia, an increase in induction of
VEGF and GLUT1 has been reported.24 In fact, we were able to
observe VEGFA and GLUT1 upregulation after hypoxia or OGD.
Intriguingly, we found that unlike the increase in expression of the
55-kDa GLUT1 isoform that resides in endothelial cells, the
expression of the 45-kDa GLUT1 isoform that resides in glial
cells25 was decreased after OGD. The functional relevance of the
GLUT1 isoforms is largely unknown, but the glycosylated
form facilitates glucose transport.26 Nevertheless, the observed
decrease in expression of the 45-kDa GLUT1 isoform suggests an
impairment of glucose transport capacity in glial cells, adding
to the potency of the OGD medium proposed by Rytter et al.:19
it was reported to induce stronger cell death after glucose
was reintroduced in the recovery period. Furthermore, the
increase of the 55-kDa GLUT1 isoform indicates that despite
the absence of blood flow, endothelial cells respond to OGD,
rendering their functionality in EHOSCs. All in all, the results of this
study suggest that our in vitro model of short-term OGD using
EHOSCs is valid and representative of hypoxia or ischemia
occurring in vivo.
Selective Cell Death and Vessel Loss in CA1
Neurodegeneration and BBB damage often cooccur after cerebral
ischemia, but it is not clear whether the events are interconnected
or separate entities. Neuronal death has been shown to be
associated with BBB leakage in the context of transient
ischemia,6,14,15 suggesting neuronal damage as the primary
event of injury. However, this idea was challenged by the
finding that intracerebral injection of kainic acid could induce
BBB damage without neuronal death in knockout mice resistant to
excitotoxic injury, supporting that BBB damage and neuronal
death are separate events.27 Thus, depending on the context of
CNS injury, the question of whether neuronal death and BBB
leakage are separate or linked events is debatable, which
encouraged us to perform the present study.
In brain slices, techniques for measuring the permeability of the
BBB do not exist. Indirect measures are the detection of tight
junction proteins. In addition, investigating the expression of
components of the cellular matrix of the neurovascular unit is
reasonable, since functioning of the BBB also depends on the
survival of the endothelium, basal lamina, astrocytes, and
pericytes.2,28,29 In the present study, we have provided evidence
of a link between neuronal death and impairment of BBB: along
with the glial impairment in glucose transport and the
upregulation of GLUT1 in the endothelium, the main tight
junction protein of the BBB, Cld-5, is markedly reduced in CA1
24 hours after OGD, that is, at the onset of neurodegeneration,
with a further reduction at 48 hours. Yet, not only tight junction
proteins are reduced with neurodegeneration, the whole
neurovascular unit is impaired as evidenced by the loss of the
extracellular matrix protein laminin. Previous studies on rodents
submitted to cerebrovascular ischemia have also seen capillary
damage in the CA1 region.14 Earlier studies in vessel density in
control animals have indicated fewer vessels in CA1 than
CA314,30,31 and more recently a higher vascular density in the
molecular layer of the dentate gyrus than in the rest of the
hippocampus was demonstrated.32 Differences in vessel density
have also been observed across the septotemporal axis,33
suggesting that the organization of the vasculature in the
hippocampus is dependent on regional factors. The regional
variation in vessel density has been considered to be caused by
differences in glucose utilization.30 Also in so-called neurovascular
niches, such as in the DG, angiogenesis is more frequent as it relies
on the same trophic factors that are involved in neurogenesis.32
In organotypic cultures, without a need for blood flow as
oxygen and glucose are equally distributed to all areas, regional
differences in vessel density were nevertheless still apparent. The
cellular organization in the single brain region might determine
vessel density. Since pyramidal cells in CA1 and CA3 are different
in terms of calcium load, mitochondrial function, glutamate
receptor expression, and proteosomal degradation, it might be
possible that factors produced by or associated within CA1
influence vessel density. Because in our in vitro model of global
ischemia, vessel loss was specifically observed in CA1, we propose
that the loss of vessels arises as a consequence of CA1 pyramidal
cell death.
Blocking Neuronal Death and Vascular Loss in CA1
Neuronal death after hypoxia or ischemia is mainly contributed to
glutamate excitotoxicity.34 The glutamate release has been linked
to sodium and calcium influx as a consequence of ionic imbalance
and neuronal depolarization. Blocking the activation of either
sodium channels by TTX or ionic glutamate receptors with NMDA
or AMPA antagonists before OGD improves neuronal resistance.35
In our OGD model, TTX as well as the AMPA receptor antagonist
CNQX prevented neuronal death proving that it is due to
glutamate excitotoxicity. This neuroprotective effect of TTX or
CNQX was associated with a preservation of blood vessels.
Moreover, in control experiments with TTX only, the vessel
density was similar to controls. Since TTX can inhibit neuronal
activity without affecting cell viability, the stability in vessel
expression in the presence of TTX implied that it is not the
absence of neuronal activity but that indeed neuronal death is
responsible for vessel loss.
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We used an AMPA antagonist, CNQX, rather than a NMDA
antagonist in our study, as it has been shown to be more effective
in preventing delayed neuronal death.36 Moreover, we wanted to
use an antagonist that was specifically affecting neurons. Evidence
for the presence and function of glutamate receptors in cerebral
endothelial cells is controversial. Cerebral endothelial cells derived
from rat or human brain have been contended as having no
expression or function of glutamate receptors,37 but subsequent
studies showed glutamate receptors in cerebral blood vessels and
even suggested NMDA receptors to be involved in BBB
regulation.38 On the other hand, AMPA receptors are only
expressed at very low levels in cerebral endothelial cells and the
application of DNQX, an AMPA receptor antagonist, but not MK-
801, an NMDA receptor antagonist, failed to counteract BBB
permeability induced by glutamate excitotoxicity, suggesting that
AMPA receptors may have little importance in BBB regulation.38 In
light of these published findings, we presumed that CNQX had
little direct effect on vessels, if at all.
Glutamate Excitotoxicity Leads to a Selective Modulation of Vessel
Architecture in the Hippocampal Formation
Since AMPA receptors seemed to be involved in OGD-induced
neurodegeneration, we challenged this finding by directly
exposing EHOSCs to a high dose of (RS)-AMPA agonist for a short
duration followed by 48 hours of recovery to mimic the glutamate
excitotoxicity induced by OGD. A widespread neuronal death
together with vessel loss in the CA1 region was observed.
Both neurodegeneration and vessel loss could be reversed when
the agonist was blocked by CNQX providing additional evidence
that excitotoxic neuronal death in the CA1 region is accompanied
by a concomitant loss of blood vessels. However, the other
subfields of the hippocampus did not react in the same way. In the
CA3 region, excitotoxic neuronal death did not induce major
changes of blood vessel density or architecture. In the DG with
neuronal survival, there was an increase of blood vessel density
and in the EC neurons survived and there were no evident
changes in the blood vessels. Interestingly, in four different areas
we thus have observed four different types of neuronal and
vascular responses to excitotoxic challenge highlighting the
importance of local factors for determining the final cellular
responses.
In in vivo and in vitro models of epilepsy, an increase of vessel
density has been demonstrated.10,16,17,32 It has been linked to
seizure-induced mossy fiber sprouting and neurogenesis, which is
prominent in the neurovascular niche of the DG.39 An
upregulation of VEGF expression by neurons and astrocytes as
well as its receptor, VEGFR2, in endothelial cells was present in
in vitro kainate seizure-induced vessel remodeling.17 In our model,
we also did observe VEGF expression to be upregulated. Further
work is necessary to determine whether the selective AMPA-
induced excitation mimics on the one hand in DG seizures
resulting in angiogenesis, and on the other hand in CA1
ischemia-induced glutamate toxicity resulting in massive
neurodegeneration and accompanying vessel loss.
Possible Mechanisms of Vascular Damage Induced by Neuronal
Death
A primary mechanism underlying ischemia-induced neuronal
death of pyramidal cells is excitotoxicity, which we observed
48 hours after injury by OGD and by excessive stimulation of
AMPA-type glutamate receptors. However, the neuronal death
was accompanied by microvessel loss confined to the CA1 region.
Ischemia-induced neuronal death has been characterized by a
mixture of apoptosis and necrosis. Neuronal death includes a large
number of changes such as the loss of ATP, production of free
radicals, loss of mitochondrial membrane potential, release of
cytochrome c, and production of reactive oxygen species.40 The
mechanisms by which death of pyramidal neurons mediate vessel
loss, are not known. The present results lay the groundwork for
further study of the biological crosstalk between pyramidal
neurons and the vasculature, in particular, the role for AMPARs
in ischemia-induced neuronal death. Understanding the regional
differences of the hippocampus and especially the interaction
between pyramidal cells and their surrounding vasculature might
be an important aspect for developing better treatments for
neurovascular disorders in particular cerebral ischemia after stroke
or short-term cardiac arrest.
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CHAPTER IV:   RBM3 IS INVOLVED IN HYPOTHERMIA-INDUCED 
NEUROPROTECTION 
4.1  NEONATAL ASPHYXIA AND CELL DEATH  
The process of brain injury following neonatal asphyxia is complex lasting from the beginning of 
insult and until the period of recovery. Lack of oxygen and glucose trigger cells to switch from 
oxidative phosphorylation to glycolysis or anaerobic metabolism reducing high-energy 
phosphate levels (including ATP) and increasing lactate production. The energy loss and 
metabolic acidosis unleash a biochemical cascade of deleterious events that lead to cell 
dysfunction and finally cell death. Furthermore, damage of brain metabolism by increases in 
oxidative stress lead to reperfusion injury (see review by Lai and Yang, 2011).  
It has been proposed that neurodegeneration in response to excitotoxicity or hypoxia-ischemia 
in the neonatal brain of rodents display an apoptosis-necrosis “continuum” (Portera-Calliau et 
al., 1997; Northington et al., 2007), which both forms of cell death are activated. Cell death after 
hypoxia-ischemia has been also described to occur in two phases. During the initial injury which 
is the primary phase that takes place in the first few hours, cell death is predominantly necrotic, 
while 12-48 hours later after energy supply and cellular pH have recuperated to baseline levels 
from reperfusion and reoxygenation, a second energy loss and a delayed phase of injury 
occurs, which apoptosis appears to be more apparent (Towfighi et al., 1995; Northington et al., 
2001). However, it is also possible that mitochondrial dysfunction and cytochrome c release 
during the second energy failure is caused by increases in calcium influx, glutamate 
excitotoxicity, or oxygen free radicals. Nevertheless, it is this delayed phase of injury that 
determines the outcome of neurodevelopment. Whether necrosis and apoptosis occur 
simultaneously or at distinct time points following neonatal asphyxia is a matter of debate. They 
both contribute to brain injury and preventing both types of cell death before the second injury 
event would be a good therapeutic strategy.           
 
4.2  THERAPEUTIC HYPOTHERMIA AS A TREATMENT FOR NEONATAL BRAIN 
INJURY 
There is no cure for encephalopathy followed by neonatal asphyxia; therefore effective 
therapies of neuroprotection have been to reduce or prevent further cerebral injury. Therapeutic 
hypothermia has been the most effective treatment at reducing brain damage and in preventing 
neurodevelopmental disabilities (Azzopardi et al., 2009). As mentioned above, brain injury after 
asphyxia is biphasic. The optimal time window to commence therapeutic hypothermia 
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comprises a few hours after the initial insult. This window is during the recovery period and 
precedes the second phase of injury which ultimately results in delayed neuronal death. Cooling 
of the head or the whole body of the newborn to 33-34°C within 6 hours after injury for 72 hours 
has shown to improve recovery; reducing the outcome of death and neurological complications 
(Drury et al., 2010).   
How does hypothermia reduce brain injury? As mentioned earlier, hypothermia has a pleiotropic 
effect. It can affect many aspects of cellular function from inhibiting metabolism, delaying protein 
synthesis, to disrupting the cascade of events leading to cell death. However, since apoptosis is 
a major contributor to cell death in neonatal asphyxia, hypothermia could potentially disrupt the 
apoptotic pathway. It was first reported in newborn pigs with transient hypoxia-ischemia that 
mild hypothermia (34.9°C) decreased the number of apoptotic cingulated neurons rather than 
necrotic neurons during the second phase of injury (Edwards et al., 1995). The specific 
inhibition of apoptotic and not necrotic cells by hypothermia was not determined in this study, 
however, it was postulated that the biochemical cascade leading to apoptosis could be 
disrupted by hypothermia while not in necrosis as the cell death was too great to be rescued. 
The activation of caspase-3 following hypoxia-ischemic brain injury was observed to be 
prominent in immature neurons and declining in mature neurons (Hu et al., 2000). Caspase-3 is 
a cysteine protease that cleaves cytoskeletal proteins, kinases, and DNA repair enzymes. It is 
also an effector caspase downstream of the initiator caspases (caspase-2, -8, -9, and -10) in the 
apoptotic pathway and when caspase-3 is activated cells undergo apoptosis. Later studies 
conducted in neonatal rats exposed to hypothermia after injury by hypoxia-ischemia found 
caspase-3 was inhibited (Fukuda et al., 2001). This suggested that blocking the apoptotic 
pathway by hypothermia could reduce secondary brain injury. Indeed, when caspase-3 was 
specifically inhibited exogenously by intracerebroventricular injection into hypoxic-ischemic 
neonatal brain injured rats, only apoptotic neurons were rescued and brain injury was reduced 
(Han et al., 2002). A subsequent study by Zhu et al. (2004) carried out further biochemical 
analyses in the apoptotic pathway, revealed that inhibition of cytochrome c, which is upstream 
of caspase-3 was also involved in hypothermia induced neuroprotection. Although, the previous 
studies indicate that therapeutic hypothermia offers neuroprotection by disrupting the apoptotic 
pathway, the exact molecular mechanisms underlying this protective effect are still not fully 
understood. The complexity in cell death and the pleiotropic effects of hypothermia on 
neuroprotection suggest a more complicated interplay of molecular mechanisms.  
 
 
 
75 
 
4.3  COLD INDUCIBLE PROTEINS 
As mild hypothermia can downregulate the expression of certain proteins (e.g. cytochrome c 
and caspase-3), it can upregulate a select group of proteins (e.g. cold-shock proteins or CSPs) 
as well, which are important determinants in the adaptation to growth and survival during low 
temperatures. CSPs, unlike heat-shock proteins (HSPs) have been less extensively studied 
even though the cold shock response seems to be important for the skin, testis, organ storage, 
hibernation, and treatment of brain damage.  
The RNA-binding motif protein 3 (Rbm3) and cold-inducible RNA-binding protein (Cirp, also 
referred as A18 hnRNP) are the only two mammalian CSPs that have been well characterized 
(Danno et al., 1997; Nishiyama et al., 1997). Both are highly conserved and induced by mild 
stress including hypothermia. They belong to the glycine-rich RNA-binding protein (GRP) family. 
Their amino termini are defined by a consensus sequence RNA-binding domain (CS-RBD); also 
known as RNA recognition motif (RRM), ribonucleoprotein motif (RNP), or RNP consensus 
sequence, which is important for RNA binding. Their carboxy termini contain a glycine-rich 
domain important for strengthening protein-protein and or protein-RNA interactions.  Mouse 
Cirp, which is 99% identical in CS-RBD to human CIRP, is also 77% structurally related to 
human RBM3 and with an overall 64% similarity in amino acid sequence (Nishiyama et al., 
1997; Danno et al., 1997). The function of these two CSPs are still currently being elucidated, 
however they have been postulated to be involved in posttranscriptional regulation of gene 
expression indicated by studies on proteins with CS-RBD (Burd and Dreyfuss, 1994; Danno et 
al., 1997; Fujita, 1999). Both have been found to be expressed in the testis, pancreas, placenta, 
adrenal gland, and brain. However, only Cirp was expressed in the heart (Derry et al., 1995; 
Danno et al., 1997)           
In mammalian cells, proliferation and growth are generally reduced during mild hypothermia or 
at 27-32°C but are not arrested unless below 27°C (Fujita, 1999; Roobol et al., 2008). 
Interestingly, in terms of recombinant protein production in cultured mammalian cells, mild 
hypothermia seems to prolong cell viability (Al-Fageeh and Smales, 2006). The inhibition of 
metabolism by reducing cell proliferation during hypothermia is thought to be a protective 
mechanism, lowering protein synthesis (Lleonart, 2010).  
In-vitro experiments assessing cell proliferation and protein synthesis, independent of mild 
hypothermia, have revealed some aspects into the function of Cirp and Rbm3. Over-expression 
of Cirp in mouse fibroblasts (BALB/3T3) reduced growth rate and prolonged the G1 phase of the 
cell cycle (Nishiyama et al., 1997), which suggested that it could be responsible for slowing 
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down metabolic events seen at low temperatures. On the other hand, Rbm3 does not reduce 
cell growth (Fujita, 1999). 
Since both CSPs are upregulated in response to protein synthesis inhibitors and protein 
synthesis is reduced at low temperatures the cold shock response in mammalian cells is 
thought to be dependent on a temperature sensory mechanism in ribosomes, moreover, that 
expression of Rbm3 and Cirp may facilitate ribosomal functions by serving as RNA chaperones, 
increasing mRNA stability and preventing formation of stable secondary structures, which has 
been previously posed for non-homologous bacterial CSPs (Jones et al., 1996; Danno et al., 
1997; Fujita, 1999).  
Hypothermia not only exposes cells to cold stress due to changes in temperature but also 
exposes them to hypoxic stress due to changes in dissolved oxygen levels at low temperatures.  
Both types of cell stress have been reported to affect cell metabolism and interestingly the 
transduction pathway of cold stress has been suggested to share similar components specific to 
the hypoxic transduction pathways and not the hyperoxic pathways (Gon et al., 1998). In fact, 
Cirp and Rbm3 have been reported to be expressed in-vitro under hypoxic conditions in a HIF 
(hypoxia-inducible factor) independent manner (Wellmann et a., 2004). 
   
4.4  CAN RBM3 BE NEUROPROTECTIVE? 
Although, their functions have not been well-characterized, CSPs have been examined in a 
variety of mammalian cells and suggested to participate in coordinating many cellular events 
involved in transcription, translation, the cell cycle, metabolism, and cytoskeleton organization 
(Al-Fageeh and Smales, 2006). Resolving the function of CSPs will be important in 
understanding the cold shock response especially in hypothermia-induced neuropotection.     
In the brain the physiological function of Cirp and Rbm3 in neuronal cells is currently unknown. 
Cirp was reported to be constitutively expressed in the hippocampus (Xue et al., 1999). By 
Northern blot analysis, Cirp mRNA expression was reduced in the hippocampus followed by 
transient forebrain ischemia at 3 and 6 hours (Xue et al., 1999). Elevation in body temperature 
and generation of reactive oxygen species were speculated by the authors to inhibit Cirp 
expression. A similar study performed a decade later showed an increase of Cirp expression at 
24 hours but not at 6 hours followed by transient ischemia in the cortex only. Cirp expression 
was significantly increased at 6 hours followed by ischemia only when hypothermia was 
introduced (Liu et al., 2010). The results of this study suggested that ischemia alone was not 
able to induce Cirp. Additionally, Cirp did not directly affect metabolic processes as lactate 
production could not be influenced by Cirp suggesting that the neuroprotective effects of 
77 
 
hypothermia-induced Cirp were rather on gene regulation. Whether Cirp expression influenced 
neuronal death followed by ischemia was not concluded in these studies.        
Unlike Cirp, Rbm3 has been proposed to promote protein synthesis under mild hypothermia 
(Danno et al., 1997; Fujita, 1999). Expression of Rbm3 has been well documented in cancer cell 
lines and its induction seems to be necessary for cell survival and proliferation (Sureban et al., 
2008; Wellmann et al., 2010). Rbm3 transcripts have also been reported to be expressed in the 
cerebrum, cerebellum, and olfactory bulb of adult mice (Danno et al., 2000; Smart et al., 2007). 
Two isoforms of Rbm3 that differ by a single arginine in the RG region have been identified in 
rat and mouse brain. Both seem to influence protein synthesis strongly however may still 
function differently since they were localized to different neuronal compartments. Depending on 
the splice variant they could be either expressed in the nuclei or dendrites (Smart et al., 2007). 
The existence of the two isoforms needs to be clarified, but the difference in localization 
suggests that they might be important for specifying local translation. Interestingly, in glia cells, 
Rbm3 Arg+ and not Arg-, was expressed (Smart et al., 2007). 
Little is known on Rbm3 in neuroprotection but so far the literature suggests that it seems 
beneficial, preventing cell death and increasing protein synthesis. Overexpression of Rbm3 
rescued PC12 cells from polyglutamine-induced apoptosis of mutated Huntington’s disease 
(Kita et al., 2002). In neuroblastoma N2a cells, overexpression of Rbm3 increased protein 
synthesis by lowering microRNA (miRNA) levels (Dresios et al., 2005). Furthermore recent 
studies in mammalian cells show Rbm3 to be critical for cell survival (Sureban et al., 2008; 
Wellmann et al., 2010). Therefore we hypothesized that Rbm3 might be able to mediate 
hypothermia induced neuroprotection in neonatal asphyxia. In COSCs, cultured from postnatal 
age 4 (P4) animals, Rbm3 was highly concentrated in nuclei after hypothermia (32°C) in 
contrast to slices at normothermia (37°C). P4 and P21 slices showed upregulation of Rbm3 at 
the mRNA and protein level after mild hypothermia, but this increase was 2-3 fold higher in 
cultures from the younger animals. Upregulation of Rbm3 was also observed in primary neurons 
under hypothermia. Here, we tested whether mild hypothermia was neuroprotective after 
induced apoptosis by staurosporine (STS) and indeed at 32°C the cells were protected from 
degeneration. Knockdown of the expression of Rbm3 by RNA interference through small- 
interfering RNA (siRNA) did not protect the cells by mild hypothermia from induced apoptosis. 
Furthermore, in the absence of mild hypothermia, vector-driven upregulation of Rbm3 rescued 
PC12 cells from degeneration suggesting that upregulation of this protein is required for 
neuroprotection. 
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4.5 THE RNA-BINDING PROTEIN RBM3 IS INVOLVED IN HYPOTHERMIA-INDUCED 
NEUROPROTECTION 
 
This study have been published in  
Neurobiology of Disease (Chip et al., 2011) 
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The only available therapy for neonatal asphyxia is cooling the
infant's body to about 33 °C (mild hypothermia) for 48–72 h. A series
of randomized multicenter trials have established a protective effect
of therapeutic hypothermia in reducing long-term sequelae (Edwards
et al., 2010; Jacobs et al., 2007; Schulzke et al., 2007; Shah et al., 2007).
Hypoxic-ischemic brain damage following asphyxia occurs in a
biphasic manner, where the early phase (first hours) is classified as
necrosis and the later phase (by 48 h) display characteristics ofneuronal apoptosis (Northington et al., 2001a, 2001b). Thus, the
primary target of hypothermia is themitigation of early cell death and
the prevention of delayed neuronal apoptosis (Robertson et al., 2009).
In neurons, hypoxia-ischemia triggers an intrinsic apoptotic
pathway (Ferrand-Drake and Wieloch, 1999; Perez-Pinzon et al.,
1999; Zhu et al., 2003), characterized by a biochemical cascade
leading to activation of caspases, cleavage of poly ADP-ribose
polymerase (PARP), internucleosomal DNA fragmentation, and
eventually cell death with release of intracellular enzymes, such
LDH (Liu et al., 1996; Susin et al., 1999a, 1999b). Hypothermia
ultimately appears to stop cell death (Edwards et al., 1995; Fukuda
et al., 2001; Han et al., 2002; Zhu et al., 2004) but the precise
molecular events of how and where hypothermia retards this
biochemical cascade are poorly understood.
The RNA-binding protein RBM3 belongs to a very small group of
cold inducible proteins being synthesized in response to either
hypothermia or other conditions of mild stress (Lleonart, 2010).
RBM3 is evolutionary highly conserved (Derry et al., 1995) and has
been suggested to play a role in hibernation (Fedorov et al., 2009;
Williams et al., 2005). While a temperature drop from 37 to 32–34 °C
is sufficient to induce the expression of RBM3 (Danno et al., 1997),
elevated temperature decreases the expression of RBM3 in the setting
of therapeutic hyperthermia (Zeng et al., 2009) and in cryptorchid
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abdominal compartment to the 33–34 °C scrotal environment (Danno
et al., 2000).
Recent studies have attributed RBM3 a role in cell survival.
Blocking RBM3 signaling by siRNAs triggers cells mitotic catastrophe
in colon carcinoma cells (Sureban et al., 2008) and causes loss of
proliferation and ultimately cell death in human embryonic kidney
cells (HEK-293) (Wellmann et al., 2010). In contrast, exogenous over-
expression of RBM3 inhibits apoptosis in neurons transfected with
mutated huntingtin (Kita et al., 2002) and increases protein synthesis
in mouse neuroblastoma N2a cells (Dresios et al., 2005; Smart et al.,
2007).
These findings on RBM3 prompted us to hypothesize that the cold-
inducible RBM3 might serve as a candidate to mediate hypothermia-
induced neuroprotection after neonatal asphyxia, via its up-regulation
in response to hypothermia. Therefore, we first determined RBM3
expression in the developing brain of mice. Second, we studied RBM3
induction in response to hypothermia in cortical organotypic slice
cultures (COSCs), primary neurons and rat pheochromocytoma cells
(PC12). Third, we investigated whether in PC12 cells neuroprotection
by hypothermia might involve RBM3, employing siRNA knockdown
and vector-driven RBM3 over-expression experiments.
Material and methods
Animals, slice preparations, cortical organotypic slice cultures, and
primary neurons
All animal experiments were performed with permission of the
local animal care committee and in accordance with international
guidelines on handling laboratory animals and current Swiss law.
C57BL/6J mice from postnatal days 1, 10, 19, and adult (4 months
old) were used. Mice were anesthetized with pentobarbital (Veta-
narcol®, 0.04 g/kg ip) and perfused with 4% paraformaldehyde in
0.1 M phosphate buffer. Brains were dissected and immersed in 4%
paraformaldehyde overnight. Serial sagittal 40 μm sections were cut
with a vibratome and collected in cold Tris-phosphate buffer (TBS,
0.05 M).
COSCs were prepared and cultivated with the classical technique
(Stoppini et al., 1991) with modifications as published recently by our
group (Camenzind et al., 2010). Briefly, brains of C57Bl/6J postnatal
day 4 (P4) or P21 mice were removed and coronal slices of the cortex
with a thickness of 400 μm were prepared on a tissue chopper. The
slices were placed on 0.4 μm Millicell-CM, 12 mm diameter culture
inserts (Millipore, Zug, Switzerland) in six-well dishes and cultured in
medium containing HEPES-buffered minimal essential medium
(50%), Hank's buffered salt solution (HBSS, 25%), and heat-inactivated
horse serum (25%) complemented with glutamax (2 mM; Invitrogen,
Basel, Switzerland), glucose (1 g/l) in a humidified incubator with 5%
CO2 at either 32 °C or 37 °C for 72 h. Medium was changed 24 h after
the COSCs were prepared.
Primary neuronal cultures were obtained from the cerebral cortex
of C57Bl/6 J mice gestational stage E14 as previously described
(Ogunshola et al., 2002). Briefly, dissected cortices were dissociated
in HBSS containing trypsin and DNase I for 5 min at 37 °C. Neurons
were seeded on poly-L-lysine coated petri dishes (1.2×106 cells per
60 mm dish) in Dulbecco's modified Eagle's medium (DMEM)/
Glutamax medium containing: B27 supplement (1X), albumax
(0.25 g/ml), sodium pyruvate (1%) and 100 U/ml penicillin strepto-
mycin, (Invitrogen, Basel, Switzerland). Neurons were maintained in
culture for 6 days in a humidified incubator at 37 °C with 5% CO2.
Immunohistochemistry
Immunohistochemistry of free-floating (adult and P19) and
mounted sections (younger ages) was carried out as describedpreviously (Maetzler et al., 2007). Sections were washed thoroughly
and solubilized with 0.4% Triton X-100 in 0.1 M phosphate-buffered
saline (PBS) for 90 min. Non-specific binding was blocked for 2 h in
normal goat serum (5% in PBS containing 0.1 M lysine). Then sections
were incubated with different preparation of the RBM3 antibody
(rabbit, 1:500 up to 1:5000, (Wellmann et al., 2010) overnight at
room temperature. Biotinylated goat-anti rabbit IgG (1:100; Anti-
bodies, Davis, CA, USA), and the avidin-biotin complex (Vector,
REACTOLAB, Servion, Switzerland) were applied for 90 min each.
Immunoreaction was visualized with 0.05% diaminobenzidine (DAB)
and 0.1% H2O2 with nickel enhancement (1% NiSO4 in the DAB
solution). Serial sections were immunoreacted for doublecortin (DCX,
rabbit polyclonal anti-DCX diluted 1:500 to 1:1000; #4604 Cell
Signaling) and developed as indicated above. All sections were
mounted on coated slides, dehydrated in graded ethanol, cleared
with xylol and coverslipped in Eukitt (Kindler, Freiburg, Germany).
For co-labeling in COSCs (Camenzind et al., 2010), monoclonal
anti-NeuN (diluted 1:250, Chemicon, Hofheim, Germany) was
incubated together with rabbit polyclonal anti-RBM3 (diluted 1:100,
ProteinTech Group, Chicago, IL, USA) and DAPI (Invitrogen) overnight
at 4 °C. Secondary antibodies were anti-rabbit Alexa-488 and anti-
mouse Alexa-568 (both diluted 1:500, Invitrogen). Slides were
incubated for 2 h at room temperature, mounted with Vectamount
(Vector) and photographed.
Cell culture
PC12 were purchased from the German Collection of Microorgan-
isms and Cell cultures (DSMZ, Braunschweig, Germany, http://www.
dsmz.de/) and were maintained in DMEM supplemented with 5%
heat-inactivated fetal calf serum (FCS), 10% heat-inactivated horse
serum and 100 units penicillin/streptomycin per mL (herein after
referred to as complete medium, all from Oxoid AG, Pratteln,
Switzerland), at 37 °C and 5% CO2 in a fully humidified incubator.
Induction of apoptosis and hypothermia
PC12 cells, primary neurons and COSCs were treated with various
concentrations of bacterial alkaloid staurosporine (STS; Sigma-Aldrich
Chemie GmbH, Buchs, Switzerland) in fresh medium supplemented
with 1% horse serum and 0.5% FCS, as indicated. In some PC12
experiments, as indicated, apoptosis was induced by serum and
glucose deprivation (SGD) for 6 h. Forty-eight hours after transfection
and seeding of PC12 cells in complete media, cells were washed twice
with PBS, then incubated with PBS for 6 h (SGD), followed by rescue
with complete medium. For immunoblotting of cleaved PARP, cells
were harvested 4 h after addition of STS 0.8 μM; for assessment of LDH
release, cell viability and internucleosomal DNA fragmentation cells
were harvested 24 to 48 h after addition of 0.2 or 0.4 μM STS, as
indicated. Hypothermia of 32 °C was achieved in a Mini Galaxy A
incubator (Sysmex Digitana, Horgen, Switzerland) and applied for
varying times starting either prior (24 h) or synchronous with
induction of apoptosis as indicated.
RNA-extraction and real-time RT-PCR analyses
RNA preparation and Reverse Transcription (RT) were performed
as described (Wellmann et al., 2004). For quantitation, cDNA was
amplified by use of SYBR GreenER qPCR SuperMix Universal
(Invitrogen) and real-time PCR was carried out on a Rotor-Gene
6000 (Corbett Life Science, Sydney, Australia) as previously described
(Wellmann et al., 2008). Primers for detection of the following mouse
mRNA molecules have been published previously, RBM3 and
reference gene RPL13A (Wellmann et al., 2004), DCX and p35 (Ge
et al., 2006). For detection of rat RBM3 mRNA the mouse RBM3
primers could be used due to 100% homology and the primers for the
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et al., 2008). All primers were purchased from Microsynth (Micro-
synth, Balgach, Switzerland).
Protein extraction and immunoblot analyses
Total cell protein extraction, quantification and immunoblotting
were performed as described previously by our group (Shalapour
et al., 2006; Wellmann et al., 2004). The following antibodies were
used: goat polyclonal anti-RBM3 (#EB09201, Everestbiotech, Oxford-
shire, UK), rabbit polyclonal anti-cleaved PARP (Asp214, Cell
Signaling, Danvers, MA, USA), and rabbit polyclonal anti-DCX
(#4604 Cell Signaling). As an internal control, blots were stripped
and reprobed with rabbit polyclonal anti-ß-actin (#4967, Cell
Signaling). Bound antibodies were detected using secondary anti-
bodies conjugated with horseradish peroxidase rabbit anti-goat
(Invitrogen) and goat anti-rabbit (Cayman, Ann Arbor, MI, USA).
Finally the enhanced chemiluminescence system (ECL, Amersham, GE
Healthcare, Glattbrugg, Switzerland) was applied.
RBM3 over-expression and short interfering RNA
The sequence of the rat RBM3 gene GenBank NM_053696 was
optimized for increased mammalian expression, re-synthesized chem-
ically by GENEART (GENEART company, Regensburg, Germany) and
cloned into the expression vector pCEP4 (Invitrogen). 2×106 PC12 cells
were transfected either with the RBM3 containing vector or the empty
vector, serving as control. For transient down-regulation of rat RBM3
mRNA 2×106 PC12 cells were transfected either with RBM3 specific
siRNA sequences (Rn_Rbm3_1 and Rn_Rbm3_4; Qiagen, Hombrechti-
kon, Switzerland) or control siRNAmolecules (AllStars Negative Control
siRNA;Qiagen). All transfectionswere performed byuse of Nucleofector
technology according to the manufacturer's instructions for PC12 cells
(Cell Line Kit V; Lonza, Basel, Switzerland). After transfection PC12 cells
were plated in four to six collagen-coated 20 mm dishes (BD-Bio-
sciences) with complete medium. Then, 24 h after transfection, plates
were subjected to the various experiments as indicated. Previously, two
RBM3 isoforms have beendescribed differing in one arginine at position
137, encoded by the first three bases of exon 6, isoform Arg+ and Arg-
(Smart et al., 2007). Our RBM3-overexpression vector codes for the
complete RBM3 protein, including arginine at position 137. The siRNA-
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Cell viability, LDH release, and internucleosomal DNA fragmentation
Viability of cells was examined by use of the MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium] tetrazolium assay according to the manufacturers
recommendations (Cell Titer96 Aqueous, Promega, Dubendorf, Swit-
zerland). LDH release was examined by Cytotoxicity Detection KitPLUS
LDH and internucleosomal DNA fragmentation by Cell Death Detection
ELISAPLUS (Roche, Rotkreuz, Switzerland). In experiments with primary
neurons, LDH release is given as absorbance (490–620 nm), in some
experimentswith PC12 cells LDH release is given as fold change relative
to control and in some as percentage of total cell lysis, as indicated. Total
cell lysis was achieved by adding supplied lysis reagent to control cells
cultivated in parallel according to themanufacturers recommendations.
Statistical analysis
Statistical significance was determined using the matched pairs
test. Student's t test was performed for each pair of data separately.
Significance with a pb0.05 is reported.
Results
RBM3 is expressed in the developing mouse brain in a temporally and
spatially restricted pattern
During postnatal murine brain development, RBM3 levels were
found to be high immediately after birth (P1) and low in adult brain,
paralleled by a very similar DCX and p35 mRNA and protein
expression dynamic (Figs. 1A and B). DCX is a microtubule associated
protein and is expressed in newborn andmigrating neurons as well as
in neuronal stem cells of the adult brain (for review of DCX and p35
see Feng and Walsh, 2001). The decrease in mRNA expression
alongside maturation was stronger for DCX than for RBM3, while
p35 exhibited only a moderate decrease (Fig. 1A).
At the immunohistochemical level, RBM3 was expressed in most
neurons of the brain during the first postnatal days (not shown). In
the course of development, RBM3 expression decreased in parallel
with thematurity of the neurons. Thus, in the somatosensory cortex of
P10 mice early generated neurons of the deep layers expressed RBM318 Ad 1 10 18  Ad
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Fig. 2. Presence of RBM3 in the postnatal mouse brain. A: In the developing (P10) somatosensory cortex overlying the hippocampus (CA1), increased expression is found in cells of
the subventricular zone (SVZ), in recently migrated neurons (arrows) and in numerous cells of the second cortical layer (L II). B and C: In the early developing cerebellar cortex (P10),
RBM3 and DCX are expressed in the external granular cell layer (EGL) as shown in neighboring sections. Similar to DCX, RBM3 is present in single cells (arrows in the high
magnification insets) crossing the molecular layer (ML) and the Purkinje cell layer (PCL) on the way to the internal granular cell layer (IGL). D and E: At P19, few neurons (arrows)
still migrate to their final destination in the IGL. Thesemigrating neurons express RBM3 and DCX (arrows). In contrast to DCX, RBM3 is present in Purkinje cells in early development
(see B) but not at later stages (see D).
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exhibited stronger RBM3 immunoreactivity (Fig. 2A). In the early
developing cerebellar cortex, RBM3 was present in the external
granule layer (EGL) where the granule cells are generated. The
centripetal migrating neurons (Figs. 2B and D) which cross through
the molecular layer (ML) and the Purkinje cell layer (PCL) were RBM3
positive. At the place where they reach their final destination, the
internal granule cell layer (IGL), RBM3 expressionwas absent (Figs. 2BAd, RBM3 A
Ad, RBM3 A
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Fig. 3. Presence of RBM3 in the adult mouse brain. A and B: In adult hippocampus,
C and D: Progenitor cells for the olfactory bulb are present in the rostral migratory stream
express RBM3 and DCX.and D). DCXwas found to stain the same type of cells in the same time
pattern as RBM3 (Figs. 2C and E).
In contrast, in adult brain, RBM3 expression was restricted to very
few neurons in the hippocampus and the forebrain. The localisation of
these cells in the subgranular layer of the adult hippocampus together
with a very similar staining pattern found for DCX in parallel sections,
suggests that neuronal stem cells of the dentate gyrus express RBM3
(Figs. 3A and B). The same is true for the rostral stream, where thed, Dcx
d, Dcx
Cx
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neuronal stem cells, within the subgranular layer (SGL), express RBM3 and DCX.
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and D). Cells of the subventricular zone were also found to express
RBM3 (see Fig. 2).
Mild hypothermia (32 °C) induces RBM3 expression in cortical
organotypic slice cultures and primary neurons
Next, we investigated RBM3 in murine COSCs drawn from
temporal cortex of newborn (P4) and adult littermates (P21). Basal
RBM3 mRNA expression (at 37 °C) was found to be about 3-fold
higher in newborn, as compared to young adult mice (Fig. 4A). In
response to 72 h of mild hypothermia (32 °C), RBM3 mRNA was up-
regulated in the P21 mice (2.8-fold) and in the P4 mice (5-fold,
Fig. 4A). Analyses of RBM3 protein expression confirmed this finding
(Fig. 4B). Primarymurine neurons exhibited a robust increase in RBM3
mRNA expression even after 24 h of mild hypothermia (Fig. 4C).
Immunohistochemistry of COSCs showed upregulation of RBM3 in
response to hypothermia for 72 h as compared to normothermia
(Fig. 5). RBM3 was particularly expressed in neurons as shown by
double-labeling with NeuN. In addition, RBM3 upregulation was
present in immature neurons as exemplified by the staining of the
subventricular zone (SVZ), which is not labeled by the marker for
mature neurons NeuN (Fig. 5). A few unidentified cells were also
positive for RBM3 which may represent immature neurons or glial
cells.
Induced apoptosis in primary neurons and PC12 cells is diminished by
mild hypothermia (32 °C)
STS is an established agent for inducing classical (caspase-
dependent) apoptosis in neurons. Primary neurons as well as PC12
cells when cultured under mild hypothermic (32 °C) conditions were
significantly less vulnerable to STS as shown by determination of LDH
release (Figs. 4D and E, respectively).
The effect of hypothermia on alleviating STS induced apoptosis
was most intense when hypothermia commenced 24 h prior to
induction of apoptosis and continued throughout the experiment,irrespective of the STS concentrations employed (Fig. 4E, temperature
profile 32/32).When comparing either exclusive pre- (32/37) or post-
cooling (37/32), the anti-apoptotic effect of hypothermia was more
effective in the experiments with post-cooling, irrespective of the
used STS concentration (Fig. 4E).
siRNA-mediated RBM3 down-regulation impedes the protective effect of
mild hypothermia (32 °C)
Down-regulation of RBM3 mRNA expression to less than 90% of
control levels was achieved in PC12 cells by combining two siRNA
sequences directed against rat RBM3. After transfection (up to 72 h) of
PC12 cells with either siRNA directed against RBM3 or nonsense
mRNA, there was no significant difference with respect to cell viability
(MTS assay) and apoptosis (DNA fragmentation and LDH release,
Fig. 6A). However, when PC12 cells were cultured after siRNA
transfection in mild hypothermic conditions (32 °C) and were
exposed to STS, the protective effect of hypothermia was almost
completely abolished in the RBM3-silenced PC12 cells. This was
shown by cleavage of PARP, internucleosomal DNA fragmentation,
and determination of LDH release (Figs. 6B, C, and D, respectively).
Vector-based RBM3 over-expression mimics the protective effect of mild
hypothermia (32 °C)
Two days after transfection of PC12 cells with either the RBM3-
pCEP4 expression-vector or the empty control vector, cells were
treated either with STS (Figs. 7A–B) or with SGD for 6 h following
complete medium for 42 h (Fig. 7C). RBM3 over-expressing cells had
less cleavage of PARP, internucleosomal DNA fragmentation, and LDH
release, as compared to controls.
Discussion
Here, we present several lines of evidence for an involvement of
the cold-inducible RNA binding protein RBM3 in mediating hypo-
thermia-induced neuroprotection. First, RBM3 is widely expressed in
Fig. 5. In COSC obtained from postnatal day 4 mice, RBM3 is present after 3 days in culture. In slices exposed to hypothermia (32 °C) RBM3 is highly concentrated in nuclei (A), as
compared to slices cultured at normothermia (37 °C; F). NeuN, a marker of differentiated neurons, exhibits a similar expression at 32 °C (B) and 37 °C (G) and is strongly colocalized
with RBM3 (C and H). The nuclear stain DAPI allows the identification of the cortical layers (D and I) and shows that under hypothermia, RBM3 is not only present in differentiated
neurons but also in the subventricular zone (SVZ) and in unidentified cells of the developing cortex (E and J).
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causes significant RBM3 mRNA and protein up-regulation in juvenile
as well as in adult neurons. Third, the degree of neuronal apoptosis is
inversely related to the level of RBM3 expression. Fourth, blocking
RBM3 over-expression that normally follows mild hypothermia
(32 °C) in cultured neuronal cells diminishes the protective effect of
hypothermia. Fifth, inducing RBM3 expression even under euthermic
conditions (37 °C) endows neuronal cells with more resistance
against induction of apoptosis.
Our observations on the spatiotemporal RBM3 protein expression
duringmurine postnatal brain development are in linewith the recent
findings in rats (Pilotte et al., 2009). An overall high neuronal RBM3
expression in the first postnatal week of mice (Figs. 1 and 2)
corresponds to a climax in RBM3 protein expression in the second
postnatal week of rats (Pilotte et al., 2009). In both species, RBM3
expression becomes restricted to the remaining neuronal proliferative
zones of the olfactory bulb and the hippocampus when animals grow
up (Fig. 3). Thus, RBM3 appears to be among several other RNA-
binding proteins exhibiting a common dynamic expression pattern,
peaking early after birth and then declining (Hambardzumyan et al.,
2009; McKee et al., 2005). This coordinated temporal expressionwave
parallels neuronal requirements of translational rate (Pilotte et al.,
2009). Within the group of RNA-binding proteins, RBM3 and the
highly related cold inducible RNA-binding protein (CIRP) stand out
due to their cold-inducibility (Lleonart, 2010).On the one hand we performed a developmental study in mice
from P1 up to adulthood. P10 and 19 are just representative examples
(Fig. 2). On the other hand, to demonstrate RBM3 expression in
response to hypothermia, we used COSCs from early postnatal
animals (P4) to mimic the situation in the newborn infant (Figs. 4A,
B, and 5). P21 animals are the oldest animals fromwhich COSCs can be
generated. Therefore, we selected this age to show the reaction in a
brain as mature as possible (Fig. 4A).
STS, a broad spectrum protein kinase inhibitor, induces cell death
by triggering the intrinsic apoptotic pathway involving cytochrome c
release from mitochondria (Johansson et al., 2003). Exposure of PC12
cells to STS has been studied extensively to investigate either
neuronal differentiation by application of low concentrations (range
of 10 nM) (Demeneix et al., 1990; Rasouly et al., 1996) or induced
apoptosis when applied at high concentrations (up to 1 μM) (Xia et al.,
1995). In response to nerve growth factor (NGF), PC12 cells
differentiate into neuronal cells with neurite extensions (Greene,
1978). In our experiments presented here, naïve PC12 cells were used
due to the following considerations: First, for transfection, cells had to
be collected according to the nucleofector protocol and then replated
in new dishes, thus in case of prior differentiation cells may lose their
differentiated phenotype including neurites. Second, the effect of
transient siRNA transfection is too short to render the possibility of a
subsequent differentiation by NGF over a couple of days. Third, it is
unknown how treatment of NGF affects RBM3 expression. However,
Fig. 6. Influence of RBM3 silencing on apoptosis and neuroprotection by hypothermia in PC12 cells. PC12 cells were transfected either with siRNA targeting RBM3 mRNA (R) or
control mRNA (c) as indicated. Panel A shows the effect of RBM3 down-regulation without further treatment. Exposure of PC12 cells to either hypothermia (32 °C) or normal
temperature (37 °C) started 24 h prior to STS treatment as indicated (panel B, C, and D). For immunoblotting of the indicated antigens (RBM3, cleaved PARP (cl. PARP), and β-actin)
cells were harvested already 4 h after STS treatment, panel B. For assessment of viability (MTS assay, panel A), DNA fragmentation (panel A and C) and LDH release (panel A and D)
cells were harvested 48 h after STS treatment. All data shown are representative of at least three independent experiments and columns, average of quintuplicates, bars, ±s.d.
Student's t-tests were conducted in A, C and D using a criteria of pb0.05 for significance, marked by asterisks.
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appropriate in vivo experiments with transgenic animals are required.
The use of LDH release assay to monitor apoptosis in neurons is
still on debate. However, while LDH release was originally used to
measure neuronal cell death occurring from necrosis (Koh and Choi,
1987), in more recent publications it was shown, that by means of
LDH release neuronal apoptosis in cortical cultures is accuratelyB
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criteria of pb0.05 for significance, marked by asterisks.detected (Gwag et al., 1995; Koh and Cotman, 1992). In a comparative
study of LDH and MTT assays in cortical cell cultures with induced
neuronal apoptosis by exposure to various pro-apoptotic stimuli some
benefits were noted when using LDH release assays (Lobner, 2000).
We decided not to use MTT assay as this assay quantifies mitochon-
drial activity which might be reduced by hypothermia, thus
negatively affecting comparability of cooled and uncooled samples.0
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395S. Chip et al. / Neurobiology of Disease 43 (2011) 388–396The boundaries between apoptosis, necrosis and other forms of cell
death are less distinct than previously thought (Vandenabeele et al.,
2010), particularly so in neurons (Yuan et al., 2003).
Further investigations will have to elucidate the mechanisms of
RBM3 action, including the physical RBM3 interaction partners and
the target molecules of RBM3 signaling in neuroprotection. RBM3
belongs to a small group of RNA-binding proteins that contains only
one single RNA-recognition motif (RRM) (Lleonart, 2010). RRMs are
extremely diverse in terms of both structure and function and bind
RNA species as well as proteins (Maris et al., 2005). Evidence suggests
that two or more RRMs located within the same protein are required
for full action (Clery et al., 2008). Moreover, it is now known that
regulated gene expression at the post-transcriptional level is based on
a network of interactions among RNA-binding proteins operating
within multifactorial ribonucleoprotein complexes (Glisovic et al.,
2008). Therefore, it is not surprising that several RNA-binding
proteins exhibit a common dynamic expression pattern during
postnatal brain development (Hambardzumyan et al., 2009; McKee
et al., 2005). Previous reports found RBM3 to be associated with
ribosomal subunits (Dresios et al., 2005; Smart et al., 2007) and at
least one heterogenous ribonucleoprotein (Sureban et al., 2008).
Exposure of mammalian cells to mild hypothermia causes a
general inhibition of protein synthesis (Burdon, 1987). The observa-
tion that RBM3 has a positive effect on protein synthesis suggests that
RBM3 may prevent a more dramatic reduction of protein synthesis
under conditions of hypothermia (Dresios et al., 2005; Smart et al.,
2007). However, it is unlikely that RBM3 rescues neuronal cells from
apoptosis by merely stabilizing the translational machinery. Thus, we
propose that in a fashion similar to the specific stabilization of
cyclooxygenase-2 (COX-2) mRNA in colon carcinoma cells (Cok et al.,
2004; Sureban et al., 2008), a number of specific target mRNAs are
stabilized by RBM3 in neuronal cells. The cold inducible protein CIRP,
also known as heterogenous ribonucleoprotein A18, shares high
homology with RBM3, especially in the RRM (Lleonart, 2010). It has
recently been found to induce the expression of thioredoxin and
thereby protecting cells from oxidative stress and apoptosis through
quenching reactive oxygen species (Yang et al., 2006). Furthermore, a
role for CIRP has recently been established in preserving the stemness
of neural stem cells and suppressing apoptosis of the cells in
conditions of moderate low temperature (32 °C) (Saito et al., 2010).
Our experiments performed on the COSCs are the first to show the
effect of hypothermia on RBM3 expression in intact brain tissue.
Ultimate proof of the neuroprotective action of RBM3 will require in
vivo experiments employing RBM3 transgenic animals which are not
available at present. The signaling cascades upstream and down-
stream of RBM3 also remain to be elucidated.
While RBM3 is expressed in brain neurons in a spatiotemporally
restricted fashion, its hypothermia-mediated upregulation may
rescue neuronal cells from apoptosis and thus contribute to the
clinical efficacy of cooling asphyxiated newborn infants.
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5.1 FINAL DISCUSSION 
The hippocampus is remarkably unique in structure, important for learning and memory as well 
as vulnerable to various neurological disorders, in particular cerebral ischemia by stroke or 
neonatal asphyxia. The mechanisms underlying CA1 neuronal death following cerebral 
ischemia are not well understood. Nevertheless, a large proportion of research on cerebral 
ischemia has been centered on neuroprotection. In vivo and in vitro models have provided a 
wealth of data, which strongly suggest that ischemic-induced neuronal death is due to glutamate 
excitotoxicity (Choi et al., 1992; Rytter et al., 2003). It is believed that upon release of glutamate, 
activation of glutamate receptors that are ionotropic and metabotropic such as NMDA, AMPA, 
KA, and mGluRs, allows Ca2+ entry leading to a cascade of signaling pathways activated by 
Ca2+ that induce processes of either neuronal survival or death (Dirnagl et al., 1999). 
Therefore, efforts have been made towards neuroprotection inhibiting activation of glutamate 
receptors with antagonists to certain receptor types in order to prevent glutamate-induced 
neuronal death. The glutamate receptor antagonists have shown to be effective in both in vivo 
and in vitro models, but unfortunately have not been proven to be effective drugs in clinical 
practice (Wahlgren and Ahmed, 2004), implicating the need for re-examination of the 
physiological relevance of experimental models used, both in vivo and in vitro and further 
highlighting the complexity of neuronal death. Neuronal death by glutamate excitotoxicity may 
contribute to a substantial portion of the initial phase of injury, but may not be the only active 
event. The neurovasculature is also affected when blood flow is blocked or reduced by an 
occlusion. BBB damage ensues during the secondary phase of injury by reperfusion, when 
oxygen and glucose are being resupplied to the brain (Kuroiwa et al., 1988, Belayev et al., 
1996; del Zoppo et al., 2003). Dysfunction of BBB contributes to CNS injury by further 
decreasing nutrient supply and allowing toxins to invade the brain, interfering with the CNS 
microenvironment (Murakami et al., 1997). Moreover, increased cerebrovascular permeability 
can lead to the development of cerebral edema and disturb the CNS ion gradient (Betz et al., 
1994).     
The BBB is found only in cerebral endothelial cells that make up the brain microvasculature, 
composed of TJs, AJs, and transporters that maintain the paracellular and transcellular 
pathways in BBB (Abbott et al., 2010). As the BBB is important for cerebral homeostasis and 
brain function a lot of research has been conducted in understanding its development and 
function. Of particular interest is the paracellular pathway not only for understanding BBB 
mechanics but for designing pharmaceutical drugs to be delivered into the CNS as it is also a 
rate limiting step.  
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Genetically modified animal models, such as Cld-5 knockout mice (Nitta et al., 2003), have 
revealed a certain amount of detail on the relevance of tight junction proteins as key players in 
maintaining an impermeable barrier. Still these in vivo models limit BBB research to 
investigating mostly developmental mechanisms. Less is known about how tight junction 
proteins are regulated after disease. A major obstacle in BBB research is the difficulty of gaining 
direct access to these anatomical features of BBB in vivo. Even with the advent of in vitro 
models, many studies have utilized epithelial cells, endothelial cells of non-neuronal origin, or 
co-cultures of cerebral endothelia and glia of different species, such that translating the data 
from in-vitro to in-vivo has been very difficult. Furthermore, BBB function is maintained by cell-
cell signaling between neuronal, glial, and vascular elements that make up the neurovascular 
unit (Abbott et al., 2006). The endothelial and glial co-culture systems that allow the fine details 
of TJs and transporters to be examined lack the structural connectivity and influences by the 
pericytes, neurons, and basement membrane encompassing this neurovascular unit which may 
also be required for a more accurate analysis of the cellular and molecular mechanisms of the 
BBB. 
In our lab an alternative in vitro BBB model was developed which incorporates culturing cortical 
organotypic slices (COSCs) of newborn mice in the presence of FGF2 (Bendfeldt et al., 2007) 
with the aim of narrowing the gap between in vitro and in vivo BBB data. Since tight junction 
proteins occludin, ZO-1, Cld-5, and -3 were well preserved in COSCs derived from newborn 
mice (P3-4), the aims of the current study were to examine the preservation of transporters 
GLUT-1 and P-gp that are also a part of the BBB and whether they were present in COSCs 
derived from older mice (P21). We postulated that in the presence of FGF-2 these transporter 
proteins would also be preserved. Furthermore, we investigated the function of P-gp transport to 
further characterize the in vitro system.  
Unlike tight junction proteins which maintain the paracellular pathway sealed, transporters are 
responsible for regulating the exchange of molecules along the transcellular pathway of BBB. 
GLUT-1 is a very essential transporter, since glucose is a major nutrient providing energy to the 
brain (Maher et al., 1993). It has been considered as a sensitive indicator of vascular integrity 
and BBB function (Dermietzel et al., 1992; Garbuzova-Davis et al., 2007). Furthermore, it is an 
important cerebral endothelial protein as it has been recently shown to be necessary in normal 
development of the cerebrovasculature and the BBB (Stenman et al., 2008; Liebner et al., 
2008). In our study, GLUT-1 expression was observed in both the luminal and abluminal 
membranes of vessels, which is comparable to observations found in vivo (Dick et al., 1984; 
Simpson et al., 2007).  The expression of GLUT1 persisted for at least 3 days in cultures 
derived from mice of P4 to P21, thus strengthening the COSC model as a suitable in vitro 
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system to study BBB at the level of glucose transport and at different developmental time points.  
Additionally, we examined the expression of multidrug resistance P-gp, an ATP-dependent 
efflux pump; another important BBB transporter in preventing the entry of xenobiotics or toxic 
metabolites and facilitating them out of the brain parenchyma (Löscher and Potschka, 2005; 
Hermann and Bassetti, 2007). At DIV3, P-gp transporters were expressed along the luminal 
membrane of vessels and became more strongly expressed as the slices were derived from 
older mice, which is consistent with the developmental pattern of P-gp expression in vivo (Tsai 
et al., 2002). Also, P-gp was demonstrated to be functional in slices, derived from P8 to P21 
mice, as rhodamine 123, a P-gp substrate, was able to specifically accumulate into the lumen of 
large and small blood vessels of both acute and cultured slices. P-gp transport capacity was 
previously shown in cerebral endothelial cell cultures (Hegmann et a., 1992), however our study 
is the first to demonstrate P-gp transport function in organotypic slice cultures which could also 
be blocked by verapamil, a P-gp inhibitor, underlining the potential value of this simple model 
system in studying mechanisms of BBB transport and furthermore as a potentially useful tool in 
the pharmaceutical industry for exploring drug penetration into the brain.   
In an effort to continue and exploit our in-vitro BBB model we employed oxygen-glucose 
deprivation to examine the components of the BBB under a pathological condition, with the 
development of neurodegeneration. In terms of the BBB, cell-to-cell interactions between the 
endothelial and perivascular cells are necessary to maintain its barrier properties (Abbott et al., 
2006). As mentioned before the integrity of BBB is often compromised in brain injuries. 
Dysfunction of non-neuronal cells along with loss of the neurovascular unit that maintains the 
BBB may be involved in the development of neurodegeneration (Zlokovic, 2008). Up to now the 
evidence linking neurodegeneration and neurovascular alterations have been circumstantial 
(Zlokovic, 2010). In vivo data have been controversial in showing whether alterations in the BBB 
and neurodegeneration are linked or separate events (Albayarak et al., 1999; Chen et al., 
1999). Furthermore, evidence available on the vascular component during neuronal injury is 
rather scarce (Zlokovic, 2010). With this in mind, the aim of the second study was to use our in-
vitro BBB model to follow the development of neurodegeneration induced by hypoxia, oxygen-
glucose deprivation or excitotoxicity; in parallel, to determine whether components of the 
neurovascular unit were also disrupted by analyzing the expression of both BBB and neuronal 
markers.  
When EHOSCs were submitted to 15 minutes of hypoxia or oxygen-glucose deprivation cell 
death was specific to CA1 which developed in a delayed manner, 24 and 48 hours later, 
consistent with other studies done in hippocampal organotypic slice cultures (Rytter et al., 2003) 
although in vivo transient global ischemia models usually exhibit a longer delay at 48-96 hours 
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(Kirino, 1982; Chen et al., 1998). The mechanism for this delayed neuronal death is currently 
not understood.    
Astrocytes have been known to be reactive and become immunopositive for glial fibrillary acidic 
protein (GFAP) following transient ischemia (Soltys et al., 2003). In terms of the BBB, their 
endfeet envelop the endothelium, which is suggested to maintain the unique endothelial 
phenotype of the BBB (Hawkins and Davis, 2005). Initially, we examined the morphology of 
astrocytes and observed noticeable features of astrogliosis by GFAP immunohistochemistry as 
well as loss of astrocytic contacts to blood vessels (preliminary data). Since the differentiation 
between reactive and non-reactive astrocytes is not easily assessed in organotypic slices 
because there is a high background expression of GFAP due to the primary lesion made from 
the preparation of brain slices, we did not continue any further analyses on this cell type. 
However, we did perform some biochemical analyses on GLUT1 and VEGF, two well known 
markers, which are known to be upregulated upon hypoxia (Ran et al., 2005) and indeed both 
were upregulated in EHOSCs by hypoxia or OGD. Because two isofoms of GLUT1 exist: 55 
kDa isoform that is endothelial cell specific and the 45 kDa isoform that is glial cell specific 
(Leino et al., 1997), we could observe that the glial cell specific GLUT1 isoform was 
downregulated only by OGD and not by hypoxia, which confirmed the presence of glial cell 
impairment. All in all, our in vitro model of short-term OGD in EHOSCs shows neuronal and glial 
impairments as well as selective vulnerability of CA1 making it a valid and comparable in vitro 
model to transient global ischemia that occurs in vivo.  
The selective cell death in CA1 was accompanied by a significant reduction in vessel density 
that was not observed in other subfields of the hippocampus raising the question whether the 
reduction of vessels in CA1 was a direct effect of OGD or whether it might be due to the CA1-
specific neurodegeneration. In rodent models of transient global ischemia, neuronal death, BBB 
leakage, and capillary damage in CA1 have been reported (Suzuki et al., 1983; Imdahl et 
al.,1986; Jingtao et al., 1999; Won et al., 2011). The density of vessels in the hippocampus has 
been quantified by perfusion staining techniques and has indicated less vascularity in the 
normal CA1 (Imdahl et al., 1986; Jingtao et al., 1999).  Also, the cell density in CA1 was 
observed to be inversely related to vessel density and vessel loss in CA1 was more pronounced 
after ischemia, suggesting that the microcirculation in CA1 was especially vulnerable to 
pathological conditions (Imdahl et al., 1986; Jingtao et al., 1999). Vascular reduction in CA1 
appeared to correlate with neurodegeneration in our in vitro model, but it was not clear whether 
the vessel changes preceded, paralleled, or followed neuronal death. Since CA1 pyramidal cell 
death in the hippocampus does not occur immediately after OGD a time course was performed 
following the development of neurodegeneration and revealed that reduction of claudin-5 
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expression neither occurred before or after the development of neuronal death, but in parallel 
with the onset of neurodegeneration, at 24 hours, suggesting that the two events 
(neurodegeneration and neurovascular loss) were linked.  
Blocking Na+-channels by TTX or ionic glutamate receptors by NMDA or AMPA antagonists has 
been reported to effectively prevent OGD-induced neuronal death, indicating excitotoxicity as 
the culprit of neurodegeneration (LoPachin et al., 2001; Rytter et al., 2003). Indeed, with the 
application of glutamate blockers during ischemia, neuronal death was reduced but also vessel 
reduction was prevented. Whether glutamate receptors are present in cerebral endothelial cells 
is controversial (Morley et al., 1998; Andras et al., 2007). Our results suggest that vessel 
preservation was a consequence of neuronal protection. We utilized CNQX, an AMPA 
antagonist since it has been shown to be more effective in ameliorating delayed neuronal death 
(Xue et al., 1994).  The evidence regarding the importance of AMPA receptors in cerebral 
endothelial cells have not been convincing since AMPA antagonists have not been effective in 
maintaining BBB integrity after glutamate exposure or OGD, in vitro and in vivo (Andras et al., 
2007; Liu et al., 2010). Therefore, the preservation of the neurovasculature in CA1 seems to be 
secondary to neuronal protection. Furthermore, vessel density was unaffected by silencing of 
neuronal activity rather than inducing neuronal death by TTX. All in all, these findings suggest 
that OGD-induced neurodegeneration is required for obtaining vessel loss and therefore is 
primary to neurovascular remodeling.      
Alternatively, to delineate whether neuronal death might be responsible for vessel reduction, 
neurodegeneration was provoked by applying a high dose of an AMPA agonist to over stimulate 
AMPA-type glutamate receptors in slice cultures. It has been observed in hippocampal 
organotypic slice cultures that the severity and location of neuronal damage induced by 
glutamate and its analogues (NMDA, KA, and AMPA) are dependent on concentration and 
duration (Kristensen et al. 2001). In our experiments, exposure to 100 µM of AMPA for 30 
minutes caused widespread neurodegeneration in CA1 and CA3 but reduced vessels 
selectively in CA1. Unexpectedly, the vessel density in CA3 was not substantially altered. 
Furthermore, in other subfields the neuronal and vascular responses were dissimilar. Neurons 
were present and viable in dentate gyrus but vessel density was significantly increased, while in 
the entorhinal cortex AMPA excitotoxicity was not effective at either inducing neuronal death or 
vessel changes. Interestingly, increases in vessel density have been observed in models of 
epilepsy both in vitro and in vivo (Rigau et al., 2007; Hellsten et al., 2005; Morin-Brureau et al., 
2011; Ndode-Ekane et al., 2010). Upregulation of VEGF by neurons and astrocytes has been 
suggested to increase vessel density (Morin-Brureau et al., 2011). In DG of seizure-induced 
animal models, mossy fiber sprouting and neurogenesis have been observed (Parent and 
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Murphy, 2008), which may release neurotrophic factors, promoting angiogenesis that might 
have also occurred in our model since VEGF was also upregulated.  All these responses were 
specific to AMPA as they could be prevented by CNQX. These findings under AMPA excitotoxic 
challenge suggest that the final vascular response is rather complex and not simply dependent 
on a single phenomenon, such as neuronal death, but due to additional local factors associated 
to the particular subfield. Further studies are necessary to disentangle the single factors 
influencing vessel loss and angiogenesis after an excitotoxic insult.  
Indeed, a primary mechanism underlying ischemia-induced neuronal death of pyramidal cells is 
excitotoxicity.  However, stroke is not simply a neuronal disorder but a neurovascular disorder 
as it involves dysfunction of blood vessels. The role of the neurovasculature in 
neurodegeneration remains elusive and the present results suggest further study of the 
biological crosstalk between the vasculature and pyramidal neurons and in particular, of the role 
of AMPARs in ischemia-induced neuronal death.  Moreover, research on vascular components 
might provide a better understanding of how certain injuries in the CNS are brought about and 
could help to improve therapeutic strategies that have been mainly viewed as neuroprotective.   
In this regard, therapeutic hypothermia has shown the most promising results in neuroprotection 
in neonates, reducing cerebral injury and also preventing the possibility for neurodevelopmental 
disabilities that may arise later in the life of a child who has suffered from neonatal asphyxia 
(Edwards et al., 2010; Jacobs et al., 2007; Schulzke et al., 2007; Shah et al., 2007). Mild-
hypothermia is a broad-spectrum approach to neuroprotection influencing multiple pathways 
(Corbett and Thornhill, 2000; Lo et al., 2003; Lo, 2009). However, the cellular mechanisms 
underlying this protective effect by mild-hypothermia have not been established. Upon mild-
hypothermia, a small group of proteins is upregulated and one of them is Rbm3 (Fujita et al., 
1999; Danno et al., 1997). Emerging evidence suggest Rbm3 to be involved in cell survival (Kita 
et al., 2000; Sureban et al., 2008; Wellmann et al., 2010). Therefore, the aim of the final part of 
my studies was to examine potential mechanisms of mild-hypothermia that is used to treat brain 
injury after neonatal asphyxia with a focus on the role of Rbm3. 
Previously, Rbm3 protein has been shown to be expressed highly in the developing rat brain 
and to a lesser extent in the adult (Pilotte et al., 2009). We showed here that a similar spatio-
temporal expression pattern of Rbm3 protein was observed in mouse from P1 to adult in the 
olfactory bulb, cortex, and cerebellum. Interestingly, in P10, Rbm3 protein was localized to cells 
of the subventricular zone and in migrating neurons of the 2nd cortical layer and of the external 
granule cell layer of the cerebellum. Furthermore, Rbm3 colocalized with doublecortin (DCX), a 
marker for newborn and migrating neurons. In the adult brain, Rbm3 protein was scarcely 
expressed and mainly restricted to the subgranular layer in the dentate gyrus of the 
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hippocampus, where neural stem cells reside, and in the rostral migratory stream, which 
contains progenitor cells of the olfactory bulb. Our findings in mouse confirm the results 
obtained in rat by Pilotte et al. (2009) and provide a foundation for further studies on Rbm3 in 
mouse brain as it is an attractive animal model for genetic manipulations.  
Currently, the function of Rbm3 is unknown, but it is a cold-inducible protein, which is 
upregulated in mammalian cells upon mild-hypothermia (Danno et al., 1997). Recently, it has 
been further suggested to regulate micro-RNA biogenesis (Pilotte et al. 2011). We found that in 
response to mild-hypothermia, Rbm3 mRNA and protein levels were upregulated in primary 
neurons, PC12 cells, and in COSCs. Again, we took advantage of the COSC system to study 
mild hypothermia, since maintaining precise brain temperature is rather difficult in vivo. Rbm3 
protein was strongly expressed in nuclei at 32°C compared to slices cultured at 37°C and was 
2-3 times higher in slice cultures derived from newborn mice than older mice. Furthermore, mild-
hypothermia was indeed neuroprotective as primary neurons and PC12 cells were rescued from 
cell death induced by staurosporine, a general protein kinase inhibitor which activates apoptosis 
by the intrinsic pathway (Johannsson et al., 2003). These findings suggest Rbm3 is functional in 
neuronal cells and is neuroprotective.   
In non-neuronal cells, Rbm3 has been shown to be involved in proliferation and cell survival, 
triggering mitotic catastrophe in colon carcinoma cells (Sureban et al., 2008) or loss of 
proliferation leading to cell death in human embryonic kidney cells (Wellmann et al., 2010) if it is 
knocked down by siRNAs. In line with these observations, when Rbm3 expression was knocked 
down by siRNA in PC12 cells the protective effect of mild-hypothermia followed by induced 
apoptosis was diminished. Intriguingly, over-expression of Rbm3 in neuroblastoma cells 
expressing a long polyglutamine form of huntingtin has been reported to prevent cell death (Kita 
et al., 2000). We also found that exogenous expression of Rbm3 in PC12 cells rescued them 
from forced apoptosis in the absence of mild-hypothermia, additionally supporting the role of 
Rbm3 in cell survival. 
Our findings provide evidence for a positive role of Rbm3 in cell survival, particularly in 
neuroprotection induced by mild-hypothermia. Further studies are necessary, as the mechanism 
of the function of Rbm3 in mild-hypothermia still remains to be elucidated. Particular studies 
directed towards understanding the signalling upstream and downstream of Rbm3 will be able 
to determine its mechanism of action and should provide better insight into the signalling 
pathways of Rbm3. In vivo models suitable for examining the function of Rbm3 should be 
investigated. However, until in vivo models are available, the COSC system has shown to be a 
useful tool and should be used to analyze the role of Rbm3 in cell survival especially in the 
setting of hypothermia-induced neuroprotection. The protective effect of therapeutic 
95 
 
hypothermia should be explored as it is the best currently available treatment for ameliorating 
brain injury after neonatal asphyxia. The finding that Rbm3 is important for hypothermia-induced 
neuroprotection is a first step towards elucidating the protective action of hypothermia.  
 
5.2 OUTLOOK AND CLOSING REMARKS 
 
In the presence of FGF2 blood vessels including tight junctions and transporters were preserved 
and functional in slice cultures without blood flow suggesting that endothelial cells along with 
neurons and glia are reactive and just as viable in vitro. Initially, immunostaining of pericytes 
was performed but unfortunately so far the commercially available antibodies for NG2 and α-
smooth muscle actin have not been yielding satisfactory staining results in COSCs. Although 
pericytes were not examined in these studies, their contribution in maintaining vessels in 
COSCs should be explored since they have been reported to contribute to BBB maintenance 
(Abbott et al., 2010). Recently, pericytes have been reported to be involved in controlling 
cerebral blood flow and their absence in the adult brain of pericyte deficient mice induces 
vascular damage, reducing blood flow leading to neurodegeneration and inflammation (Bell et 
al., 2010). It will be interesting to observe whether pericytes survive in the absence of blood flow 
in COSCs, but since endothelial cells do they most likely will also. Moreover, cultured pericytes 
seem to perform better at maintaining barrier properties of cerebral endothelial cells in vitro than 
astrocytes (Al-Ahmad et al., 2009).  
Inducing selective neuronal death in CA1 of EHOSCs by OGD suggested that our in vitro model 
was comparable to in vivo models of transient global ischemia. This was certainly not a novel 
finding as it has been reported before in many studies but the selective vascular loss 
accompanying neurodegeneration was previously not observed in organotypic hippocampal 
cultures. Vessel loss was reversible by neuroprotection through glutamate receptor blockers 
suggesting a remodeling of the neurovasculature, in vitro. The vessel loss appeared to be 
preceded by neuronal death, but the type of death mechanism (necrosis or apoptosis) was not 
determined. Short-term OGD induced a delayed form of cell death rather than immediate, which 
suggest that apoptosis was predominant. In AMPA-induced excitotoxic neurodegeneration, the 
timing of cell death was more rapid occurring within 3 hours after a brief exposure to a high 
dose of agonist, which suggested that necrosis was predominant. However, the timing of cell 
death alone does not exclude the possibility that both types of death mechanisms occurred. 
Further studies on the death mechanisms should be undertaken because the factors involved in 
necrosis or apoptosis or both processes may contribute to remodeling of the neurovasculature.   
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Differences in the vulnerability to ischemia in different hippocampal subfields have been 
suggested to be due to intrinsic differences between these regions of the hippocampal formation 
(Kirino et al, 1984). Responses in neurons and more recently glial cells of CA1 have been 
investigated (Stanika et al., 2010; Tsuchiya et al., 2011; Xu et al., 2010). We observed that 
neurodegeneration and the response of the local blood vessels after AMPA-induced 
excitotoxicity was different in each of the hipppocampal subfields. These findings suggest that 
regional differences were involved in the final vascular response. Therefore, investigations 
directed towards examining local factors related to endothelial signaling as observed for 
neuronal and glial cells may offer more hints on the nature of neurovascular remodeling in the 
hippocampus and in particular why CA1 is selectively vulnerable to the loss of vessels.     
Our results on Rbm3 were promising as we could provide evidence in various in vitro models 
that this cold-inducible protein may be involved in hypothermia-induced neuroprotection. Its 
ability to prevent apoptotic cell death induced by staurosporine or serum-glucose deprivation 
suggests a role in cell survival and makes it an attractive candidate in reducing long-term 
sequelae after neonatal asphyxia. Studies directed towards elucidating its role in neuronal 
survival should determine which part of the survival pathway Rbm3 is involved in. Therefore, 
further examining Rbm3 under various forms of stress induced by neonatal asphyxia, such as 
excitotoxic neuronal death or inflammation may provide more clues on the mechanisms of 
Rbm3 neuroprotection. At present, there are only few in vivo studies on Rbm3 expression in 
brain (Pilotte et al., 2009; Chip et al., 2011). We have only characterized the expression of 
Rbm3 in developing and adult brain of mouse. Unlike the in vitro models presented here, where 
Rbm3 was knocked down by siRNA to show its neuroprotective effect, the absence of Rbm3 in 
vivo may offer a better understanding of its role in the complex brain environment. Both 
constitutive and conditional Rbm3 knockout mice should be investigated. If Rbm3 is important in 
neuronal survival, then we would expect to see a slower recovery rate from neuronal injury in 
Rbm3 knockout mice. Slice cultures from Rbm3 deficient mice should be considered as a 
complement to in vivo data. Until Rbm3 knockout mice are available, the expression of Rbm3 in 
brain exposed to hypoxia-ischemia should be examined since Rbm3 has been reported to be 
upregulated in hypoxia, in vitro (Wellman et al., 2004). Neuroprotection by ischemic 
preconditioning has been observed in animal models (Narayanan et al., 2012) and perhaps 
Rbm3 is also involved here. 
In conclusion, the brain is an organ composed of many cell types and to understand its function 
under physiological or pathological conditions requires studying more than one cell-type. 
Research which integrates cell-cell interactions in the specialization of the BBB has not been 
well-established yet. The main goal of my studies was to utilize organotypic slice cultures of 
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mouse brain as a model system to study cell-cell interactions that are present within the nervous 
system. The focus was on the neurovascular unit that encompasses the interaction of vascular 
elements (endothelial and pericytes) with the nervous tissue (neurons and astrocytes), which 
maintain the BBB. Our data show that the neurovasculature of organotypic brain slices is 
preserved with a variety of components of the BBB, including transporter proteins which remain 
functional. Moreover, under pathological conditions of oxygen-glucose deprivation, blood vessel 
remodeling in CA1 was observed without blood flow and this was dependent on death or 
survival of the neurons. Lastly, we demonstrated that Rbm3 is involved in neuronal survival and 
postulate that it may be involved in therapeutic hypothermia-induced neuroprotection.    
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